

AHA SCIENTIFIC STATEMENT

Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association

Joshua J. Joseph¹, MD, MPH, FAHA, Chair; Prakash Deedwania, MD, FAHA, Vice Chair; Tushar Acharya, MBBS, MPH; David Aguilar, MD, MSc, FAHA; Deepak L. Bhatt, MD, MPH, FAHA; Deborah A. Chyun, PhD, RN, FAHA; Katherine E. Di Palo, PharmD, BCACP, BCGP, FAHA; Sherita H. Golden, MD, MHS, FAHA; Laurence S. Sperling, MD, FAHA; on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Clinical Cardiology; and Council on Hypertension

ABSTRACT: Cardiovascular disease remains the leading cause of death in patients with diabetes. Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk factors leads to substantial reductions in cardiovascular events. The 2015 American Heart Association and American Diabetes Association scientific statement, "Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence," highlighted the importance of modifying various risk factors responsible for cardiovascular disease in diabetes. At the time, there was limited evidence to suggest that glucose-lowering medications reduce the risk of cardiovascular events. At present, several large randomized controlled trials with newer antihyperglycemic agents have been completed, demonstrating cardiovascular safety and reduction in cardiovascular outcomes, including cardiovascular death, myocardial infarction, stroke, and heart failure. This AHA scientific statement update focuses on (1) the evidence and clinical utility of newer antihyperglycemic agents in improving glycemic control and reducing cardiovascular events in diabetes; (2) the impact of blood pressure control on cardiovascular events in diabetes; and (3) the role of newer lipid-lowering therapies in comprehensive cardiovascular risk management in adults with diabetes. This scientific statement addresses the continued importance of lifestyle interventions, pharmacological therapy, and surgical interventions to curb the epidemic of obesity and metabolic syndrome, important precursors of prediabetes, diabetes, and comorbid cardiovascular disease. Last, this scientific statement explores the critical importance of the social determinants of health and health equity in the continuum of care in diabetes and cardiovascular disease.

Key Words: AHA Scientific Statements ■ antihypertensive agents ■ cardiovascular diseases ■ diabetes complications ■ hypoglycemic agents ■ life style ■ social determinants of health

The prevalence of diabetes has increased sharply in the United States over the past 4 decades with >34.2 million Americans with diabetes.¹ More than 90% to 95% of the diabetes population are classified as type 2 diabetes (T2D).¹ Type 1 diabetes, characterized by an inability to produce insulin because of autoimmunity, accounts for 5% to 10% of cases. Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in type 1 diabetes and T2D.² From 1998 to 2015, rates of cardiovascular mortality in the United States have declined in those with and without diabetes, with a

25% greater decline in diabetes populations; but disparities still persist, with cardiovascular mortality remaining higher in those with diabetes in the United States and similar findings in other western countries.²⁻⁴

CVD comprises a group of disorders of the heart and blood vessels including coronary heart disease, cerebrovascular disease, heart failure, peripheral artery disease (PAD), congenital heart disease, etc. In this scientific statement, the focus is mostly on components of the major adverse cardiovascular events (MACE) including coronary artery disease (CAD), cerebrovascular disease,




Figure 1. Cardiovascular risk reduction in adults with type 2 diabetes: central illustration.

GLP-1 indicates glucagon-like peptide 1; PCSK-9, proprotein convertase subtilisin/kexin type 9 serine protease; and SGLT-2, sodium-glucose cotransporter-2.

and heart failure. Atherosclerosis begins with the deposition of lipoproteins in the arterial wall. In the sub-endothelial space, foam cells accumulate and low-density lipoprotein (LDL) particles are oxidized, which ultimately leads to vascular modifications. Acute coronary and cerebrovascular syndromes occur when arterial plaque deposits become unstable and rupture.⁵ Several factors in the development of atherosclerosis and CVD are often comorbid in individuals with T2D; these include hypertension,⁶ insulin resistance,⁷ hyperglycemia,⁸ obesity,⁹ and dyslipidemia.¹⁰ Insulin resistance promotes macrovascular abnormalities through formation of atheroma plaques, diastolic dysfunction, and ventricular hypertrophy.⁷ Hyperglycemia promotes the development of CVD through advanced glycosylated end products and oxidative stress among other factors.¹¹ Both insulin resistance and hyperglycemia promote CAD, cerebrovascular disease, and heart failure.

Lifestyle change, weight reduction, and cardioprotective therapeutics are vital tools in primary and secondary prevention of CVD. Since the “Update on Prevention of CVD in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the

American Heart Association and the American Diabetes Association” in 2015,¹² there have been a number of important clinical trials advancing our understanding of lifestyle, blood pressure (BP), blood glucose, antithrombotic, and cholesterol management in primary and secondary prevention of CVD. This scientific statement (1) synthesizes the current science and best practices for the comprehensive management of cardiovascular risk factors in adults with T2D and (2) provides additional context on the importance of the social determinants of health (SDoH) and health equity in cardiovascular risk factor management from the individual to the population level (Figure 1).

DEFINITIONS AND DIAGNOSTIC CRITERIA

The pathophysiological progression to T2D includes metabolic syndrome and prediabetes with glucose dysregulation attributable to liver, skeletal muscle, and adipocyte insulin resistance, along with proinflammatory cytokines. These processes cause hepatic glucose production and impaired glucose uptake in skeletal muscle, and adipocytes leading to hyperglycemia and lipolysis.

The combined impact of these effects causes eventual β -cell decline with decreased insulin secretion and T2D. According to the International Diabetes Federation, metabolic syndrome is defined as having ≥ 3 of the following: (1) a waist circumference ≥ 35 inches for women or 40 inches for men, (2) elevated triglycerides (≥ 150 mg/dL), (3) a high-density lipoprotein cholesterol (HDL-C) < 40 mg/dL in men or < 50 mg/dL in women, (4) hypertension ($\geq 130/85$ mmHg), and (5) elevated fasting plasma glucose (FPG; ≥ 100 mg/dL).¹³ Even for obesity without metabolic syndrome, there is a 45% higher relative risk of CVD events compared with individuals who have a normal body mass index (BMI).¹⁴ A diagnosis of prediabetes is based on FPG levels between 100 mg/dL and 125 mg/dL, glucose ranging from 140 mg/dL to 199 mg/dL in response to an oral glucose tolerance test (2-hour post glucose load), or a hemoglobin A1c (A1c) between 5.7% and 6.4%.¹⁵ The diagnostic cut-off values for diabetes based on FPG, A1c, oral glucose tolerance test, and random glucose are ≥ 126 mg/dL, $\geq 6.5\%$, ≥ 200 mg/dL, and ≥ 200 mg/dL, respectively.¹⁵ All 4 methodologies are considered suitable for the diagnosis of diabetes with a follow-up second abnormal test, although they are not perfectly concordant with one another. The 2-hour glucose measurement of an oral glucose tolerance test is the preferred test for assessing postmeal glucose tolerance and is a more sensitive diagnostic marker for both prediabetes and diabetes compared with A1c and FPG.¹⁶ A1c has distinct advantages to plasma glucose testing because it is able to assess average blood glucose levels over a longer time frame (3 months) and has less inter/intraday variability attributable to external factors like stress. However, the A1c test alone with a $\geq 6.5\%$ cutoff identifies only 30% of prevalent diabetes compared with A1c, oral glucose tolerance test, or FPG combined.^{15,17} In relation to CVD, each of these disease states carries significant risk, and the combination of metabolic syndrome with diabetes increases CVD risk nearly 5-fold.^{18,19}

LIFESTYLE MANAGEMENT

Lifestyle modification is a critical component of cardiovascular risk factor reduction in adults with T2D.^{20–23} Lifestyle management of T2D includes diabetes self-management education and support, medical nutrition therapy, physical activity, smoking cessation, and psychosocial care. In adults with T2D, greater adherence to an overall healthy lifestyle is associated with a substantially lower risk of incident CVD and CVD mortality (Table 1).^{24,25}

The Look AHEAD trial (Action for Health and Diabetes) tested the impact of intensive lifestyle intervention focused on weight loss and increased physical activity versus diabetes support and education on adverse cardiovascular events among overweight adults with T2D.⁴⁰

The intensive lifestyle intervention included a calorie goal of 1200 to 1800 kcal per day (with $< 30\%$ from fat and $> 15\%$ from protein), the use of meal replacement products, and at least 175 minutes of moderate-intensity physical activity per week. The intensive lifestyle intervention did not reduce the rate of MACE in Look AHEAD. However, it produced greater weight loss and reductions in A1c versus control, in particular, in the first year.⁴⁰ In post hoc analyses, individuals who lost $\geq 10\%$ of their body weight or had a > 2 metabolic equivalent increase in fitness in the first year of the trial experienced reductions in cardiovascular outcomes compared to those with stable weight/weight gain or stable fitness/fitness loss.³⁶ Similarly, although the intensive lifestyle intervention did not lower the risk of heart failure (HF) compared with control, sustained, long-term improvements in weight loss and cardiorespiratory fitness were associated with lower risk of HF in the entire cohort.⁴¹ Furthermore, intensive lifestyle intervention yielded improvements in other cardiovascular risk factors,^{40,42} sleep apnea,⁴³ fitness,⁴⁴ renal disease,⁴⁵ peripheral neuropathy,⁴⁶ and depressive symptoms.⁴⁷ Thus, among patients with T2D with overweight or obese status, intensive lifestyle intervention results in moderate and sustained weight loss, control of cardiovascular risk factors, and substantial cardiovascular benefit for those with greater weight loss and fitness.^{36,41,48}

Physical Activity

Physical activity is important in cardiovascular risk reduction among individuals with T2D (Table 1). Consistent with other prevention guidelines,²¹ the American Diabetes Association (ADA) recommends ≥ 150 minutes of moderate-to-vigorous intensity aerobic activity per week, over at least 3 days, with no more than 2 consecutive days without activity for most adults with T2D.^{20,49} Recommendations also include 2 to 3 sessions per week of resistance exercise on nonconsecutive days, decreasing time spent sedentary with prolonged sitting being interrupted every 30 minutes, and flexibility and balance training 2 to 3 times per week.²⁰ Shorter durations (≥ 75 minutes per week) of vigorous activity or interval training may also be considered.²⁰

Increased physical activity and exercise have been shown to improve glycemic control, lipids, BP, insulin sensitivity, and inflammatory biomarkers in T2D.^{49–53} Physical activity has also been associated with lower risk of CVD and mortality in T2D.⁵⁴ Structured exercise training recommendations by health care workers, consisting of aerobic exercise, resistance training, or both, are more effective than physical activity advice alone.⁵³

Nutrition

For adults with T2D, a tailored nutrition plan is a key component for cardiovascular risk reduction, and a heart-

Table 1. Risks of All-Cause Mortality, and Cardiovascular and Microvascular Events Associated With Control of Lifestyle Factors

	Lifestyle factors	Physical activity/exercise	Smoking	Alcohol
Total mortality	Bariatric surgery: ²⁶ HR=0.33; 95% CI 0.21–0.52	Low vs higher: ²⁷ HR=1.41; 95% CI 1.16–1.72	vs nonsmokers: ²⁸ RR=1.55; 95% CI 1.46–1.64 vs never smokers: Former: RR=1.19; 95% CI 1.11–1.28 Daily smoking: ²⁹ HR 1.52; 95% CI 1.27–1.83 Women: HR=1.78; 95% CI 1.23–2.59 Men: HR=1.45; 95% CI 1.18–1.80 Cessation: HR=0.70; 95% CI 0.57–0.87 BARI 2D vs never smokers: ³⁰ Current smokers: HR=1.49; 95% CI 0.97–2.29 Former smokers: HR=1.37; 95% CI 1.04–2.79	Moderate vs none (for wine): ³¹ HR=0.77; 9.5% CI 0.62–0.95 Alcohol consumers vs nonconsumers (6 g/d): ³² RR=0.64; 95% CI 0.49–0.82 NS at higher levels
CV mortality	≥3 low-risk factors: ³³ HR=0.48; 95% CI 0.40–0.59 ≤2 risk factor control vs all: ³⁴ HR=2.0; 95% CI 1.3–3.3	Low vs higher: ²⁷ HR=1.54; 95% CI 1.07–2.22 Increase from inactive to 150 min moderate-intensity aerobic activity per wk: ³⁵ RR=0.83; 95% CI 0.77–0.89	vs nonsmokers: ²⁸ RR=1.49; 95% CI 1.29–1.71 vs never smokers: ²⁸ Former: RR=1.15; 95% CI 1.00–1.32 BARI 2D vs never smokers: ³⁰ Current smokers: NS Former smokers: NS	Alcohol consumers vs nonconsumers: ³² ≤6 g/d: RR=0.72; 95% CI 0.52–1.00 6 to <18 g/d: RR=0.57; 95% CI 0.42–0.76 ≥18 g/d: RR=0.34; 95% CI 0.22–0.53
Total CVD	None vs 3 of 4 factors: ²⁵ HR=4.17; 95% CI 1.02–17.09 ≥3 low-risk factors: ³³ HR=0.48; 95% CI 0.40–0.59 >10% weight loss first y: ³⁶ Primary outcome: RR=0.79; 95% CI 0.64–0.98 Secondary outcome: RR=0.79; 95% CI 0.64–0.98 ≤2 risk factor control vs all: ³⁴ HR=1.7; 95% CI 1.2–2.5	Low vs higher: HR=1.18; 95% CI 1.02–1.36 Increase from inactive to 150 min moderate-intensity aerobic activity per wk: ³⁵ RR=0.83; 95% CI 0.77–0.89	Compared with nonsmokers: ²⁸ RR=1.44; 95% CI 1.34–1.54 vs never smokers: ²⁸ Former: RR=1.09; 95% CI 1.05–1.13 vs smokers: ³⁷ Quit ≤4 y: HR=0.49; 95% CI 0.11–2.19 Quit >4 y: HR=0.57; 95% CI 0.28–1.15 Nonsmokers: HR=0.49; 95% CI 0.22–1.09	
Coronary heart disease/coronary artery disease	≥3 low-risk factors: ³³ HR=0.53; 95% CI 0.42–0.66 Bariatric surgery: ²⁶ HR=0.64; 95% CI 0.42–0.99	Low vs higher: ²⁷ HR=1.19; 95% CI 1.00–1.42 Increase from inactive to 150 min moderate-intensity aerobic activity per wk: ³⁵ RR=0.80; 95% CI 0.75–0.86	vs nonsmokers: ²⁸ RR=1.51; 95% CI 1.41–1.62 Compared with never smokers: ²⁸ Former: RR=1.14; 95% CI 1.00–1.30 BARI 2D vs never smokers: ³⁰ Current smokers: No Former smokers: No	Heavy drinking and highest depressive symptoms: ³⁸ Odds ratio=1.02; 95% CI 1.00–1.04 Alcohol consumers vs nonconsumers: ³² ≤6 g/d: RR=0.75; 95% CI 0.61–0.93 6 to <18 g/d: RR=0.57; 95% CI 0.39–0.83 ≥18 g/d: RR=0.59; 95% CI 0.41–0.81
Heart failure		Increase from inactive to 150 min moderate-intensity aerobic activity per wk: ³⁵ RR=0.81; 95% CI 0.76–0.86	vs nonsmokers: ²⁸ RR=1.43; 95% CI 1.19–1.72	

(Continued)



Table 1. Continued

	Lifestyle factors	Physical activity/exercise	Smoking	Alcohol
CV events	>10% weight loss first y: ³⁶ RR=0.76; 95% CI 0.63–0.91 Achieving 5 factors vs ≤2: ³⁹ HR=0.60; 95% CI 0.47–0.77 Bariatric surgery: ²⁶ HR=0.60; 95% CI 0.42–0.86		vs smokers: Quit ≤4 y: HR=0.36; 95% CI 0.04–2.97 Quit >4 y: HR=0.42; 95% CI 0.16–1.10 Nonsmokers: HR=0.15; 95% CI 0.04–0.57	Moderate vs none: ³¹ adjusted HR=0.83; 95% CI 0.72–0.95

BARI 2D indicates Bypass Angioplasty Revascularization Investigation 2 Diabetes; CV, cardiovascular; CVD, cardiovascular disease; HR, hazard ratio; MI, myocardial infarction; NS, nonsignificant; and RR, relative risk.

Details on some of the studies noted in Table 1.

Population-based prospective cohort study of newly diagnosed patients with type 2 diabetes (n=867); composite first CV event: CV mortality, nonfatal MI, and nonfatal stroke and revascularization; risk in those who did not change any health behavior vs those who adopted 3 out of 4 (physical activity, alcohol intake, smoking, and diet).²⁵

Retrospective cohort study over 5 years.²⁶

Observational study from Swedish National Diabetes Register (n=15 462; low=never or 1 to 2 times per week; higher=3 times per week or more; adjusted for age, sex, diabetes duration, diabetes treatment, smoking, systolic blood pressure, low- and high-density lipoproteins, triglycerides, body mass index, and albuminuria.²⁷

Meta-analysis and systematic review of 89 prospective, cohort studies.²⁸

ADVANCE trial (The Action in Diabetes and Vascular Disease: Preterax and Diamicon MR Controlled Evaluation): all-cause mortality; major cardiac events (CVD death, nonfatal stroke, or nonfatal MI); all CV events (major+ peripheral artery disease or transient ischemic attack); coronary events (fatal and nonfatal MI; nephropathy [new or worsening renal disease]); adjusted for CVD risk factors and weight change.²⁹

Adjusted for factors that differed by smoking status and smoking status as a time-dependent covariate.³⁰

Meta-analysis of 7 prospective studies.³²

Umbrella review of systematic reviews and meta-analyses.³³

Nonrandomized analysis (n=2265) of survival and CV events (composite death, MI, or stroke) and control of 6 risk factors (nonsmoker, non-high-density lipoprotein <130 mg/dL, triglycerides <150 mg/dL, systolic blood pressure <130 mm Hg, diastolic blood pressure <80 mm Hg, hemoglobin A1c <7%) in BARI2D; time-varying number of risk factors in control adjusted for baseline numbers of risk factors in control. Clinical characteristics and randomization assignment.³⁴

Systematic review of 36 prospective cohort studies; increase from being inactive to achieving recommended PA levels of 150 minutes of moderate-intensity aerobic activity per week; adjusted for body weight.³⁵

Composite. End point of CVD death, MI, stroke, or angina hospitalization in Look AHEAD; these events plus coronary artery bypass grafting, carotid endarterectomy, percutaneous coronary intervention, hospitalization for heart failure, peripheral vascular disease, or total mortality.³⁶

Prospective community-based cohort study data from Framingham Offspring Study from 1984 to 2011; total CVD events—coronary heart disease, cerebrovascular events, peripheral artery disease, and congestive heart failure; age and sex-adjusted; multiple cardiac risk factor adjusted; and 4-year weight change adjusted.³⁷

Evaluation of Diabetes Treatment annual survey, n=1413; adjusting for socioeconomic, lifestyle, and diabetes-related covariates.³⁸

TECOS trial (Trial Evaluating Cardiovascular Outcomes with Sitagliptin; n=13 616) attainment of 5 secondary prevention goals (aspirin use, lipid control [low-density lipoprotein cholesterol <70 mg/dL or statin use], systolic blood pressure <140 mm Hg, diastolic blood pressure <90 mm Hg, angiotensin-converting enzyme or angiotensin receptor blocker use, nonsmoking) on CV death, MI, or stroke.³⁹

healthy dietary pattern is recommended to improve glycemic control, achieve weight loss when needed, and improve other atherosclerotic CVD (ASCVD) risk factors. The ADA recommendations support various healthy dietary approaches to achieve glycemic control and weight management,^{20,23} although the effects of dietary interventions on CVD outcomes in individuals with T2D has not been widely studied. The Mediterranean, Paleolithic, low-carbohydrate, high-protein, vegetarian, and nut-enriched diets have demonstrated benefits on glycemic control and weight loss in T2D, with the Mediterranean diet producing the greatest improvements in glycemic control and a 29% CVD reduction over 4.8 years.^{55–60} Very low-energy diets can lower A1c, BMI, cholesterol, and BP.^{61,62} Very low-carbohydrate versus moderate carbohydrate diets yield a greater decrease in A1c, more weight loss and use of fewer diabetes medications in individuals with diabetes.^{63–65} For those who are unable to adhere to a calorie-restricted diet, a low-carbohydrate diet reduces A1c and triglycerides.^{63–65} Very low-carbohydrate diets were effective in reducing A1c over shorter time periods (<6 months) with less differences in interventions ≥12 months.^{65a–65d} For individuals using very low-carbohydrate dietary approaches, it is important for health care professionals to maintain medical oversight and adjust diabetes

medications to prevent hypoglycemia.²⁰ Overall, weight loss of 5% to 10% is associated with A1c reductions of 0.6% to 1.0% and reduced diabetes medications.⁶⁶ Thus, the ADA recommends an individualized nutrition plan focusing on total calorie and metabolic goals, using a medical nutrition program as needed to achieve goals.

Obesity and Weight Management

Overweight (BMI >25 kg/m²), obesity (BMI >30 kg/m²), and central/visceral adiposity are associated with adverse CVD outcomes.^{66,67} Obesity increases CVD risk ≈2-fold, and diabetes with metabolic syndrome increases CVD risk ≈5-fold.⁶⁸ Obesity promotes CVD directly through cardiac adaptations including decreased cardiac output, increased peripheral resistance, left ventricular mass/wall thickness, and poor left ventricular systolic function.⁶⁸ Obesity adversely impacts hypertension, dyslipidemia, endothelial function, and inflammation indirectly.⁶⁸ Diet, physical activity, and behavioral therapy are recommended at all levels of BMI, with pharmacologic and surgical interventions recommended for weight management in obesity.²³

Pharmacological Therapy

Weight-loss medications are indicated as adjuncts to diet, physical activity, and behavioral therapy for selected

patients with T2D and BMI ≥ 27 kg/m².²³ Orlistat, lorcaserin, liraglutide, naltrexone/bupropion sustained release, and phentermine/topiramate are US Food and Drug Administration (FDA)-approved for weight management with demonstrated cardiovascular safety and the additional benefit of A1c lowering.^{69,70} If weight loss after 3 months is $< 5\%$ or safety issues arise, the medication should be discontinued and alternative medications or treatment approaches should be considered.²³ Long-term cardiovascular event reduction has not been formally tested, but notable cardiovascular risk reduction was shown for liraglutide at lower doses among those with ASCVD or high cardiovascular risk.⁷¹ Non-weight loss–approved medications commonly used in T2D lower weight, including pramlintide, sodium-glucose cotransporter-2 inhibitors (SGLT-2Is), metformin, and other glucagon-like peptide 1 receptor agonists (GLP-1RA).⁶⁹ Further studies are ongoing to determine the combinations of these therapies that may be most beneficial for weight loss.^{69,70}

The recently published STEP (Semaglutide Treatment Effect in People with Obesity) 1,⁷² STEP 2,⁷³ STEP 3,⁷⁴ and STEP 4⁷⁵ trials demonstrate the tremendous impact of once weekly GLP-1RA treatment with semaglutide on weight loss and cardiovascular risk factors. The STEP 2 trial specifically evaluated individuals with diabetes taking ≤ 3 oral hypoglycemic agents at baseline with BMI of ≥ 27 kg/m².⁷³ Average bodyweight reductions were 9.6%, 7.0%, and 3.4% with semaglutide 2.4 mg, 1.0 mg, and placebo, respectively, over 68 weeks combined with lifestyle intervention (counseling provided every fourth week to maintain a 500 kcal per day reduction relative to the estimated total daily energy expenditure and 150 minutes per week of physical activity).⁷³ Cardiovascular risk factors improved significantly on semaglutide 2.4 mg daily with reductions in A1c, glucose, very-low-density lipoprotein cholesterol, free fatty acids, triglycerides, and C-reactive protein.⁷³ The findings of STEP 1 and STEP 3 were consistent with STEP 2 in duration but were conducted among participants without diabetes. Both trials exhibited significant weight loss on the semaglutide 2.4 mg daily (14.9% and 16.0%, respectively),^{72,74} with similar cardiovascular risk factor reduction. In STEP 1, among participants with prediabetes at baseline, 84% reverted to normoglycemia on intervention versus 48% in the control.⁷² STEP 4 demonstrated the importance of long-term therapy with GLP-1 RAs by evaluating semaglutide 2.4 mg for the first 20 weeks, after which participants were randomly assigned to receive either semaglutide or placebo for the remaining 48 weeks.⁷⁵ The semaglutide 2.4 mg group had sustained weight loss over the 68 weeks, whereas the placebo group experienced weight regain and worsening of cardiovascular risk factors from weeks 21 to 68.⁷⁵ Gastrointestinal side effects were common with semaglutide, but rates of discontinuation were simi-

lar to placebo. Thus, once weekly semaglutide 2.4 mg delivers impressive weight loss and cardiovascular risk factor improvement and is FDA approved for chronic weight management in adults with BMI ≥ 30 kg/m² or BMI ≥ 25 kg/m² with a comorbid condition (ie, T2D, hypertension, hyperlipidemia).

Surgical Procedures

Growing evidence supports the use of metabolic surgery for the treatment of comorbid obesity in T2D.^{23,76} The extant literature from numerous randomized controlled (nonblinded) clinical trials, matched studies, and meta-analyses demonstrate that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors including body weight, fasting glucose, A1c, BP, HDL, and triglycerides in patients with T2D and obesity compared with various lifestyle/medical interventions.^{77–79} Improvements in CVD, CVD mortality, and all-cause mortality have been observed in nonrandomized observational studies, matched cohort studies, and meta-analyses (ranging from $\approx 40\%$ to 80% risk reduction in meta-analyses) with potentially greater benefits for mortality among patients with versus without diabetes.^{26,79–81} It is notable that most of the current studies were performed before the increased utilization of SGLT-2Is and GLP-1RAs with proven CVD reduction in T2D. The risk of metabolic surgery includes both short-term (< 30 days) and long-term (≥ 30 days) complications. Short-term complications include postsurgical complications (bowel obstruction, venous thromboembolism, gastrointestinal bleeding, anastomotic leaks, wound infections, etc).⁷⁹ Long-term complications include marginal ulceration, cholelithiasis, dumping syndrome, nutritional and vitamin deficiencies, malabsorption, fistulas, etc.⁷⁹ At present, perioperative mortality ranges from 0.03% to 0.20%, which continues to improve over time.⁷⁹ Thus, a balanced discussion of the procedural and long-term risks and benefits should guide a patient-informed decision.

Metabolic surgery is recommended to treat patients who have T2D with BMI ≥ 40 kg/m² and in those with BMI 35.0 to 39.9 kg/m² without durable weight loss and improvement in comorbidities with nonsurgical methods, and should be considered in those with T2D and BMI of 30.0 to 34.9 kg/m² without similar improvements.²³ In Asian individuals, these BMI cut points are reduced by 2.5 kg/m².²³ In addition to these 2nd Diabetes Surgery Summit (DSS-II) recommendations, the ADA recommends that (1) metabolic surgery should be performed in high-volume centers with experienced, multidisciplinary teams; (2) long-term lifestyle support and routine monitoring of micronutrient and nutritional status must be provided; and (3) people presenting for metabolic surgery should receive comprehensive readiness and mental health assessment.²³

Alcohol

Data from observational studies of the general population have linked light-to-moderate alcohol intake with lower risk of myocardial infarction (MI) compared with nondrinkers with no impact on stroke,⁸² whereas increasing alcohol intake versus light intake is associated with a similar lower risk of MI but higher risk of stroke, HF, and fatal hypertensive disease.⁸³ The discrepancy for MI versus stroke may be attributable to the impact of alcohol on increasing BP but also increasing HDL.⁸³ Recent mendelian randomization studies suggest a causal link between alcohol consumption and cardiovascular outcomes including stroke and PAD.⁸⁴ Among individuals with T2D, light-to-moderate alcohol consumption, particularly wine consumption, has also been associated with fewer MIs compared with nondrinkers, whereas heavy alcohol consumption has been associated with higher risk.^{31,32,85,86} There is a lack of evidence regarding alcohol's impact on other CVD outcomes including stroke in T2D. Recent evidence shows higher odds of hypertension in those with T2D who consume moderate or heavy amounts of alcohol.⁹⁷ These observational studies are unable to fully account for confounding and reverse causality, and randomized controlled cardiovascular outcomes trials (CVOTs) have not been performed. Small clinical trials in patients with diabetes have suggested that light-to-moderate alcohol intake may improve cardiometabolic measures such as A1c, insulin, and lipids.^{88,89} In the ADDITION (Anglo-Danish-Dutch Study of Intensive Treatment In People with Screen Detected Diabetes in Primary Care)-Cambridge study, decreasing alcohol intake by ≥ 2 units/week (20 mL pure alcohol) over 1 year was associated with a 44% (95% CI, 13%–64%) lower risk of CVD over 10 years versus sustained intake in individuals newly diagnosed with T2D.⁹⁰ Thus, light-to-moderate intake may have a benefit on A1c, lipids, and MI but with the concern of higher BP, thus a need for future studies on other cardiovascular outcomes.

Individuals who have underlying medical conditions that preclude alcohol use (eg, alcohol use disorders, liver disease, concomitant medications) should be advised to abstain from alcohol. Despite potentially beneficial effects of light-to-moderate alcohol intake on CVD, particularly MI, individuals who are not currently drinking should not be advised to consume alcohol for its potential health benefit. Adults with diabetes who choose to drink should be cautioned regarding the potential risks of hypoglycemia and delayed hypoglycemia, weight gain, hyperglycemia, and elevated BP that may occur with excess alcohol consumption. For women, no more than 1 drink per day, and for men, no more than 2 drinks per day is recommended (in the United States, 1 drink is equal to a 12-ounce beer, a 5-ounce glass of wine, or 1.5 ounces of distilled spirits).^{20,23}

Smoking

Smoking increases the risk of coronary heart disease, HF, PAD, stroke, and cardiovascular mortality in T2D.²⁸ In general populations, secondhand smoke increases risk of CVD and all-cause mortality.⁹¹ Smoking is associated with worse dyslipidemia, proinflammatory markers, and glycemic measures among adults with T2D.⁹² Given the importance of tobacco as a remediable risk factor, current guidelines recommend assessing tobacco use at every health care visit and recording as a vital sign, and all adults who use tobacco should be counseled to quit, including behavioral interventions.²¹ Pharmacological therapies to assist with smoking cessation include nicotine replacement therapy, bupropion, or varenicline, although data are limited specifically in T2D.⁹³

Quitting smoking can be associated with weight gain.^{94,95} Smoking cessation without subsequent weight gain is associated with a reduced risk of CVD and mortality among smokers with T2D.^{94,95} Weight gain after smoking cessation attenuates the reduction in risk of developing CVD, but does not attenuate the beneficial effect on mortality.^{94,95} Thus, weight management strategies should be discussed to maximize the health benefits of smoking cessation.⁹⁵



Lifestyle Management in T2D Summary

Lifestyle behavior change and management is key to CVD risk reduction in T2D, but can be difficult to achieve through routine care. Important relationships also exist between glycemic control and concomitant depression, stress, and anxiety.^{96,97} Thus, patient-centered, culturally appropriate recommendations through diabetes self-management education and support and medical nutrition therapy are key to meeting individualized goals for behavioral change and diabetes self-management.^{20,22,33,98}

GLYCEMIC TARGETS AND CONTROL IN T2D

Lessons Learned From the Observational Studies

Higher glycemia increases the risk of CVD in T2D.^{99,100} A 1-unit increase in A1c among individuals with diabetes increases the risk of macrovascular disease (MI, stroke, or PAD) by 18%, and attaining a target of $<7\%$ reduces CVD risk by 37% over 11 years.^{99,101} Observational studies show the lowest mortality at A1c 6% to 6.9% with a dose-dependent increase in mortality with each 1-unit increase in A1c.¹⁰² Fasting glucose in the prediabetes range (100–125 mg/dL) and in the diabetes range (≥ 126 mg/dL) moderately and dramatically increases CVD risk 3 to 4 times over 30 years, respectively.¹⁰³

Table 2. Study Characteristics of Cardiovascular Outcome Trials Since January 1, 2014

Characteristics		1° Outcome				2° Outcomes							
		A1C↓	HR (95% CI)	↓ MACE P value Superiority	HR (95% CI)	Nonfatal stroke	Nonfatal MI	CV death	Heart failure hospitalization	Renal outcome			
Study	Population studied: Type 2 diabetes and one of the following:	N	Mean age, y	Baseline A1C, %	Median follow-up, y	CVD, %	A1C↓ between groups	HR (95% CI)	Nonfatal stroke	Nonfatal MI	CV death	Heart failure hospitalization	Renal outcome
DPP4 inhibitors													
*Saxagliptin SAVOR-TIMI ⁵³ ¹⁰⁸	Age ≥40 y and CAD, CVA, or PVD or men ≥55 y or women ≥60 y with hypertension, dyslipidemia, or smoking	16 492	65	8	2.1	78	-0.2% P<0.001	1.00 (0.89-1.12) P=0.99 3-pt MACE	1.11 (0.88-1.39)	0.95 (0.80-1.12)	1.03 (0.87-1.22)	1.27 (1.07-1.51)	1.08 (0.88-1.32)
*Alogliptin EXAMINE ¹⁰⁹	MI or UA hospitalization within the previous 15-90 d	5380	61	8	1.5	100	-0.36% P<0.001	0.96 (≤1.16) P=0.32 3-pt MACE	0.91 (0.55-1.50)	1.08 (0.88-1.33)	0.79 (0.60-1.04)	1.07 (0.79-1.46)	N/A
Stagliptin TECOS ¹¹⁰	Age ≥50 y with CAD, stroke, or PAD	14 671	65	7.2	3	100	-0.29% P<0.001	0.98 (0.89-1.08) P=0.65 4-pt MACE	0.97* (0.79-1.19)	0.95* (0.81-1.11)	1.03 (0.89-1.19)	1.00 (0.83-1.20)	N/A
Linagliptin CARMELINA ¹¹¹	High CV risk (CAD, stroke, PVD, and urine-albumin creatinine ratio >200 mg/g), and high renal risk (↓ eGFR and micro- or macroalbuminuria)	6991	66	8	2.2	57	-0.36% P<0.001	1.02 (0.89-1.17) P=0.74 3-pt MACE	0.88 (0.63-1.23)	1.15 (0.91-1.45)	0.96 (0.81-1.14)	0.90 (0.74-1.08)	1.04 (0.89-1.22)
Linagliptin CAROLINA ¹¹²	High CV risk and A1C of 6.5%-8.5%	6042	64	7.2	6.3	42	0%	0.98 (0.84-1.14) P=0.76 3-pt MACE	0.87 (0.66-1.15)	1.01 (0.80-1.28)	1.00 (0.81-1.24)	1.21 (0.92-1.59)	N/A
GLP-1 receptor antagonists													
Lixisenatide ELIXA ¹¹³	MI or UA hospitalization within the previous 180 d	6068	60	7.6	2.1	100	-0.27% P<0.001	1.02 (0.89-1.17) P=0.81 4-pt MACE	1.12 (0.79-1.58)	1.03 (0.87-1.22)	0.98 (0.78-1.22)	0.96 (0.75-1.23)	N/A
Liraglutide LEADER ^{71,114}	Age ≥50 y with CAD, CVA, PAD, HF, or CKD stage ≥3 Age ≥60 y with microalbuminuria/proteinuria, hypertension with LVH, LV dysfunction, or ABI <0.9	9 340	64	8.7	3.8	81	-0.40% (-0.45 to -0.34)	0.87 (0.78-0.97) P=0.01 3-pt MACE	0.89 (0.72-1.11)	0.88 (0.75-1.03)	0.78 (0.66-0.93)	0.87 (0.73-1.05)	0.78 (0.67-0.92)
Semaglutide SUSTAIN-6 ¹¹⁵	Age ≥50 y with CAD, CVA, PAD, HF, or CKD stage ≥ 3 Age ≥60 y with microalbuminuria/proteinuria, hypertension with LVH, LV dysfunction, or ABI <0.9	3297	65	8.7	2.1	83	(0.5 mg): -0.7% (1.0 mg): -1.0% P<0.001	0.74 (0.58-0.95) P=0.02 3-pt MACE	0.61 (0.38-0.99)	0.74 (0.51-1.08)	0.98 (0.65-1.48)	1.11 (0.77-1.61)	0.64 (0.46-0.88)
Semaglutide Oral PIONEER-6 ¹¹⁶	Age ≥50 y with established CVD or CKD, or age ≥60 y with CV risk factors	3183	66	8.2	1.3	85	-0.7% (N/A)	0.79 (0.57-1.11) P=0.17 3-pt MACE	0.74 (0.35-1.57)	1.18 (0.73-1.90)	0.49 (0.27-0.92)	0.86 (0.48-1.55)	N/A

(Continued)

Table 2. Continued

Characteristics		1° Outcome						2° Outcomes						
		HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)		
Study	Population studied: Type 2 diabetes and one of the following:	N	Mean age, y	Baseline A1C, %	Median follow-up, y	CVD, %	A1C↓	A1C↓ between groups	↓ MACE P value Superiority	Nonfatal stroke	Nonfatal MI	CV death	Heart failure hospitalization	Renal outcome
Exenatide EXSCEL ¹¹⁷	CAD, ischemic CVA, ≥50% carotid artery stenosis, or PAD	14 752	62	8	3.2	73	A1C↓ -0.53% P<0.001	0.91 (0.83-1.00) P=0.06 3-pt MACE	0.85 (0.70-1.03)*	0.97 (0.85-1.10)*	0.88 (0.76-1.02)	0.94 (0.78-1.13)	0.88 (0.76-1.01)	
Albiglutide HARMONY ¹¹⁸	Age ≥40 y with CAD, ischemic CVA, ≥50% carotid artery stenosis/procedure, or PAD	9463	64	8.7	1.6	100	A1C↓ -0.52% (-0.58 to -0.45)	0.78 (0.68-0.90) P=0.0006 3-pt MACE	0.86 (0.66-1.14)*	0.75 (0.61-0.90)*	0.93 (0.73-1.19)	N/A	N/A	
Dulaglutide REWIND ¹¹⁹	Age ≥50 y with CAD, ischemic CVA, carotid or PAD, or ≥2 of the following: hypertension, dyslipidemia, smoking, or obesity	9901	66	7.3	5.4	31	A1C↓ -0.61% P<0.0001	0.88(0.68-0.90) P=0.026 3-pt MACE	0.76 (0.61-0.95)	0.96 (0.79-1.16)	0.91 (0.78-1.06)	0.93 (0.77-1.12)	0.85 (0.77-0.93)	
Elipegnatide AMPLITUDE-O ¹²⁰	Age ≥18 y with CAD, ischemic CVA or PAD, or age ≥50 y (M) or 55 y (F) with CKD (eGFR 25.0-59.9 mL·min ⁻¹ ·1.73 m ⁻²) and ≥1 CV risk factor	4076	65	8.9	1.8	90	A1C↓ -1.24% (-1.17 to -1.32)	0.73 (0.58-0.92) P=0.007 3-pt MACE	0.80 (0.48-1.31)	0.78 (0.55-1.10)	0.72 (0.50-1.03)	0.61 (0.38-0.98)	0.68 (0.57-0.79)	
Sodium-glucose cotransporter-2 inhibitors														
Empagliflozin EMPA-REG ^{121,122}	MI, multivessel CAD, CAD with ischemia/UA, stroke, or PAD	7020	63	8.7	3.1	100	A1C↓ 10 mg: -0.24% (-0.40 to -0.08) 25 mg: -0.36% (-0.51 to -0.20)	0.86 (0.74-0.99) P=0.04 3-pt MACE	1.24 (0.92-1.67)	0.87 (0.70-1.09)	0.62 (0.49-0.77)	0.65 (0.50-0.85)	0.54 (0.40-0.75)	
Canagliflozin CANVAS ¹²³	≥30 y with symptomatic CVD ≥50 y with ≥2 of the following: diabetes for ≥10 y, smoking, hypertension, micro-/macroalbuminuria, HDL<38.7 mg/dL	10 142	63	8.2	3.6	66	A1C↓ -0.58% (-0.61 to -0.56)	0.86 (0.75-0.97) P=0.02 3-pt MACE	0.90 (0.71-1.15)	0.85 (0.69-1.05)	0.87 (0.72-1.06)	0.67 (0.52-0.87)	0.60 (0.47-0.77)	
Dapagliflozin DECLARE-TIMI ¹²⁴	CAD, CVA, or PAD Men ≥55 y or women ≥60 y with hypertension, dyslipidemia, or smoking	17 160	64	8.3	4.2	41	A1C↓ -0.42% (-0.40 to -0.45)	0.93 (0.84-1.03) P=0.17 3-pt MACE	1.01 (0.84-1.21)	0.89 (0.77-1.01)	0.98 (0.82-1.17)	0.73 (0.61-0.88)	0.76 (0.67-0.87)	
Ertugliflozin VERTIS-CV ¹²⁵	≥40 y with atherosclerotic CVD (CAD, cerebrovascular, or PAD)	8246	64	8.2	3.5	100	A1C↓ ≈ -0.3%	0.97 (0.85-1.11) 3-pt MACE	1.00 (0.76-1.32)	1.04 (0.86-1.27)	0.92 (0.77-1.11)	0.70 (0.54-0.90)	0.81 (0.63-1.04)	
Sotagliflozin SCORED ¹²⁶	≥18 y with CKD (eGFR, 25-60 mL·min ⁻¹ ·1.73 m ⁻²), and ≥1 major CV risk factor in ≥18 y or ≥2 minor CV risk factors in ≥55 y	10 584	69	8.3	1.3	49	A1C↓ -0.42% (-0.47 to -0.38)	0.72 (0.63-0.83) 4-pt MACE	N/A	N/A	0.77 (0.65-0.91)	0.67 (0.55-0.82)	0.71 (0.46-1.08)	

(Continued)

CLINICAL STATEMENTS AND GUIDELINES

Table 2. Continued

Characteristics	Population studied: Type 2 diabetes and one of the following:	N	Mean age, y	Baseline A1C, %	Median follow-up, y	CVD, %	A1C↓	1° Outcome		2° Outcomes			
								HR (95% CI)	↓ MACE P value Superiority	HR (95% CI)	Nonfatal stroke	Nonfatal MI	CV death
Study	18–85 y hospitalized with HF and received IV diuretics	1222	70	7.2	0.8	N/A	N/A	0.72 (0.56–0.92)	N/A	N/A	0.84 (0.58–1.22)	0.64 (0.49–0.83)	N/A
Insulin													
Insulin Degludec DEVOTE ²⁸	≥50 y and CAD/MI, CVA, PAD, HF, or CKD (GFR 30–59)	7637	65	8.4	2	63	0.01% P=0.78	0.91 (0.78–1.06) (P=0.21)	0.90 (0.65–1.23)	0.85 (0.68–1.06)	0.96 (0.76–1.21)
	≥60 y with micro/ macroalbuminuria, hypertension with LVH, LV dysfunction, ABI <0.9							3-pt MACE					
Glitazars													
Aleglitazar ALECARDIO ²⁹	MI or UA hospitalization	7226	61	7.8	2	100	–0.60% P<0.001 at 3 mo	0.96 (0.83–1.11) P=0.57	0.98 (0.66–1.45)	0.89 (0.74–1.07)	1.15 (0.87–1.50)	1.22 (0.94–1.59)	2.85 (2.25–3.60)
Peroxisome proliferator-activated receptor gamma agonists													
Pioglitazone TOSCA-IT ³⁰ (Unblinded Trial, Block Randomized)	All-cause death, nonfatal MI, nonfatal stroke, or urgent coronary revascularization (futility)	3028	62	7.7	5.7	11	0.06, P=0.01	0.96 (0.74–1.26) P=0.79	0.79 (0.41–1.53)	0.87 (0.48–1.55)	1.03 (0.89–1.19)†
Pioglitazone IRIS ^{31,32}	Insulin resistance without diabetes, with recent CVA	3876	64	5.8	4.8	100	...	0.76 (0.62–0.93) P=0.007	0.82 (0.61–1.10)*	...	0.93 (0.73–1.17)§

ABI indicates ankle brachial index; CAD, coronary artery disease; CKD, chronic kidney disease; CVA, cerebrovascular events; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HF, heart failure; LV, left ventricular; LVH, left ventricular hypertrophy; MACE, major adverse cardiovascular events; MI, myocardial infarction; N/A, not available; PAD, peripheral artery disease; pt, point; PVD, peripheral vascular disease; SBP, systolic blood pressure; and UA, unstable angina.

3-Point MACE: Cardiovascular death, nonfatal MI, nonfatal stroke, hospitalization for UA or HF; 4-point MACE for TECOS, ELIXA: Cardiovascular death, nonfatal MI, nonfatal stroke, hospitalization for UA; 2-pt MACE for IRIS: Fatal or nonfatal stroke or MI; 2-pt MACE for SOLOIST-WHF: Deaths from cardiovascular causes and hospitalizations and urgent visits for HF.

Renal Composite Outcome: SAVOR-TIMI53 (Saxagliptin): Doubling of creatinine level, initiation of dialysis, renal transplantation, or creatinine >6.0 mg/dL; CARMELINA (Linagliptin): First sustained end-stage renal disease, death attributable to renal failure, or sustained decrease of ≥40% in estimated glomerular filtration rate from baseline. (Participants with preexisting end-stage renal disease were excluded from the trial.) LEADER (Liraglutide): Composite of new-onset persistent macroalbuminuria, persistent doubling of the serum creatinine level, end-stage renal disease, or death due to renal disease; SUSTAIN-6 (Semaglutide): New or worsening nephropathy includes persistent macroalbuminuria, persistent doubling of the serum creatinine level and a creatinine clearance of less than 45 mL·min⁻¹·1.73 m⁻² of body-surface area (according to the Modification of Diet in Renal Disease criteria), or the need for continuous renal-replacement therapy; EXSCCEL (Exenatide): 40% eGFR decline, renal replacement, renal death, or new macroalbuminuria; EMPA-REG (Empagliflozin): Doubling of the serum creatinine level, the initiation of renal-replacement therapy, or death from renal disease; CANVAS (Canagliflozin): Sustained 40% reduction in the estimated glomerular filtration rate, the need for renal-replacement therapy, or death from renal disease; DECLARE-TIMI68 (Dapagliflozin): ≥40% decrease in estimated glomerular filtration rate to <60 mL·min⁻¹·1.73 m⁻² of body-surface area, new end-stage renal disease, or death from renal or cardiovascular causes; VERTIS-CV (Ertugliflozin): Death from renal causes, renal replacement therapy, or doubling of the serum creatinine level; SCORED (Sotagliflozin): First occurrence of a sustained decrease of ≥50% in the eGFR from baseline for ≥30 days, long-term dialysis, renal transplantation, or sustained eGFR of <15 mL·min⁻¹·1.73 m⁻² for ≥30 days; ALECARDIO (Aleglitazar): Composite renal end point of the development of end-stage renal disease, doubling of serum creatinine, or >50% increase in creatinine leading to study drug discontinuation; AMPLITUDE-O (Epipeglatide): Composite renal end point of incident macroalbuminuria, increase in the urinary albumin-to-creatinine ratio of ≥30% from baseline, a sustained decrease in the eGFR of ≥40% for ≥30 days, renal-replacement therapy for ≥90 days, or a sustained eGFR of <15 mL·min⁻¹·1.73 m⁻² for ≥30 days; A1C Difference: Difference of A1C between active agent and placebo treatment groups (with Least Squares P value or 95% CI) at study end.

*Fatal and nonfatal MI or stroke.
 †Published before January 1, 2014.
 ‡New or worsening nephropathy.
 §Death from any cause.

Randomized Trials With Intensive Glycemic Control Using Traditional Antihyperglycemic Drugs

Earlier randomized controlled trials (RCTs) focused on CVD prevention in T2D through intensive glycemic control targeting an A1c <6% to 6.5% compared with standard therapy (A1c 7%–7.9%).^{104–106} In meta-analyses, Ray et al¹⁰⁴ found a 17% reduction in MI and a 15% reduction in coronary heart disease with tight glycemic control, but no effect on stroke or all-cause mortality. Kelly et al¹⁰⁵ found a 16% reduction in nonfatal MI, no effect on cardiovascular or all-cause mortality, and twice the risk of hypoglycemia with intensive control. Bousageon et al¹⁰⁶ found no effect of intensive glycemic control on overall or cardiovascular mortality but a 2-fold higher risk of severe hypoglycemia and 47% increase in HF. These results suggest that any potential benefit of intensive glycemic control on CVD is modest and may be counterbalanced by increased risk of hypoglycemia and death, especially in older individuals. Most of these trials studied intensive glucose control with insulin, whereas intensive glucose control with lifestyle and newer antihyperglycemic agents is an area for further study.

CVOTs of Newer Antihyperglycemic Agents

Background

Because rosiglitazone was linked to increased risk of HF and MI, the FDA mandated that, in addition to demonstrating cardiovascular safety in phase 3 trials, newer agents should undergo a postmarketing phase 4 CVOT and show noninferiority to standard care in patients with preexisting CVD over a 2-year follow-up period.¹⁰⁷ Since 2014, there have been a number of CVOTs using newer antihyperglycemic agents with traditional glucose-lowering effects, but with the addition of a significant number of favorable cardiometabolic effects (Table 2).

Dipeptidyl Peptidase-4 Inhibitors

Dipeptidyl peptidase-4 (DPP4) inhibitors inhibit the DPP4 enzyme, prolonging the action of the incretin hormones GLP-1 and glucose-dependent insulinotropic polypeptide leading to inhibition of glucagon release, increased insulin secretion, decreased gastric emptying, and lower glucose. DPP4 inhibitors tested in CVOTs include saxagliptin (SAVOR-TIMI53 [Saxagliptin Assessment of Vascular Outcomes Recorded in Patients With Diabetes Mellitus–Thrombolysis in Myocardial Infarction 53]),¹⁰⁸ alogliptin (EXAMINE [Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care]),¹⁰⁹ sitagliptin (TECOS [Trial Evaluating Cardiovascular Outcomes With Sitagliptin]),¹¹⁰ linagliptin (CARMELINA [Cardiovascular and Renal Microvascular Outcome Study With Linagliptin]) and CAROLINA [Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes])^{111,112} with inclusion criteria ranging from high cardiovascular risk to known CVD with

median follow-up of 1.5 to 3 years. DPP4 inhibitors reduced A1c by 0.2% to 0.36% but showed no reduction in MACE (Table 2). There are concerns for increasing the risk of HF with saxagliptin but not the other DPP4 inhibitors.^{133,134}

GLP-1 Receptor Agonists

GLP-1RAs stimulate insulin release, inhibit glucagon release, and slow gastric emptying to slow glucose absorption (Figure 2).¹³⁵ GLP-1RAs are administered as daily (liraglutide, lixisenatide) or once weekly (albiglutide, dulaglutide, efpeglenatide, exenatide, and semaglutide) injections. Semaglutide is also available for oral administration. Seven GLP-1RAs have completed CVOT trials: lixisenatide (ELIXA [Evaluation of Lixisenatide in Acute Coronary Syndrome]),¹¹³ liraglutide (LEADER [Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results]),^{71,114} semaglutide (SUSTAIN-6 [Trial to Evaluate Cardiovascular and Other Long-Term Outcomes With Semaglutide in Subjects With Type 2 Diabetes]), PIONEER-6 [Peptide Innovation for Early Diabetes Treatment 6]),^{115,116} exenatide (EXSCCEL [Exenatide Study of Cardiovascular Event Lowering Trial]),¹¹⁷ albiglutide (HARMONY [Albiglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Cardiovascular Disease]),¹¹⁸ dulaglutide (REWIND [Researching Cardiovascular Events With a Weekly Incretin in Diabetes]),¹³⁶ and efpeglenatide (AMPLITUDE-O [A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk]).¹²⁰ Established ASCVD at baseline ranged from 31% in REWIND up to 100% in ELIXA and HARMONY. GLP-1RAs decreased A1c (0.27%–1.0%), weight (0.8–4 kg), and systolic BP (SBP; 0.8–2.6 mmHg) over 2.1 to 3.8 years (Table 2).

Although lixisenatide, exenatide, and oral semaglutide were noninferior to standard care, liraglutide, semaglutide SQ, albiglutide, dulaglutide, and efpeglenatide showed a statistically significant 12% to 27% MACE reduction (Table 2). This reduction was driven by fewer cardiovascular deaths with liraglutide, less MI with albiglutide, and fewer strokes with injectable semaglutide and dulaglutide. In meta-analyses, GLP-1RAs reduced risk of 3-point MACE (10%–12%), cardiovascular mortality (12%–13%), all-cause mortality (12%), MI (6%–9%), and stroke (13%–14%).^{137,138} There was no significant effect on hospitalizations for HF (HHF). In subgroup analyses, GLP-1RAs performed better among individuals without HF, except for albiglutide.

Adverse Effects

Gastrointestinal disturbances and increased heart rate are common GLP-1RA side effects. Major concerns regarding pancreatitis, pancreatic cancer, and medullary

Potential Indirect Cardiovascular Effects of GLP-1R Agonists




Figure 2. Proposed indirect effects of GLP-1R agonists.

GLP-1 indicates glucagon-like peptide 1; LV, left ventricular; and SNS, sympathetic nervous system. Adapted with permission from Ussher et al.¹³⁵ © 2014 American Heart Association, Inc.



thyroid cancer have not panned out in meta-analyses of clinical trials.¹³⁹ Retinopathy occurred at a higher rate with semaglutide.¹³⁹

Sodium-Glucose Cotransporter-2 Inhibitors

SGLT-2Is reduce filtered glucose reabsorption in the proximal renal tubule, leading to glucosuria (Figure 3).¹⁴⁰ SGLT-2Is tested in CVOTs: empagliflozin (EMPA-REG [BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients]),^{121,122} canagliflozin (CANVAS [Canagliflozin Cardiovascular Assessment Study]),¹²³ dapagliflozin (DECLARE-TIMI 58 [Dapagliflozin Effect on Cardiovascular Events trial]),¹²⁴ ertugliflozin (VERTIS-CV [Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes trial]),¹²⁵ and sotagliflozin (SCORED [Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk]; SOLOIST-WHF [Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure]; SGLT-1/2I).^{126,127} All of the EMPA-REG and VERTIS-CV, 41% of CANVAS, 66% of DECLARE-TIMI 58, and 49% of SCORED subjects had established ASCVD at baseline. SGLT-2Is lowered A1c (0.36%–0.58%), SBP (2–3.9 mmHg), and weight (1.0–2.8 kg) compared with placebo over 1 to 4 years (Table 2).

EMPA-REG and CANVAS both showed a significant 14% lower risk of MACE.^{121,123} MACE reduction with empagliflozin was primarily driven by a significant (38%) reduction in cardiovascular death. In CANVAS, none of the individual MACE components (cardiovascular death, MI, or stroke) were significantly reduced except in the established ASCVD subgroup.^{121,123} CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) established the MACE benefit of canagliflozin in those with diabetes, chronic kidney disease (CKD), and proteinuria.¹⁴¹ DECLARE-TIMI 58 and VERTIS-CV did not demonstrate a significant MACE reduction (3%–7%) in overall, primary, or secondary prevention cohorts, although there was a trend toward benefit in secondary prevention in DECLARE-TIMI 58.¹²⁴ CANVAS did not show MACE benefit in the primary prevention subcohort either.¹²³

The SGLT-2I trials have shown a congruently lower risk (27%–35%) of HHF.^{121,123–125} In magnitude, this is the largest cardiovascular benefit of SGLT-2Is. HHF was reduced more in those with CVD but appeared independent of baseline HF. DAPA-HF (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure) and EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction) trials confirmed reduction in HHF and cardiovascular death in patients with preexisting HF with or without diabetes.^{142,143}

SGLT2 inhibitors modulate several CV risk factors, but direct mechanism of cardioprotection unknown




Figure 3. Potential risk factor targets of SGLT-2 inhibitors.

BP indicates blood pressure; CV, cardiovascular; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; and SGLT-2, sodium-glucose cotransporter-2.

Adapted from Inzucchi et al.¹⁴⁰ ©2015 The Authors. Published on behalf of the Authors by Sage Publishing. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Meta-analyses of CVOTs (excluding ertugliflozin and sotagliflozin) reveal that SGLT-2is reduced MACE (11%), cardiovascular mortality or HHF (23%), all-cause mortality (15%), MI (11%), and cardiovascular mortality (16%) with no effect on stroke.¹³⁸ The 3-point MACE, MI, and cardiovascular mortality benefits were only reduced among those with established ASCVD, whereas the HFs were reduced independent of baseline ASCVD or HF.¹³⁸ Real-world observational studies have largely shown similar findings of reduced HHF and cardiovascular mortality, but additionally suggest lower risk of MI and stroke (Table 3).^{144–155}

Adverse Effects

Higher risk of genital and urinary tract mycotic and bacterial infections exists across the SGLT-2i class because of glucosuria. There have been rare postmarketing reports of perineal necrotizing fasciitis including 55 cases from March 2013 to January 2019, with no clear causative link but requiring vigilance.¹⁵⁷ Polyuria-related side effects of dehydration and acute kidney injury are more likely with higher dosages and preexisting CKD and HF. Studies have shown reduced bone mineral density at the

hip with SGLT-2is, but meta-analyses of clinical trials have not shown increased hip fracture risk.¹⁶²

Insulin Degludec, Aloglitazar, and Pioglitazone

Glitazars are dual peroxisome proliferator-activated receptor agonists that lower glucose and lipids. Glitazones improve insulin sensitivity through peroxisome proliferator-activated receptor gamma and impact lipid metabolism through peroxisome proliferator-activated receptor alpha. Insulin Degludec (DEVOTE [A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events]),¹²⁸ Aloglitazar (ALECARDIO [The Effect of Aloglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus]),¹²⁹ and Pioglitazone (TOSCA-IT [Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents: Intervention Trial])¹³⁰ did not demonstrate CVD risk reduction. Pioglitazone (IRIS [Insulin Resistance Intervention After Stroke]) after ischemic stroke or transient ischemic attack in participants with insulin resistance (without diabetes) reduced the risk of fatal or

Table 3. Observational Studies of SGLT-2 Inhibitors

Study	Study characteristics and design	Population studied: type-2 diabetes with and without baseline CVD defined as:	N	Baseline CVD, %	Mean follow-up time	Mean age with CVD at baseline	Mean age without CVD at baseline	Outcomes Hazard ratio (95% CI)					Composite outcomes
								Heart failure hospitalization	Stroke	Myocardial infarction	Mortality		
CVD-REAL													
SGLT-2 inhibitor vs oGLD CVD-REAL ¹⁵⁴ (United States, United Kingdom, Sweden, Norway, and Denmark)	Multinational observational study Propensity score matching	Previous history of acute MI, UA, stroke, heart failure, transient ischemic attack, coronary revascularization, occlusive PAD	306 156	13	313–387 d SGLT-2i 299–383 d oGLDs	62.7 SGLT-2i 63.5 oGLD	56.0 SGLT-2i 56.0 oGLD	0.72 (0.63–0.82) with CVD 0.61 (0.48–0.78) without CVD	N/A	N/A	0.56* (0.44–0.70) with CVD 0.56* (0.50–0.63) without CVD	0.63† (0.57–0.70) with CVD 0.56† (0.50–0.62) without CVD	
SGLT-2 inhibitor vs oGLD (on-treatment) CVD-REAL ¹⁴⁵ (United States, Sweden, Norway and Denmark)	Multinational observational study Nonparadoxical propensity score matching	Previous history of acute MI, UA, stroke, heart failure, transient ischemic attack, coronary revascularization, occlusive PAD	205 160	14	254 d SGLT-2i 232 d oGLD	57 No differentiation by baseline CVD status	N/A	N/A	0.80 (0.66–0.97)	0.78 (0.65–0.95)	N/A	N/A	
SGLT-2 inhibitor vs oGLD (intent-to-treat) CVD-REAL ¹⁴⁸ (United States, Sweden, Norway, and Denmark)	Multinational observational study Nonparadoxical propensity score matching	Previous history of acute MI, UA, stroke, heart failure, transient ischemic attack, coronary revascularization, occlusive PAD	205 160	14	339 d SGLT-2i 332 d oGLD	57 No differentiation by baseline CVD status	N/A	N/A	0.83 (0.71–0.97)	0.85 (0.72–1.00)	N/A	N/A	
SGLT-2 inhibitor vs oGLDs CVD-REAL ¹⁴⁷ (United States, Norway, Denmark, Sweden, Germany;† United Kingdom)	Retrospective multinational observational study 1:1 propensity score matched	Previous history of acute MI, UA, heart failure, atrial fibrillation, stroke, PAD	309 056	13.1 oGLDs	253 d SGLT-2i 283 d oGLDs	56.9 SGLT-2i 57.0 oGLDs No differentiation by baseline CVD status	N/A	0.61 (0.51–0.73)	N/A	0.49* (0.41–0.57)	N/A	0.54† (0.48–0.60)	
SGLT-2 inhibitor vs oGLDs CVD-REAL Nordic ¹⁴⁸ (Denmark, Norway, and Sweden)	Retrospective multinational observational study Propensity score matched	Previous history of MI, stroke, UA, heart failure, atrial fibrillation	91 320	24.9 SGLT-2i 24.8 oGLDs	0.9 y	61.2 SGLT-2i 61.2 oGLDs No differentiation by baseline CVD status	N/A	0.70 (0.61–0.81)	0.86 (0.72–1.04) nonfatal	0.87 (0.73–1.03) nonfatal	0.51 (0.45–0.58)* 0.53 (0.40–0.71)§ Baseline CVD 0.60 (0.42–0.85)§ No CVD: 0.70 (0.59–0.83) No CVD: 0.90 (0.76–1.07)	0.78 (0.69–0.87)† Baseline CVD 0.70 (0.59–0.83) No CVD: 0.90 (0.76–1.07)	
SGLT-2 inhibitor vs oGLD (intent-to-treat) CVD-REAL 2 ¹⁴⁹ (South Korea, Japan, Singapore, Israel, Australia, and Canada)	Retrospective multinational observational study Nonparadoxical propensity score matching	Previous history of acute MI, UA, stroke, heart failure, atrial fibrillation, PAD	470 128	26.8 SGLT-2i 25.6 oGLD	374 d SGLT-2i 392 d oGLD	56.7 No differentiation by CVD status No postmatch data available	N/A	0.64 (0.50–0.82)	0.68 (0.55–0.84)	0.81 (0.74–0.88)	0.51 (0.37–0.70)*	0.60 (0.47–0.76)†	

(Continued)

Downloaded from http://ahajournals.org by on January 10, 2022

Table 3. Continued

Study characteristics		Outcomes Hazard ratio (95% CI)										
Study	Study characteristics and design	Population studied: type-2 diabetes with and without baseline CVD defined as:	N	Baseline CVD, %	Mean follow-up time	Mean age with CVD at baseline	Mean age without CVD at baseline	Heart failure hospitalization	Stroke	Myocardial infarction	Mortality	Composite outcomes
Truven Health MarketScan database												
SGLT-2 inhibitor vs sulfonylureas	Retrospective cohort analysis Propensity score matching	Previous history of MI, angina pectoris, stroke, coronary revascularization, coronary artery disease, cerebrovascular diseases, cerebral infarction, transient ischemic attack, cerebral hemorrhage and subarachnoid hemorrhage	125 534	14.28 SGLT-2i 14.28 sulfonylureas	12 mo	54 SGLT-2i 54 sulfonylureas No differentiation by CVD status	54 SGLT-2i 54 sulfonylureas No differentiation by CVD status	0.48 (0.40–0.57)	0.69 (0.61–0.78)	0.70 (0.61–0.81)	N/A	0.50 (0.45–0.55)
SGLT-2 inhibitor vs DPP-4	Retrospective cohort analysis Propensity score matching	Previous history of MI, angina pectoris, stroke, coronary revascularization, coronary artery disease, cerebrovascular disease, cerebral infarction, transient ischemic attack, cerebral hemorrhage and subarachnoid hemorrhage	133 266	12.72 SGLT-2i 14.28 sulfonylureas	12 mo	55 SGLT-2i 54 sulfonylureas No differentiation by CVD status	55 SGLT-2i 54 sulfonylureas No differentiation by CVD status	0.54 (0.48–0.60)	0.61 (0.50–0.73)	0.72 (0.63–0.82)	N/A	0.57 (0.52–0.62)
DPP-4 inhibitors vs sulfonylureas	US retrospective observational study Propensity scoring	Previous history of acute MI, ischemic heart disease, stroke, PAD, percutaneous coronary intervention, revascularizations, bypasses, stenting, angioplasty, atherectomy, or lower extremity amputation	218 556	24.94	6 mo	63.9 DPP-4i 63.9 sulfonylureas	54.7 DPP-4i 54.8 sulfonylureas	0.95 (0.78–1.15) with CVD 0.59 (0.38–0.89) without CVD	0.87 (0.65–1.16) with CVD 0.53 (0.37–0.74) without CVD	0.84 (0.65–1.09) with CVD 0.74 (0.57–0.95) without CVD	N/A	0.87 (0.78–0.96) with CVD 0.70 (0.61–0.81) without CVD
Korean HIRA												
SGLT-2 inhibitor vs DPP-4i	South Korean nationwide population-based cohort study Propensity score matching	Previous history of acute MI, other ischemic heart disease, heart failure, cerebral infarction, cerebrovascular event, occlusive PAD, coronary revascularization	118 958	18.8 SGLT-2i 18.8 DPP-4i	318.5 d	59.7 SGLT-2i 59.7 DPP-4i	51.9 SGLT-2i 51.7 DPP-4i	0.66 (0.58–0.75)	N/A	N/A	N/A	N/A
Optum Clinformatics Datamart												
Canagliflozin vs DPP-4 inhibitor	Population-based retrospective cohort Pairwise 1:1 propensity score matched	Previous history of coronary heart disease, cerebrovascular disease, peripheral vascular disease, and heart failure	35 334	30.10 SGLT-2i 30.38 DPP-4i	0.6 y	56.5 SGLT-2i 56.5 DPP-4i No differentiation by CVD status	56.5 SGLT-2i 56.5 DPP-4i No differentiation by CVD status	0.70 (0.54–0.92)	N/A	N/A	N/A	0.89 (0.68–1.17)#

(Continued)

CLINICAL STATEMENTS AND GUIDELINES

Table 3. Continued

Study characteristics		Outcomes Hazard ratio (95% CI)										
Study	Study characteristics and design	Population studied: type-2 diabetes with and without baseline CVD defined as:	N	Baseline CVD, %	Mean follow-up time	Mean age with CVD at baseline	Mean age without CVD at baseline	Heart failure hospitalization	Stroke	Myocardial infarction	Mortality	Composite outcomes
Canagliflozin vs GLP-1RA Optum Clinformatics Datamart ⁵² (United States)	US Population-based retrospective cohort Pairwise 1:1 propensity score matched	Previous history of coronary heart disease, cerebrovascular disease, peripheral vascular disease, and heart failure	41 078	31.38 SGLT-2i 31.92 GLP-1RA	0.6 y	56.8 SGLT-2i 56.7 GLP-1RA No differentiation by CVD status	56.8 SGLT-2i 56.7 GLP-1RA No differentiation by CVD status	0.61 (0.47–0.78)	N/A	N/A	N/A	1.03 (0.79–1.35)#
Canagliflozin vs sulfonylurea Optum Clinformatics Datamart ⁵² (United States)	US Population-based retrospective cohort Pairwise 1:1 propensity score matched	Previous history of coronary heart disease, cerebrovascular disease, peripheral vascular disease, and heart failure	34 708	29.09 SGLT-2i 28.93 sulfonylurea	0.6 y	55.9 SGLT-2i 55.8 sulfonylurea No differentiation by CVD status	55.9 SGLT-2i 55.8 sulfonylurea No differentiation by CVD status	0.51 (0.38–0.67)	N/A	N/A	N/A	0.86 (0.65–1.13)#
Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World (EASEL) Cohort												
SGLT-2 inhibitor vs oGLDs US Department of Defense Military Health System ¹⁵³ (United States)	Retrospective, observational study Propensity matching	Previous history of coronary artery disease, heart failure, cerebrovascular disease, and peripheral artery disease	25 258	100	1.6 y	65.8 SGLT2i 65.9 oGLDs No differentiation by CVD status	65.8 SGLT2i 65.9 oGLDs No differentiation by CVD status	0.57 (0.45–0.73)	0.85 (0.66–1.10)	0.81 (0.64–1.03)	0.57 (0.49–0.66)*	0.67 (0.60–0.75)¶
HealthCore Integrated Research Environment database												
SGLT-2 inhibitors vs DPP4 inhibitors HealthCore Integrated Research Environment database ¹⁵⁴ (United States)	Retrospective observational study Propensity score matched	N/A	14 697	13.7 SGLT-2i 13.5 DPP-4i	22.9 mo SGLT2i 24 mo DPP4i	54.9 SGLT2i 55.1 DPP4i No differentiation by CVD status	54.9 SGLT2i 55.1 DPP4i No differentiation by CVD status	0.68 (0.54–0.86)	N/A	N/A	N/A	N/A
The Health Improvement Network												
Dapagliflozin vs oGLD The Health Improvement Network ¹⁵⁵ (United States)	Retrospective cohort study Propensity score matched	Prior history of ischemic heart disease, stroke, and heart failure	22 124	19.6	9.8 y SGLT2i 8.5 y oGLDs	58.3 SGLT2i 58.5 oGLDs (with CVD)	58.3 SGLT2i 58.5 oGLDs (with CVD)	N/A	N/A	N/A	Adjusted incidence rate ratio: 0.50 (0.33–0.75)#	N/A

CVD indicates cardiovascular disease; CVD-REAL, Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors; DPP-4i, dipeptidyl peptidase-4 inhibitor; HIRA, Health Insurance Review and Assessment Service; MI, myocardial infarction; GLP-1RA, glucagon-like peptide 1 receptor agonist; oGLD, other glucose lowering drug; PAD, peripheral artery disease; SGLT-2, sodium-glucose cotransporter 2; SGLT-2i, sodium-glucose co-transporter 2 inhibitor; and UA, unstable angina.

*Denotes all-cause mortality.
 †Denotes hospitalizations for heart failure or all-cause mortality.
 ‡Denotes cardiovascular mortality, nonfatal MI, nonfatal ischemic or nonfatal hemorrhagic stroke.
 §Denotes cardiovascular mortality.
 ¶Denotes stroke and myocardial infarction.
 ¶¶Hospitalization for acute MI, hospitalization for stroke, hospitalization for UA, coronary revascularization, and hospitalizations for heart failure.
 #Denotes acute MI, ischemic stroke, hemorrhagic stroke.



nonfatal stroke or myocardial infarction by 24% over 4.8 years.¹³¹

Regulatory Approvals, Roles, and Indications of Newer Antihyperglycemic Drugs for CVD Risk Reduction

The FDA has approved a cardiovascular death reduction label for empagliflozin and a MACE reduction label for liraglutide, semaglutide (subcutaneous), and canagliflozin in adults with T2D and established CVD and for dulaglutide in adults with T2D and established CVD or multiple CVD risk factors. In addition, dapagliflozin is approved to decrease HHF in T2D and established CVD or multiple CVD risk factors and to decrease HHF and CVD-related death in HF and reduced ejection fraction, with or without diabetes. The important question is which agent to prescribe for which patient in the pursuit of diabetes precision medicine. Some GLP-1RA trials have shown impressive improvement of MACE and atherosclerotic outcomes including MI and stroke. SGLT-2I trials have shown major reductions in HHF and renal outcomes in all trials, and cardiovascular death in the EMPA-REG trial. EMPA-REG and CANVAS, which showed a positive outcome for MACE, were more effective in individuals ≥ 65 years of age. Choice of diabetes therapy should be tailored per patients' risk profile and preference. In this context, the direct and indirect effects of GLP-1RA and SGLT-2Is are important because improved glycemia does not account for all the cardiovascular benefit (Figures 2 and 3).¹⁵⁹

Risk of Hypoglycemia and Related Cardiovascular Events

SGLT-2Is, GLP-1RA, and DPP4 inhibitors have higher risk of hypoglycemia (24%–44%), but serious hypoglycemia (resulting in hospitalization, medical assistance, trial withdrawal, or study-defined major or serious hypoglycemia) is similar to placebo.¹³⁸ Risk increases at higher dosages in patients with CKD and HF and coadministration with insulin or sulfonylureas.^{160,161} In LEADER, individuals with severe hypoglycemia were more likely to experience MACE, cardiovascular death, and all-cause death, with higher risk shortly after hypoglycemia.¹⁶²

Glycemic Targets and Antihyperglycemic Medications in T2D Summary

The ADA guidelines recommend individualization of A1c targets using a patient-centered approach: $< 7\%$ (53 mmol/mol) for most nonpregnant adults; $< 6.5\%$ for young patients, long life expectancy, and no significant CVD; and less stringent targets (ie, $< 8\%$) for those with a history of severe hypoglycemia, limited life

expectancy, advanced microvascular, or macrovascular complications.¹⁶³ In the ADA guidelines, metformin is first-line therapy. Among patients with established ASCVD, SGLT-2Is, or GLP-1RA with demonstrated cardiovascular benefit are recommended with preference for a SGLT-2I in those at high risk of HF.¹⁶⁴ In most patients who require the greater glucose-lowering effects of an injectable medication, the ADA guidelines initially prefer GLP-1RA over insulin (Figure S1 in the Supplemental Material).¹⁶⁴ The American Association of Clinical Endocrinologists guidelines support an A1c goal of $\leq 6.5\%$ for most patients or $> 6.5\%$ if the lower target cannot be achieved without adverse outcomes or established macrovascular disease.¹⁶⁵ The addition of either a GLP-1RA or SGLT-2I is recommended for patients with established ASCVD.¹⁶⁵ The 2019 American College of Cardiology (ACC)/American Heart Association (AHA) Guideline on the Primary Prevention of CVD gives a class IIa recommendation for metformin as first-line therapy for T2D and a class IIb recommendation to initiate SGLT-2Is or GLP-1RAs for adults with ASCVD risk factors who require glucose lowering despite lifestyle modifications and metformin (Figure S2 in the Supplemental Material).²¹ The 2019 European Society of Cardiology Guidelines/European Association for the Study of Diabetes and ACC 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With T2D guidelines prefer GLP-1RA or SGLT-2Is as first-line therapies for individuals with high cardiovascular risk or established ASCVD (Figures S3 and S4 in the Supplemental Material).^{166,167} Ongoing and future studies may further clarify the role of metformin or GLP-1RA/SGLT-2Is as first-line therapy.

BLOOD PRESSURE MANAGEMENT

Historically, studies have repeatedly demonstrated a J-curve or U-shape relationship in patients with T2D reflecting increased cardiovascular risk and negative outcomes at both low and high BP levels.^{168–171} Conversely, intensive BP lowering has reduced nonfatal stroke rates and microvascular events such as nephropathy.¹⁷² Stroke prevention may not be without consequence because higher rates of hypotension, hypokalemia, and serum creatinine elevation are noted, mainly because of the effects of aggressive antihypertensive treatment.¹⁷³ Therefore, optimal BP levels continue to be debated.¹⁷⁴

Randomized Trials With Intensive BP Control and Impact of SPRINT Data

The landmark clinical trial ACCORD BP (Action to Control Cardiovascular Risk in Diabetes Blood Pressure) randomized 4733 patients with T2D to intensive therapy, targeting an SBP of < 120 mm Hg, or standard therapy,

Table 4. Recent Publications Comparing BP Targets and Cardiovascular Outcomes

Publication	Year	Analysis	Number of trials/patients	Key findings in patients with diabetes	Impact of findings on target BP in patients with diabetes
Ilkun et al ¹⁷⁶	2020	Post hoc analysis of ACCORD BP study stratified by baseline DBP and glycemic control	1/4731	Intensive SBP lowering decreased risk of CV events irrespective of baseline DBP in the setting of standard glycemic control	Favors lower boundary
Rahman et al ¹⁷⁷	2019	Post hoc analysis of ADVANCE study stratified by baseline SBP and CVD risk	1/10 498	Reduction in mortality, macrovascular, and microvascular events regardless of baseline SBP (evaluated down to <120 mmHg and <70 mmHg)	Favors lower boundary
Wang et al ¹⁷⁸	2019	Systematic review and meta-analysis of RCTs comparing intensive vs standard BP control in diabetic patients only	16/24 444	Intensive BP lowering resulted in significant reductions in all-cause mortality, major CV events, stroke, and CV death	Favors lower boundary
Böhm et al ¹⁷⁹	2019	Pooled patient data from ONTARGET and TRANSCEND studies	2/30 937	CV death, MI, stroke, and heart failure hospitalization event rates lower at SBP <140 mmHg and DBP 80 to <90 mmHg Low BP levels (<120 or <70 mmHg) associated with increased CV outcomes (except stroke) and death	Favors lower boundary
Beddhu et al ¹⁸⁰	2018	Post hoc analysis of patient data from ACCORD BP and SPRINT studies	2/14 904	Intensive BP lowering decreased risk of CV events similarly in SPRINT (HR, 0.75) and in the ACCORD BP standard glycemia arm (HR, 0.77) Interaction between intensive SBP lowering and intensive glycemic control may have masked beneficial effects of intensive SBP lowering in ACCORD BP	Favors lower boundary
Buckley et al ¹⁸¹	2018	Post hoc subgroup analysis of ACCORD and its long-term observation follow-up study	1/1284	5 y of intensive BP control reduced risk of CV death, nonfatal MI, nonfatal stroke, and unstable angina	Favors lower boundary
Brouwer et al ¹⁸²	2018	Post hoc analysis of pooled patient data from ACCORD-BP and SPRINT studies	2/14 904	Nonsignificant interaction between intensive BP lowering and type 2 diabetes, however lower event rate of unstable angina, MI, acute heart failure, stroke, and CV death	Favors lower boundary
Wan et al ¹⁸²	2018	Population-based retrospective cohort study comparing outcomes stratified by achieved SBP in diabetic patients only	1/28 014	Intensive BP lowering associated with higher CVD risk compared with <130 mmHg (HR, 1.75) or 140 mmHg (HR, 1.67)	Favors higher boundary
Thomopoulos et al ¹⁸³	2017	Systematic review and meta-analysis of RCTs comparing outcomes stratified by achieved SBP and DBP	81/253 125	Standard BP lowering to SBP <140 mmHg demonstrated significantly greater relative and absolute reductions of most CV outcomes Little or no further benefit seen in lowering SBP <130 mmHg	Favors higher boundary
Buckley et al ¹⁸⁴	2017	Post hoc subgroup analysis of ACCORD-BP study	2/652	Intensive BP control to <120 mmHg significantly reduced risk of CVD death, nonfatal MI, nonfatal stroke, revascularization, or heart failure	Favors lower boundary
Ettehad et al ¹⁸⁵	2016	Systematic review and meta-analysis of large-scale BP-lowering trials	123/613 815	Treatment to SBP <130 mmHg reduced risk of major CV events, coronary heart disease, stroke, and heart failure	Favors lower boundary
Brunstrom et al ¹⁸⁶	2016	Systematic review and meta-analysis of RCTs including ≥100 patients with diabetes treated for ≥12 mo, comparing any antihypertensive agents or different BP targets	49/73 738	In patients with baseline SBP <140 mmHg, further treatment increased risk of CV mortality with a tendency toward increased risk of all-cause mortality with no observed benefit	Favors higher boundary
Xie et al ¹⁸⁶	2016	Systematic review and meta-analysis of RCTs comparing intensive vs standard BP control or different BP changes from baseline	19/44 989	Intensive treatment reduced risk for major CV events, MI, and stroke, but had no clear effects on heart failure or CV death	Favors lower boundary

ACCORD-BP indicates Action to Control Cardiovascular Risk in Diabetes Trial; ADVANCE, Action in Diabetes and Vascular Disease: Preterax and Diamiron MR Controlled Evaluation trial; BP, blood pressure; CV, cardiovascular; CVD, cardiovascular disease; DBP, diastolic blood pressure; HR, hazard ratio; MI, myocardial infarction; ONTARGET, Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial; RCT, randomized controlled trial; SBP, systolic blood pressure; SPRINT, Systolic Blood Pressure Intervention Trial; and TRANSCEND, Telmisartan Randomised Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.

targeting an SBP of <140 mmHg.¹⁷³ The investigators found no significant difference in the primary composite outcome of nonfatal MI, nonfatal stroke, or death from cardiovascular causes with event rates of 1.87% versus 2.09% per year in the intensive group and standard group, respectively (hazard ratio [HR] with intensive therapy, 0.88 [95% CI, 0.73–1.06]; $P=0.20$).

The results of SPRINT (Systolic Blood Pressure Intervention Trial) created a paradigm shift in BP goals and reinvigorated the deliberation of ideal BP goals. Although it is important to note that patients with diabetes were excluded, the trial was stopped prematurely because of the overwhelming evidence of benefit. Intensive SBP lowering to <120 mmHg in high-risk patients (defined as the presence of clinical or subclinical CVD other than stroke, CKD, 10-year Framingham Risk $\geq 15\%$ or age >75 years) resulted in a 25% risk reduction in MI, ACS, stroke, HF, and death attributable to CVD compared with standard BP lowering to <140 mmHg.¹⁷⁵

Recent Analyses

Antihypertensive treatment in T2D results in cardiovascular risk reduction when initiated at mean baseline BP of $\geq 140/90$ mmHg (Table 4). Although those without diabetes may receive continued benefit with SBP <130 mmHg, this target, and an intensive target <120 mmHg as well, does not appear to have robust cardioprotective effects in patients with T2D.

Subanalyses of MACE end points in diabetes therapy trials have also provided insight on the relationship between stringent BP control and outcomes. In SAVOR-TIMI 53, the adjusted risk of the composite end point of cardiovascular death, MI, or ischemic stroke showed U-shaped relationships with nadirs at SBP 130–140 mmHg or diastolic BP 80–90 mmHg. In addition, diastolic BP <60 mmHg was associated with increased risk of MI compared to diastolic BP 80–90 mmHg.⁴ Similar findings were also noted in EXAMINE. Among patients who have diabetes with recent acute coronary syndromes, adjusted hazard ratios for MACE, cardiovascular death, or HF were significantly higher for SBP <130 mmHg and diastolic BP <80 mmHg.¹⁷⁵

BP Control in T2D Summary

Although treatment algorithms are similar, there are noteworthy differences in hypertension definitions and goals between the 2017 ACC and AHA Guideline for the Prevention, Evaluation and Management of High BP in Adults¹⁸⁷ and the 2017 ADA Position Statement on Diabetes and Hypertension (Table 5).¹⁸⁸ The ADA does not promote a uniform BP target and instead risk stratifies to avoid overtreatment in frail patients with comorbidities and to decrease the potential of polypharmacy and adverse drug events. Given the significant clinical heterogeneity of patients with T2D, treatment strategies should be patient centered with shared decision-making. A multidisciplinary approach to ensure patients safely achieve BP goals should be incorporated, because the rigorous protocols and intensive follow-up utilized in RCTs are difficult to reproduce in real-world clinical practice.

LIPID ABNORMALITIES AND LIPID-LOWERING THERAPIES

Management of dyslipidemia is central to comprehensive cardiovascular risk factor control and cardiovascular risk reduction for adults with T2D. The most commonly encountered lipid abnormalities in T2D are related to the clustering of risk factors associated with the metabolic syndrome, including increased serum triglycerides, triglyceride-rich very-low-density lipoprotein, triglyceride-rich lipoproteins, small dense low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, LDL particle number, non-HDL-C, and decreased HDL-C. LDL-C is often mild-to-moderately increased. This atherogenic dyslipidemia is associated with both chronic low-level vascular inflammation and a prothrombotic state.¹⁸⁹ Accumulating clinical evidence suggests serum triglyceride is a predictor of ASCVD, comparable to LDL-C in populations with T2D, which both exceed the predictive power of A1c.¹⁹⁰

The 2018 Cholesterol Guidelines highlight lifestyle-focused therapies as foundational to addressing lipid abnormalities in T2D in addition to consideration of pharmacotherapies. Modest regular physical activity, reducing

Table 5. Summary of Clinical Treatment Guidelines for Hypertension Treatment

Guidelines	Definition	Target blood pressure	First-line agents	Indication for dual antihypertensive therapy
ACC/AHA	130/80	<130/80	Diuretics Angiotensin-converting enzyme inhibitors* Angiotensin receptor blockers* Calcium channel blockers	>140/90
ADA	140/90	<140/90 Or <130/80 with high cardiovascular risk (existing atherosclerotic cardiovascular disease or 10-y risk score $\geq 15\%$) provided it can be safely attained	Angiotensin-converting enzyme inhibitors* Angiotensin receptor blockers* Thiazide-like diuretics Dihydropyridine calcium channel blockers	>160/100

*Preferred agents with albuminuria.

sedentary behavior, gradual weight reduction, and a healthy dietary pattern emphasizing vegetables, fruits, whole grains, legumes, healthy protein sources, and vegetable oils should be encouraged. Foods that should be limited include refined sugar, processed carbohydrates, sugar-sweetened beverages, and red meats.¹⁹¹

LDL-C Lowering With Statins

Statins are the cornerstone of lipid therapy in T2D. Consistent cardiovascular risk reduction with statins is established with reductions in MI, coronary death, coronary revascularization, and stroke. Among people with T2D, statins are beneficial irrespective of a previous history of ASCVD with those with the highest absolute cardiovascular risk likely to receive the greatest absolute benefit.^{192–194}

The 2018 Cholesterol Guidelines¹⁹² provide guidance on recommended statin therapy for primary and secondary prevention in diabetes. In patients ≤ 75 years of age with diabetes and clinical ASCVD, the highest intensity statin tolerated should be initiated or continued with the aim of achieving a $\geq 50\%$ reduction in LDL-C. In patients > 75 with diabetes and ASCVD, it is reasonable to continue high-intensity statins or the highest intensity statin tolerated after the evaluation of net clinical benefit, potential adverse effects, and significant comorbidities potentially limiting life expectancy.

For primary prevention, adults 40 to 75 years of age with diabetes should be considered for at least a moderate-intensity statin regardless of estimated ASCVD risk (COR I). Moderate-intensity statin therapy is associated with a cardiovascular risk reduction of at least 25%.¹⁹³ High-intensity statins are recommended in people with diabetes with multiple ASCVD risk factors, risk-modifying factors, or diabetes-specific risk-enhancing factors including duration of diabetes (> 10 years), presence of microalbuminuria, greater than stage 2 nephropathy, evidence of retinopathy, neuropathy, or an ABI < 0.9 . Since the decision regarding statin intensity is affected by ASCVD risk, assessment of a 10-year estimated risk is recommended. Of note, there have been no primary prevention RCTs in diabetes specifically utilizing high-intensity statins; however, given the significant risk of those with diabetes and multiple risk factors, the 2018 Guidelines¹⁹¹ give this a class IIa recommendation. In individuals with diabetes > 75 already on a statin, it is reasonable to continue, and it is reasonable to initiate statin therapy after a clinician-patient discussion focused on net clinical benefit. In adults 20 to 39 years of age with diabetes, the presence of diabetes-specific risk enhancers favors the initiation of statin therapy (COR IIb).¹⁹¹

Statin use is associated with a modest increased incidence of new-onset diabetes. This is most often seen in individuals with predisposing risk factors for diabe-

tes, metabolic syndrome, and those treated with higher intensity statins. The specific mechanisms related to statin-associated diabetes are unclear, and this risk is small relative to the cardiovascular risk reduction seen in people with diabetes or prediabetes treated with statins.^{195–198} This association should not be a contraindication to statins or a reason to discontinue therapy, but it should lead to discussion in partnered care focused on strategies to either prevent diabetes or improve glycemic control.^{191,199}

LDL-C Lowering With Nonstatins

An important addition to the 2018 Cholesterol Guidelines¹⁹¹ is the consideration for on-statin therapies in people living with diabetes. In T2D with ASCVD and very high risk (multiple ASCVD events or 1 major event and at least 1 other high-risk condition [age > 65 , familial hypercholesterolemia, hypertension, tobacco use, history of congestive HF]) on maximally tolerated statins who have not achieved a 50% reduction of LDL-C or with an LDL-C > 70 mg/dL adding ezetimibe is reasonable (class IIa) and is the preferred initial agent given the event reduction seen in the IMPROVE-IT trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), where the addition of ezetimibe reduced MIs by 24% and ischemic stroke by 39% in participants with diabetes (27% of trial participants).²⁰⁰ The addition of ezetimibe to moderate-intensity statin therapy can achieve a similar LDL-C reduction as a high-intensity statin. In adults with diabetes and a 10-year ASCVD risk of $\geq 20\%$, it may be reasonable to add ezetimibe to maximally tolerated statin therapy to reduce LDL-C by $\geq 50\%$.¹⁹¹

Data from the FOURIER²⁰¹ (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) and ODYSSEY Outcomes²⁰² (A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab [SAR236553/REGN727] on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome) trials support the consideration of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor therapy for very high-risk individuals with ASCVD who have not achieved a 50% LDL-C reduction (or with LDL-C > 70 mg/dL/non-HDL-C > 100 mg/dL) with maximally tolerated statin and ezetimibe. PCSK9 inhibitors appear to be effective with an expected mean reduction of LDL-C of 60%, and safe in those with and without T2D. Available data suggest that there is no PCSK9 inhibitor-induced increased risk of new-onset diabetes or impact on glycemic control.²⁰³ A clinician-patient discussion including cost-benefit consideration is important before initiating PCSK9 inhibitors.¹⁹¹

Bile acid sequestrants (expected to lower LDL-C by 15%–30%) can also be considered in diabetes with significant statin-associated side effects or if additional

LDL-C lowering is warranted. Clinical studies have demonstrated that colesevelam provides both lipid-lowering and glycemic benefits in adults with T2D and is FDA approved for both indications.²⁰⁴

Bempedoic acid, a prodrug that inhibits ATP citrate lyase and cholesterol synthesis upstream from hydroxymethylglutaryl coenzyme A reductase, appears to be a promising oral agent for those with statin intolerance or where modest additional LDL-C lowering is needed.²⁰⁵

Triglyceride Lowering in Diabetes

The initial approach to hypertriglyceridemia in diabetes should focus on potential secondary causes or contributory factors, including glycemic control, that should be addressed with pharmacologic and lifestyle approaches with evidenced-based cardiovascular benefit.^{139,191} Modest weight loss, increased physical activity, reduction of sugar-sweetened beverages, processed carbohydrates, and reduction in alcohol use can lead to significant serum triglyceride reduction. Occult hypothyroidism and nephrosis should be excluded, and adjustment of medications that can raise triglycerides such as β -blockers, thiazide diuretics, and others should be considered.

In adults with diabetes and severe hypertriglyceridemia (fasting triglycerides >500 mg/dL), pharmacological and lifestyle therapy is warranted to prevent acute pancreatitis. In addition to the aforementioned lifestyle therapies, first-line pharmacotherapy includes fibrates or high-dose prescription omega-3 fatty acids. If a fibrate is necessary in a patient treated with concomitant statin therapy, fenofibrate is recommended rather than gemfibrozil, given the lower risk of drug interaction and myopathy.¹⁹¹

Moderate hypertriglyceridemia (fasting triglycerides 135–499 mg/dL) is considered a risk-enhancing factor,¹⁹¹ and is often a manifestation of cardiometabolic risk. Moderate hypertriglyceridemia and an abnormal non-HDL-C are commonly encountered as components of diabetic dyslipidemia. In diabetes with moderate hypertriglyceridemia, statins are the recommended first-line pharmacotherapy.¹⁹¹ The intensity of statin therapy should be based on both the absolute risk of ASCVD and the degree of hypertriglyceridemia because higher-intensity statins are more effective at lowering triglycerides. In patients with diabetes and ASCVD or patients with diabetes at high risk for ASCVD with serum triglycerides of 135 to 500 mg/dL despite maximally tolerated statin, and addressing contributory factors including lifestyle modification prescription icosapent ethyl at a dose of 4 g/d, as well, should be considered given the 30% additional cardiovascular risk reduction in the REDUCE-IT trial (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial).²⁰⁶ Of note, the median baseline LDL-C in this trial was 75 mg/dL, and 29% of the study population had diabetes. Several RCTs have assessed the additional impact on cardiovascular events of fibrates when used in combination

with statins; thus far, the data are inconclusive, although post hoc analyses have suggested potential benefit in those with residual modest hypertriglyceridemia.²⁰⁷

HDL-Raising Therapies in Diabetes

Overall, HDL-C-raising therapies, other than lifestyle and behavioral approaches, have been disappointing. Mendelian randomization data suggest that HDL-C is likely a marker of ASCVD risk versus a causative factor.²⁰⁸ Low HDL-C is a common finding in individuals with diabetes and metabolic risk, in addition to dysfunctional HDL-C. Despite significantly increasing HDL-C, cholesterol ester transfer protein inhibitors have not demonstrated a reduction in cardiovascular events.²⁰⁹ Niacin would not be favored in people with diabetes given the potential adverse effect on glycemic control. RCTs have not demonstrated additional cardiovascular benefit of niacin in combination with statin therapy.²⁰⁹

Lipid-Lowering Therapy in Diabetes Summary

Timely and aggressive lipid-lowering therapy is warranted for both primary and secondary prevention in diabetes as a component of comprehensive cardiovascular risk reduction. Lifestyle- and behavioral-focused approaches are recommended for all individuals with diabetes as the cornerstone to addressing dyslipidemia. Statins are the foundation of lipid therapy in diabetes given the consistent and compelling evidence supporting cardiovascular risk reduction. The 2018 Cholesterol Guidelines recommend statins as first-line therapy for both primary and secondary prevention in diabetes. In those with established ASCVD, the highest intensity statin tolerated should be initiated or continued with the aim of reducing LDL-C by at least 50% with a more individualized approach for those >75 years of age. For primary prevention in T2D, at least moderate-intensity statin should be considered based on age, absolute ASCVD risk, or the presence of risk-enhancing factors. Nonstatin therapies including ezetimibe, PCSK9 inhibitors, icosapent ethyl, bile acid resins, and fibrates should be considered after thorough evaluation of risk, LDL-C after optimal statin therapy, and presence of hypertriglyceridemia. An ongoing process of shared decision-making focused on net clinical benefit, patient preference, potential cost concerns, and medication adherence should be a consistent thread of care.²¹⁰

ANTITHROMBOTIC THERAPY

Among the primary factors contributing to the increased cardiovascular risk in diabetes is a generalized prothrombotic state^{211,212} that can be attributed to altered coagulation and platelet function and exacerbated in the setting of common comorbid conditions such as CKD (Table 6).^{213–231} Although antiplatelet-based secondary

Table 6. Impact of Diabetes on Formation and Dissolution of Thrombus

Platelet activation
Increased platelet turnover
Decreased platelet cAMP
Decreased platelet cGMP
Increased thromboxane synthesis
Increase in glycoprotein IIb/IIIa receptor density on larger platelets
Increased vitronectin circulating fibrinogen and thrombin/antithrombin II complexes
Increased P-selection
Coagulation cascade activation
Increased fibrinogen
Increased von Willebrand factor and procoagulant activity
Increased fibrinopeptide A (increased thrombin activity)
Decreased activity of antithrombin III
Decreased sulfation of endogenous heparin
Chronic low-grade inflammation
Impaired fibrinolysis
Increased plasminogen activator inhibitor type 1 synthesis and activity (directly increased by insulin and insulin-like growth factor 1)
Decreased concentrations of alpha-2 antiplasmin

prevention is well established, an important advance in diabetes care over the past decade has been greater clarification of the appropriate role of antiplatelet therapy in the primary prevention of cardiovascular end points in individuals at increased risk.

The relative benefits and risks of aspirin and other primary preventive antiplatelet regimens need to be weighed carefully in at-risk patients with diabetes. The ASCEND trial (A Study of Cardiovascular Events In Diabetes) included 15 480 patients with diabetes but no overt CVD randomly assigned to aspirin 100 mg daily or placebo. At a mean follow-up of 7.4 years, there was a 1% absolute reduction in major cardiac and cerebrovascular events among these low-risk patients treated with aspirin (8.5% versus 9.6%, $P=0.01$), but a 1% increase in major bleeding (4.1% versus 3.2%, $P=0.003$) in that same group. Bleeding events were primarily gastrointestinal and other noncranial origin, with no excess in fatal bleeding.²³² Thus, in carefully selected patients with diabetes at low bleeding risk, aspirin provides a modest benefit in reducing ischemic events. In elderly patients, the CVD benefit with aspirin therapy for primary prevention is outweighed by bleeding risk, as demonstrated in the ASPREE trial (Aspirin in Reducing Events in the Elderly), which included 19 114 people ≥ 70 years of age (or ≥ 65 years in the United States and Black or Hispanic individuals), including 11% with diabetes. After a mean follow-up of 4.7 years, aspirin was found to have an insignificant effect on ischemic events but a significant increase in

major hemorrhage. Overall, aspirin has a modest beneficial effect in primary prevention in nonelderly adults (50–70 years of age) with diabetes and increased cardiovascular risk based on additional clinical risk factors or imaging (see “The role of traditional and new imaging tests to assess subclinical CVD”). The risk-benefit ratio may be favorable in patients at low bleeding risk, and careful discussion and shared decision-making is appropriate before the initiation of long-term preventive therapies. The optimal aspirin dose in the setting of a demonstrable impairment in the biochemical response to aspirin is uncertain but may be improved somewhat by more frequent and higher dosing regimens,^{233,234} although the safety of alternative regimens is not proven.

Newer, more potent antiplatelet agents and dosing regimens offer enhanced effects in treated patients, including those with diabetes, high on-treatment platelet reactivity, and relative clopidogrel and aspirin resistance.²³⁵ Extending the previously documented secondary risk reduction benefit of dual antiplatelet therapy after MI among participants with diabetes,^{236–238} the THEMIS trial (Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study)²³⁹ evaluated the secondary prevention effects of dual antiplatelet therapy among 19 271 participants ≥ 50 years of age with diabetes and documented CAD but without a history of MI or stroke. Eligible patients were randomly assigned to ticagrelor or placebo, with low-dose aspirin included in each arm. After the initiation of the trial, the ticagrelor dose was reduced from 90 mg twice daily to 60 mg twice daily for all participants in light of excess premature ticagrelor discontinuation rates in previous trials²⁴⁰ and recognition of the improved tolerability, safety, and adherence noted with this lower dose in the PEGASUS-TIMI 54 trial (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 trial).²³⁸ With an average follow-up of ≈ 40 months, the composite primary efficacy end point of freedom from cardiovascular death, MI, or stroke was better in the patients randomly assigned to ticagrelor with low-dose aspirin compared with placebo and aspirin.^{240a,240b} Findings of a protective effect of potent antiplatelet regimens in this secondary preventive setting have important implications in the growing population of patients with diabetes.

The effect of antithrombin therapy with aspirin in stable but high ischemic risk patients with CAD or PAD has recently been evaluated. The COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies)^{241–244} showed that adding rivaroxaban 2.5 mg twice a day to low-dose aspirin reduced ischemic events, including cardiovascular death. There was an associated cost of increase in bleeding risk, although no significant excess in fatal bleeding was

noted. The benefits were consistent in the subgroup with diabetes, suggesting that low-dose anticoagulation added to antiplatelet therapy may be another option for risk modification in high-risk patients with diabetes and provides another option for these patients with enhanced cardiovascular risk.

Antithrombotic Therapy in T2D Summary

Antiplatelet-based secondary prevention is well established in T2D. For primary prevention of CVD in T2D, the relative benefits of antithrombotic approaches need to be weighed carefully against risks using a patient-centered approach.

SCREENING FOR CARDIOVASCULAR AND RENAL COMPLICATIONS

Kidney Disease and Cardiovascular Risk in Diabetes

Diabetic nephropathy is the leading cause of CKD and end-stage renal disease in the United States.^{245,246} Defined by the Kidney Disease Improving Global Outcomes Work Group as functional or structural abnormalities of the kidneys persisting for ≥ 3 months as manifested by decreased estimated glomerular filtration rate (eGFR) $\leq 60 \text{ mL}\cdot\text{min}^{-1}\cdot 1.73 \text{ m}^{-2}$ or by evidence of kidney damage (eg, albuminuria or proteinuria),²⁵¹ prevalence among patients with diabetes is $\approx 20\%$ – 40% .^{248–250} Concomitant CKD and diabetes impacts risk for an array of CVDs, including arrhythmias, HF, acute coronary syndrome, and stroke.²⁵¹ Cardiovascular morbidity and mortality is markedly high, and patients with diabetic kidney disease (DKD) are far more likely to die of cardiovascular complications than progress to end-stage renal disease. Although albuminuria is a risk marker of both kidney disease and CVD, it may not be present in patients with reduced eGFR.

Traditional management to reduce risk or delay advancement of kidney disease includes glycemic control, BP control, and renin-angiotensin-aldosterone system inhibition. In the ACCORD trial, a higher risk of hypoglycemia and mortality was seen in patients with baseline CKD. However, a recent meta-analysis of 27 049 participants from 4 landmark RCTs (ACCORD, ADVANCE [The Action in Diabetes and Vascular Disease: Preterax and Diamicon MR Controlled Evaluation], UKPDS [UK Prospective Diabetes Study], and VADT [Veterans Affairs Diabetes Trial]) noted a 20% relative risk reduction for kidney events (composite of end-stage kidney disease, renal death, development of an eGFR $< 30 \text{ mL}\cdot\text{min}^{-1}\cdot 1.73 \text{ m}^{-2}$ or development of overt diabetic nephropathy) with more intensive glucose control over 5 years compared with less intensive.²⁵² Similar findings were observed in posttrial follow-up of participants in

ADVANCE; intensive glucose control was associated with long-term reduction of end-stage kidney disease (defined as need for dialysis or kidney transplantation or death because of kidney disease) without evidence of any increased risk of cardiovascular events or death after 9.9 years of overall follow-up (29 versus 53 events, HR 0.54, $P < 0.01$).²⁵³ Stringent glucose control to prevent kidney failure may not be as clear. A meta-analysis by Ruospo et al²⁵⁴ found that patients with intensive glycemic control had similar risks of kidney failure, defined as doubling of serum creatinine (RR=0.84 [95% CI, 0.64–1.11]; $P=73\%$), and development of end-stage renal disease (RR=0.62 [95% CI, 0.34–1.12]; $P=52\%$) compared with patients with less stringent treatment goals. Small clinical benefits were observed in the onset and progression of microalbuminuria.

In the CVOTs of SGLT-2Is and GLP-1RAs, secondary end points or subanalyses included renal outcomes (Table 7). When comparing drug classes, a recent meta-analysis of these trials found that GLP-1RAs primarily reduced macroalbuminuria risk, whereas SGLT-2Is reduced the risk of worsening eGFR.¹³⁸ Data from clinical trials focused on primary renal outcomes are emerging. In CREDENCE, patients with T2D and albuminuric CKD concurrently receiving renin-angiotensin-aldosterone system blockade were randomly assigned to canagliflozin 100 mg daily or placebo.¹⁴¹ A 30% relative risk reduction of the primary outcome (composite of end-stage renal disease defined as dialysis, transplantation, or sustained eGFR of $< 15 \text{ mL}\cdot\text{min}^{-1}\cdot 1.73 \text{ m}^{-2}$, doubling of serum creatinine or death from renal or cardiovascular cause) was observed over 2.6 years in the canagliflozin group. Reduced risk of cardiovascular death, MI, or stroke was also noted in the canagliflozin group (HR, 0.80 [95% CI, 0.67–0.95]; $P=0.01$) and HHF (HR, 0.61 [95% CI, 0.47–0.80]; $P < 0.001$). In the DAPA-CKD trial (A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease), a composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes was evaluated over 2.4 years in CKD participants with or without T2D. Dapagliflozin versus placebo reduced the risk of the composite outcome by 39% overall and 36% (HR, 0.64 [95% CI, 0.52–0.79]) among participants with T2D.²⁵⁵

The most recent advances have been trials of selective nonsteroidal mineralocorticoid receptor antagonists in patients with T2D and DKD. The FIDELIO-DKD trial (Finerenone in Reducing Kidney Failure and Disease Progression in DKD Trial) evaluated kidney and cardiovascular outcomes over 2.6 years in 5734 participants with T2D and DKD on maximal renin-angiotensin-aldosterone system blockade at baseline.²⁵⁶ Finerenone reduced the primary renal composite outcome (kidney failure, a sustained decrease of at least 40% in the eGFR from baseline, or death from renal causes) by 18%

Table 7. Renal Events in Cardiovascular Outcome Trials

Drug	Renal end points	Event rate (intervention vs placebo)	Relative risk reduction
Empagliflozin ¹²²	Composite of progression to urine albumin-to-creatinine ratio >300 mg/g, doubling of SrCr, ESRD, or death from ESRD	12.7% vs 18.8%	39%
	Doubling of SrCr accompanied by estimated glomerular filtration rate ≤ 45 mL·min ⁻¹ ·1.73m ⁻²	1.5% vs 2.6%	44%
Canagliflozin ¹²³	Progression of albuminuria	89.4 vs 128.7 participants with an event per 1000 patient-years	27%
	Composite of sustained 40% reduction in estimated glomerular filtration rate, kidney replacement therapy, or death from ESRD	5.5 vs 9.0 participants with the outcome per 1000 patient-years	40%
Dapagliflozin ¹²⁴	Composite of sustained decrease of 40% or more in estimated glomerular filtration rate, new ESRD, or death from renal or cardiovascular causes	4.3% vs 5.6%	24%
Liraglutide ¹¹⁴	Composite of persistent macroalbuminuria, doubling of SrCr, ESRD, or death from ESRD	5.7% vs 7.2%	22%
Semaglutide ¹¹⁵	Composite of persistent urine albumin-to-creatinine ratio >300mg/g, creatinine, doubling of SrCr of ESRD	3.8% vs 6.1%	36%

ESRD indicates end-stage renal disease; and SrCr, serum creatinine.

(HR, 0.82 [95% CI, 0.73–0.93]; $P=0.001$) and reduced the secondary cardiovascular composite outcome (death from CVD, nonfatal stroke, nonfatal MI, and HHF) by 14% (HR, 0.86 [95% CI, 0.75–0.99]; $P=0.03$) with no difference by baseline CVD status.^{256,257} FIGARO-DKD (Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease) is a completed 6400 patient trial examining a cardiovascular composite as the primary outcome with results due in late 2021. Thus, SGLT-2Is, GLP-1Ras, and nonsteroidal mineralocorticoid receptor antagonists are critical advancements in delaying the progression of CKD in T2D.

THE ROLE OF TRADITIONAL AND NEW IMAGING TESTS TO ASSESS SUBCLINICAL CVD

Diabetes has been regarded as a CAD equivalent, but not all individuals with diabetes have an equally elevated risk. The following section discusses how cardiovascular imaging to detect subclinical atherosclerosis can help risk-stratify patients with diabetes and tailor therapy.

Coronary Artery Calcification

Coronary artery calcification (CAC), a surrogate marker for atherosclerosis, is detected more commonly in metabolic syndrome (59%) and diabetes (75%) than in control subjects (53%) and is associated with duration and control of diabetes.^{258–260} Twelve-year follow-up from MESA (Multi-Ethnic Study of Atherosclerosis) showed increasing CAC scores predict MI and cardiovascular events after controlling for glycemic control.²⁶¹ Sequential testing has shown faster CAC progression in diabetes.²⁶² The PREDICT study (Prospective Evaluation of Diabetic Ischemic Disease by Computed To-

mography) found CAC doubling in diabetes increased cardiovascular risk by 32% over 4 years.²⁶³ Accordingly, the MESA-HNR risk score that includes CAC performs better in diabetes than Framingham (net reclassification improvement 0.19, integrated discrimination improvement 0.046, $P<0.05$), and UKPDS (net reclassification improvement 0.215, integrated discrimination improvement 0.046, $P<0.05$) scores.²⁶⁴

Up to 39% of individuals have zero CAC.²⁶⁵ In MESA, such individuals had a very low CVD event rate (3.7 per 1000 person-years), similar to those without diabetes and no CAC.²⁶¹ Thus, the absence of CAC can reclassify up to a third of patients with diabetes to a low-risk category, whereas higher CAC may prompt tighter risk-factor control including statin and aspirin prescription.

Coronary Artery Computed Tomography Angiography

Asymptomatic individuals can be further stratified using coronary artery computed tomography angiography (cCTA) and can further stratify asymptomatic individuals with diabetes by (1) the degree of luminal stenosis and (2) plaque morphology. The absence of luminal stenosis has been seen in 25% to 30% and obstructive CAD in 25% to 30% in cCTA studies. South Asian patients tend to have even more prevalent CAD (41% versus 28%) compared with White patients with T2D.²⁶⁶

In the CONFIRM registry (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multi-center Registry), patients with T2D without CAD by cCTA had similar cardiovascular risk as propensity-matched patients without T2D, whereas those with obstructive CAD had higher risk at 5 years.²⁶⁷ Risk increased with segment involved and segment stenosis scores.²⁶⁸ cCTA has incremental risk prediction, discrimination, and reclassification advantage beyond CAC for asymptomatic individuals with diabetes.²⁶⁹

The FACTOR-64 trial (Screening for Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using CT Angiography, Following Core 64) compared a cCTA-based screening strategy in diabetes to standard care, but found no difference in all-cause death, nonfatal MI, or unstable angina (6.2% versus 7.6%; $P=0.38$) over 4 years.²⁷⁰ The apparent lack of benefit may have been attributable to low event rates from risk factor control at baseline (75% statin use). It is plausible that asymptomatic but higher-risk groups with longstanding or poorly controlled diabetes, hypertension, and dyslipidemia may derive benefit from cCTA screening, but confirmatory evidence is needed. Benefits from cCTA were seen in the T2D subcohort of the PROMISE trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain), but these were symptomatic patients.²⁷¹

T2D is associated with high plaque burden.^{272–274} The PARADIGM (Progression of Atherosclerotic Plaque Determined by Computed tomographic Angiography Imaging) study of 1602 subjects showed a higher plaque volume, necrotic core volume, and faster plaque progression with T2D.^{275,276} Coronary plaque also provides reclassification advantage over UKPDS and CAC scores over a 7-year follow-up.²⁷⁷ Any potential benefits also need to be weighed against risks of radiation and iodinated contrast exposure.

Cardiac Magnetic Resonance Imaging

Presence of unrecognized MI detected by cardiac magnetic resonance imaging may be a stronger prognostic marker than conventional risk factors in diabetes.^{278,279} In the ICELAND-MI study, unrecognized MI (17%) was more common than clinically recognized MI (10%) in individuals >65 years, and its prevalence was even higher in the T2D subgroup (21%).²⁸⁰ On a 13-year follow-up, mortality of unrecognized MI in T2D was also higher, possibly from lower prescription of preventive therapy.²⁸¹ In type 1 diabetes, a cardiac magnetic resonance study found scar in 4.3%.²⁸² Early detection could facilitate treatment and improve outcomes, but this requires testing in clinical trials.

Stress Testing

Exercise ECG stress testing can detect silent ischemia in $\approx 7.6\%$ of asymptomatic individuals with diabetes.^{283,284} Detection rates with technetium-99m sestamibi single-photon emission-computed tomography myocardial perfusion are higher (22%). Although a screening strategy was ineffectual in the DIAD clinical trial (Detection of Ischemia in Asymptomatic Diabetics; 2.7% versus 3% events; $P=0.73$), the BARDOT trial (The Basel Asymptomatic High-Risk Diabetics' Outcome Trial) documented higher events in the abnormal stress test group (9.8% versus 2.9% at 2 years).^{285,286}

In a meta-analysis, a normal single-photon emission-computed tomography study predicted an annual event rate of 1.6% with and <1% without T2D.²⁸⁷ Absence of ischemia and late gadolinium enhancement on stress perfusion cardiac magnetic resonance can also effectively stratify patients with diabetes to low risk (1.4% and 0.5% event rates, respectively).²⁸⁸

Cardiac Positron Emission Tomography

Reduced coronary flow reserve in T2D (1.58 versus 1.87; $P=0.0001$) as measured by positron emission tomography can predict a 4.9-fold higher risk of cardiac death.²⁸⁹ Patients with T2D without epicardial stenosis but with a coronary flow reserve <1.6 have cardiac event rates (2.8%) similar to those with stenosis (2.9%), suggesting prognostic implications of microvascular dysfunction. In MESA, higher fasting glucose was associated with lower hyperemic myocardial blood flow.²⁹⁰

CVD Screening in T2D Summary

Many imaging tests can facilitate risk stratification in asymptomatic patients with T2D, but there are limited data to support routine screening. CAC appears to provide the most actionable triggers for lipid-lowering and antiplatelet therapy. The 2018 Cholesterol Guidelines and the 2019 ACC/AHA Guideline on the Primary Prevention of CVD recommend moderate-intensity statin prescription for adults 40 to 75 years of age with diabetes without further risk stratification.^{21,191} The National Lipid Association's scientific statement on CAC scoring recommends escalation to high-intensity statin for CAC >100.²⁹¹ CAC is also deemed reasonable in 30- to 39-year-old adults with long-standing diabetes and >75-year-old adults if it would facilitate statin prescription. Aspirin is also considered reasonable by the National Lipid Association and the Society of Cardiovascular Computed Tomography for CAC >100.²⁹² Ischemia testing in asymptomatic individuals with diabetes is not currently recommended.

CLINICAL IMPLICATIONS OF RECENT CVOTS

The leading cause of mortality in diabetes remains CVD; thus, strategies to reduce CVD are paramount. The majority of CVOTs for GLP-1RAs and SGLT-2Is have shown significant reduction in cardiovascular outcomes: (1) GLP-1RAs having greater ASCVD benefits, and (2) SGLT-2Is have shown greater reduction in HHF and renal outcomes among those with established ASCVD and high cardiovascular risk. FIDELIO-DKD showed a reduction in CVD among individuals with T2D and DKD with a selective nonsteroidal mineralocorticoid receptor antagonist as a secondary out-

come with the results pending for the larger primary outcome trial FIGARO-DKD.^{256,257} The findings are impressive, given that the trials occurred in an era of comprehensive ASCVD risk management with effective therapies for lipid, BP, and antithrombotic management. There remains an opportunity to increase prescribing and utilization of these medications among cardiologists for their CVD benefit, because they are currently mostly prescribed by internists and endocrinologists.^{293,294} Thus, approaches to increase utilization of collaborative approaches, in particular among patients with ASCVD and T2D, is important, leading some to call for a new cardiometabolic medicine specialty to improve prevention and treatment of cardiometabolic diseases at the interface of cardiology, endocrinology, and general medicine.²⁹⁵

Even with the large amount of high-quality evidence, important areas for research remain. MACE, MI, and cardiovascular mortality reduction with GLP-1RA and SGLT-2Is is firmly established for individuals with diabetes and ASCVD. Consistent beneficial impacts in the primary prevention of ASCVD among those with T2D, although desired, remain to be established.¹³⁸ Second, differences in therapy response across racial and ethnic groups deserve further evaluation. For example, empagliflozin was associated with a 32% lower ASCVD risk in Asian populations and 48% higher ASCVD risk in Black populations compared with placebo, whereas canagliflozin was associated with a 8% higher ASCVD risk in Asian populations and a 55% lower ASCVD risk in Black populations.^{121,123} Recent analyses also indicate potential lower use of GLP-1RA and SGLT-2Is in racial and ethnic minority groups and lower socioeconomic status groups.^{296,297} Third, there are no head-to-head comparison trials between newer antihyperglycemic medications and their impact on ASCVD outcomes. Last, long-term safety of the newer agents remains under investigation.

CONCLUSION

Although efficacious therapies are available to improve cardiovascular risk factors, in the United States and across the world, comprehensive management of various cardiovascular risk factors in T2D remains poor.^{298,299} In the United States, <20% of adults with T2D without known CVD meet control targets for a combination of A1c, BP, LDL-C, and nonsmoking status and that drops to <10% if including BMI <30 kg/m² target.²⁹⁸ Among those with known ASCVD, the realities are worse with only 6.8% meeting the combined target and 2.7% with inclusion of BMI <30 kg/m² target.²⁹⁸ Similar challenges exist throughout the world to varying degrees, as is seen in the EUROASPIRE V survey, where large proportions of people at high cardiovascu-

lar risk had unhealthy lifestyles and inadequate control of BP, lipids, and diabetes.²⁹⁹ Explanations for the discordance between effective therapies and poor control include medical factors (ie, clinical inertia, monotherapy, patient adherence, cost, lack of guideline-based treatment), but these all occur in the environmental context of a patient.

Clinical care and treatment accounts for 10% to 20% of the modifiable contributors to healthy outcomes.³⁰⁰ The other 80% to 90% are the SDoH, which includes health-related behaviors, socioeconomic factors, environmental factors, and racism, which have been recognized to have a profound impact on CVD and T2D and their outcomes by the AHA and ADA.^{301–303} If we are to continue to advance the management of cardiovascular risk factors, we must also address the SDoH in the delivery of health care.^{304,305} Concurrent interventions to (1) directly address the SDoH condition (ie, approaches to improve food insecurity have shown reductions in A1c)³⁰⁶ and (2) address the root causes of SDoH through policy changes are critical.³⁰⁷ Racism is increasingly recognized as an upstream SDoH that drives midstream SDoH and downstream health outcomes.^{301–303} A reinvested focus on efforts to address and improve racism is 1 pillar on which to intervene to eliminate the disparities in cardiovascular risk factors and cardiovascular death in our work to advance health equity.^{68,302,303}

Multifaceted efforts are needed to prevent CVD in patients with diabetes. Data from 4 EUROASPIRE surveys since the 1990s showed worsening of lifestyle factors, obesity and diabetes prevalence, and control among individuals with coronary heart disease or high CVD risk.³⁰⁸ In response, the European Society of Cardiology developed the EUROACTION plan aimed at improving preventive care for these individuals in clinical practice. After 1 year, participants assigned to the EUROACTION intervention program were less likely to smoke, more likely to have improved their dietary habits and be prescribed angiotensin-converting enzyme inhibitors and statins.³⁰⁹ In the United States, the AHA and ADA have partnered in a groundbreaking program, “Know Diabetes by Heart.” Know Diabetes by Heart works with patients, communities, professionals, and health systems to reduce cardiovascular deaths, heart attacks, and strokes in people living with T2D by raising awareness of the link between diabetes and CVD, empowering patients, and supporting health care professionals in patient engagement and prevention of CVD. The Target:T2D ambulatory program, part of Know Diabetes by Heart, is a quality improvement initiative for outpatient care of T2D and cardiovascular risk factors. The initiative brings together resources, regional support, education, and recognition to target clinical improvement. These strategies recognize the impor-

tance of multifaceted approaches to CVD prevention and treatment in T2D.

Overall Summary

Diabetes is a major public health problem. CVD is the leading cause of death and disability in diabetes. A large number of RCTs have demonstrated that the risk of cardiovascular events can be significantly reduced by incorporating evidence-based therapies for control/modification of multiple cardiometabolic abnormalities in patients with T2D. We recommend a comprehensive approach to management of all cardiovascular risk factors in patients with T2D, including glycemia, BP, lipid abnormalities, thrombotic risk, obesity, and smoking, using lifestyle and pharmacological approaches with proven benefit using a patient-centered approach. A patient-centered approach in this context means reframing our clinical encounters to think about patients as people who live in families, communities, and societies that must be considered in their cardiovascular risk management. Further research exploring the role of combined lifestyle, pharmacological, and SDoH intervention approaches remain an area of further investigation. An example of such an approach would study the impact of an SGLT-2I in the setting of a specific dietary approach (ie, Mediterranean, Ketogenic, and DASH) that also uses a produce-provision prescription to ensure access to healthy food choices. Cardiovascular risk management from global risk assessment through individual- and population-level interventions to increase the control of cardiovascular risk factors in T2D are critical to the AHA mission to be a relentless force of longer and healthier lives.

Disclosures

Writing Group Disclosures

Writing group member	Employment	Research grant	Other research support	Speakers' bureau/honoraria	Expert witness	Ownership interest	Consultant/ advisory board	Other
Joshua J. Joseph	The Ohio State University Wexner Medical Center	None	None	None	None	None	None	None
Prakash Deedwania	University of California at San Francisco School of Medicine, Fresno	Novartis*	None	None	None	None	None	None
Tushar Acharya	NHLBI/NIH	None	None	None	None	None	None	None
David Aguilar	University of Texas Health Science Center	None	None	None	None	None	None	None

(Continued)

ARTICLE INFORMATION

The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.

This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on October 11, 2021, and the American Heart Association Executive Committee on October 26, 2021. A copy of the document is available at <https://professional.heart.org/statements> by using either "Search for Guidelines & Statements" or the "Browse by Topic" area. To purchase additional reprints, call 215-356-2721 or email Meredith.Edelman@wolterskluwer.com

Supplemental material is available with this article at <https://www.ahajournals.org/doi/suppl/10.1161/10.1161/CIR.0000000000001040>

The American Heart Association requests that this document be cited as follows: Joseph JJ, Deedwania P, Acharya T, Aguilar D, Bhatt DL, Chyun DA, Di Palo KE, Golden SH, Sperling LS; on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Clinical Cardiology; and Council on Hypertension. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association. *Circulation*. 2021;144:e•••–e•••. doi: 10.1161/CIR.0000000000001040

The expert peer review of AHA-commissioned documents (eg, scientific statements, clinical practice guidelines, systematic reviews) is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit <https://professional.heart.org/statements>. Select the "Guidelines & Statements" drop-down menu, then click "Publication Development."

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at <https://www.heart.org/permissions>. A link to the "Copyright Permissions Request Form" appears in the second paragraph (<https://www.heart.org/en/about-us/statements-and-policies/copyright-request-form>).

Acknowledgments

The authors thank V. Banfi, MSLS, Reference and Science Librarian at the University of Connecticut, B. Kluwe, BS, and L. Zappe, BA, at The Ohio State University for assisting in literature searches, reference management, and the central illustration.

Writing Group Disclosures Continued

Writing group member	Employment	Research grant	Other research support	Speakers' bureau/honoraria	Expert witness	Ownership interest	Consultant/ advisory board	Other
Deepak L. Bhatt	Brigham and Women's Hospital, Harvard Medical School	Research funding: Abbott; Afimmunit; Amarin; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cardax; CellProtherat; Cereno Scientific; Chiesi; CSL Behring; Eisai; Ethicon; Ferring Pharmaceuticals; Forest Laboratories; Fractyl; Garmint; HLS Therapeutics; Idorsia; Ironwood; Ischemix; Janssen; Lexicon; Lilly; Medtronic; MyoKardia; NirvaMed; Novartis; Novo Nordisk; Owkint; Pfizer; PhaseBio; PLx Pharma; Regeneron; Roche; Sanofi; Stasys; Synaptic; The Medicines Company; 89Bio; Site Co-Investigator: Abbott; Biotronik; Boston Scientific; CSI; St. Jude Medical (now Abbott); Philips; Svelte; Unfunded research: FlowCo; Merck; Takeda; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott); Boston Scientific (Chair, PEITHO trial); Cleveland Clinic (including for the ExCEED trial, funded by Edwards); Contego Medical (Chair, PERFORMANCE 2); Duke Clinical Research Institute; Mayo Clinic; Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo); Novartis; Population Health Research Institute†	None	American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee)†; Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation)†; Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring)†; Belvoir Publications (Editor in Chief, Harvard Heart Letter)†; Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees)†; Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals)†; Ferring Pharmaceuticals; HMP Global (Editor in Chief, <i>Journal of Invasive Cardiology</i>) †; <i>Journal of the American College of Cardiology</i> (Guest Editor, Associate Editor)†; K2P (Co-Chair, interdisciplinary curriculum)†; Level Ex, Medtelligence/ReachMD (CME steering committees)†; MJH Life Sciences; Piper Sandler; Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer)†; Slack Publications (Chief Medical Editor, <i>Cardiology Today's Intervention</i>); Society of Cardiovascular Patient Care (Secretary/Treasurer)†; WebMD (CME steering committees)†	None	Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease)†	Advisory Board: Boehringer Ingelheim; Cardax; CellProtherat; Cereno Scientific; Elsevier Practice Update Cardiology; Janssen; Level Ex; Medscape Cardiology; MyoKardia; NirvaMed; Novo Nordisk; PhaseBio; PLx Pharma; Regado Biosciences; Stasys; Board of Directors: Boston VA Research Institute; Society of Cardiovascular Patient Care; TobeSoft; Chair: Inaugural Chair, American Heart Association Quality Oversight Committee†	Trustee: American College of Cardiology
Deborah A. Chyun	University of Connecticut	None	None	None	None	None	None	None
Katherine E. Di Palo	Montefiore Medical Center	None	None	None	None	None	None	None
Sherita H. Golden	Johns Hopkins University	None	None	None	None	None	Member, Health Equity Advisory Board, Medtronic, Inc.* Member, Health Disparities Advisory Committee, Abbott*	None
Laurence S. Sperling	Emory University School of Medicine, Emory Clinical Cardiovascular Research Institute	None	None	None	None	None	None	None

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives \$10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns \$10 000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

*Modest.

†Significant.

Reviewer Disclosures

Reviewer	Employment	Research grant	Other research support	Speakers' bureau/honoraria	Expert witness	Ownership interest	Consultant/advisory board	Other
Michael J. Blaha	Johns Hopkins University School of Medicine	Novo Nordisk*	None	Novo Nordisk*	None	None	Novo Nordisk*; Kalliedo*; Amgen*; Sanofi/Regeneron*; Bayer*	None
Michael D. Miedema	Minneapolis Heart Institute and Minneapolis Heart Institute Foundation	None	None	None	None	None	None	None
Judith Wylie-Rosett	Albert Einstein College of Medicine	None	None	None	None	None	None	None

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives \$10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns \$10 000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

*Significant.

REFERENCES

- Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020: estimates of diabetes and its burden in the United States. Accessed August 30, 2021. <https://www.cdc.gov/diabetes/data/statistics-report/index.html>
- Cheng YJ, Imperatore G, Geiss LS, Saydah SH, Albright AL, Ali MK, Gregg EW. Trends and disparities in cardiovascular mortality among U.S. adults with and without self-reported diabetes, 1988–2015. *Diabetes Care*. 2018;41:2306–2315. doi: 10.2337/dc18-0831
- Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson AM, Miftaraj M, McGuire DK, Sattar N, Rosengren A, Gudbjörnsdóttir S. Mortality and cardiovascular disease in type 1 and type 2 diabetes. *N Engl J Med*. 2017;376:1407–1418. doi: 10.1056/NEJMoa1608664
- Harding JL, Shaw JE, Peeters A, Davidson S, Magliano DJ. Age-specific trends from 2000–2011 in all-cause and cause-specific mortality in type 1 and type 2 diabetes: a cohort study of more than one million people. *Diabetes Care*. 2016;39:1018–1026. doi: 10.2337/dc15-2308
- Bergheanu SC, Bodde MC, Jukema JW. Pathophysiology and treatment of atherosclerosis: current view and future perspective on lipoprotein modification treatment. *Neth Heart J*. 2017;25:231–242. doi: 10.1007/s12471-017-0959-2
- Bakris GL. The importance of blood pressure control in the patient with diabetes. *Am J Med*. 2004;116(suppl 5A):30S–38S. doi: 10.1016/j.amjmed.2003.10.018
- Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. *Cardiovasc Diabetol*. 2018;17:122. doi: 10.1186/s12933-018-0762-4
- Pistrosch F, Natali A, Hanefeld M. Is hyperglycemia a cardiovascular risk factor? *Diabetes Care*. 2011;34(suppl 2):S128–S131. doi: 10.2337/dc11-s207
- Bhupathiraju SN, Hu FB. Epidemiology of obesity and diabetes and their cardiovascular complications. *Circ Res*. 2016;118:1723–1735. doi: 10.1161/CIRCRESAHA.115.306825
- Goldberg IJ. Clinical review 124: Diabetic dyslipidemia: causes and consequences. *J Clin Endocrinol Metab*. 2001;86:965–971. doi: 10.1210/jcem.86.3.7304
- Fowler MJ. Microvascular and macrovascular complications of diabetes. *Clin Diabetes*. 2008;26:77–82. doi: 10.2337/diaclin.26.2.77
- Fox CS, Golden SH, Anderson C, Bray GA, Burke LE, de Boer IH, Deedwania P, Eckel RH, Ershov AG, Fradkin J, et al; on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardio-metabolic Health, Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, Council on Quality of Care and Outcomes Research, and the American Diabetes Association. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. *Circulation*. 2015;132:691–718. doi: 10.1161/CIR.0000000000000230
- Grundty SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. *Circulation*. 2005;112:2735–2752. doi: 10.1161/CIRCULATIONAHA.105.169404
- Eckel N, Meidtner K, Kalle-Uhlmann T, Stefan N, Schulze MB. Metabolically healthy obesity and cardiovascular events: a systematic review and meta-analysis. *Eur J Prev Cardiol*. 2016;23:956–966. doi: 10.1177/2047487315623884
- American Diabetes Association. 2. Classification and diagnosis of diabetes: *Standards of Medical Care in Diabetes—2019*. *Diabetes Care*. 2019;42(suppl 1):S13–S28. doi: 10.2337/dc19-S002
- Meijnikman AS, De Block CEM, Dirinck E, Verrijken A, Mertens I, Corthouts B, Van Gaal LF. Not performing an OGTT results in significant underdiagnosis of (pre)diabetes in a high risk adult Caucasian population. *Int J Obes (Lond)*. 2017;41:1615–1620. doi: 10.1038/sj.ijo.2017.165
- Cowie CC, Rust KF, Byrd-Holt DD, Gregg EW, Ford ES, Geiss LS, Bainbridge KE, Fradkin JE. Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988–2006. *Diabetes Care*. 2010;33:562–568. doi: 10.2337/dc09-1524
- Alexander CM, Landsman PB, Teutsch SM, Häfner SM; Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. *Diabetes*. 2003;52:1210–1214. doi: 10.2337/diabetes.52.5.1210
- Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F, Poli M, Perbellini S, et al. The Metabolic Syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. *Diabet Med*. 2004;21:52–58. doi: 10.1046/j.1464-5491.2003.01068.x
- American Diabetes Association. 5. Facilitating behavior change and well-being to improve health outcomes: *Standards of Medical Care in Diabetes—2021*. *Diabetes Care*. 2021;44(suppl 1):S53–S72. doi: 10.2337/dc21-S005
- Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;140:e596–e646. doi: 10.1161/CIR.0000000000000678
- American Diabetes Association. 10. Cardiovascular disease and risk management: *Standards of Medical Care in Diabetes—2021*. *Diabetes Care*. 2021;44(suppl 1):S125–S150. doi: 10.2337/dc21-S010
- American Diabetes Association. 8. Obesity management for the treatment of type 2 diabetes: *Standards of Medical Care in Diabetes—2021*. *Diabetes Care*. 2021;44:S100–S110.
- Liu G, Li Y, Hu Y, Zong G, Li S, Rimm EB, Hu FB, Manson JE, Rexrode KM, Shin HJ, et al. Influence of lifestyle on incident cardiovascular disease and mortality in patients with diabetes mellitus. *J Am Coll Cardiol*. 2018;71:2867–2876. doi: 10.1016/j.jacc.2018.04.027
- Long GH, Cooper AJ, Wareham NJ, Griffin SJ, Simmons RK. Healthy behavior change and cardiovascular outcomes in newly diagnosed type 2 diabetic patients: a cohort analysis of the ADDITION-Cambridge study. *Diabetes Care*. 2014;37:1712–1720. doi: 10.2337/dc13-1731
- Fisher DP, Johnson E, Haneuse S, Arterburn D, Coleman KJ, O'Connor RJ, O'Brien R, Bogart A, Theis MK, Anau J, et al. Association between

- bariatric surgery and macrovascular disease outcomes in patients with type 2 diabetes and severe obesity. *JAMA*. 2018;320:1570–1582. doi: 10.1001/jama.2018.14619
27. Zethelius B, Gudbjörnsdóttir S, Eliasson B, Eeg-Olofsson K, Cederholm J; Swedish National Diabetes Register. Level of physical activity associated with risk of cardiovascular diseases and mortality in patients with type-2 diabetes: report from the Swedish National Diabetes Register. *Eur J Prev Cardiol*. 2014;21:244–251. doi: 10.1177/2047487313510893
 28. Pan A, Wang Y, Talaei M, Hu FB. Relation of smoking with total mortality and cardiovascular events among patients with diabetes mellitus: a meta-analysis and systematic review. *Circulation*. 2015;132:1795–1804. doi: 10.1161/CIRCULATIONAHA.115.017926
 29. Blomster JI, Woodward M, Zoungas S, Hillis GS, Harrap S, Neal B, Poulter N, Mancia G, Chalmers J, Huxley R. The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicon modified release Controlled Evaluation) trial. *BMJ Open*. 2016;6:e009668. doi: 10.1136/bmjopen-2015-009668
 30. Khan AA, Chung MJ, Novak E, Mori Brooks M, Brown DL. The long-term risk of smoking in diabetic patients with stable ischemic heart disease treated with intensive medical therapy and lifestyle modification. *Eur J Prev Cardiol*. 2017;24:1506–1514. doi: 10.1177/2047487317711046
 31. Blomster JI, Zoungas S, Chalmers J, Li Q, Chow CK, Woodward M, Mancia G, Poulter N, Williams B, Harrap S, Neal B, et al. The relationship between alcohol consumption and vascular complications and mortality in individuals with type 2 diabetes. *Diabetes Care*. 2014;37:1353–1359. doi: 10.2337/dc13-2727
 32. Koppes LL, Dekker JM, Hendriks HF, Bouter LM, Heine RJ. Meta-analysis of the relationship between alcohol consumption and coronary heart disease and mortality in type 2 diabetic patients. *Diabetologia*. 2006;49:648–652. doi: 10.1007/s00125-005-0127-x
 33. Liu XL, Shi Y, Willis K, Wu CJ, Johnson M. Health education for patients with acute coronary syndrome and type 2 diabetes mellitus: an umbrella review of systematic reviews and meta-analyses. *BMJ Open*. 2017;7:e016857. doi: 10.1136/bmjopen-2017-016857
 34. Bittner V, Bertololet M, Barraza Felix R, Farkouh ME, Goldberg S, Ramanathan KB, Redmon JB, Sperling L, Rutter MK; BARI 2D Study Group. Comprehensive cardiovascular risk factor control improves survival: the BARI 2D trial. *J Am Coll Cardiol*. 2015;66:765–773. doi: 10.1016/j.jacc.2015.06.019
 35. Wahid A, Manek N, Nichols M, Kelly P, Foster C, Webster P, Kaur A, Friedemann Smith C, Wilkins E, Rayner M, et al. Quantifying the association between physical activity and cardiovascular disease and diabetes: a systematic review and meta-analysis. *J Am Heart Assoc*. 2016;5:e002495. doi: 10.1161/JAHA.115.002495
 36. Look AHEAD Research Group; Gregg E, Jakicic J, Blackburn G, Bloomquist P, Bray G, Clark J, Coday M, Curtis J, Egan C, Evans M, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. *Lancet Diabetes Endocrinol*. 2016;4:913–921. doi: 10.1016/S2213-8587(16)30162-0
 37. Clair C, Rigotti NA, Porneala B, Fox CS, D'Agostino RB, Pencina MJ, Meigs JB. Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. *JAMA*. 2013;309:1014–1021. doi: 10.1001/jama.2013.1644
 38. Elgendy R, Deschênes SS, Burns RJ, Levy M, Schmitz N. Alcohol consumption, depressive symptoms, and the incidence of diabetes-related complications. *J Diabetes*. 2019;11:14–22. doi: 10.1111/1753-0407.12822
 39. Pagidipati NJ, Navar AM, Pieper KS, Green JB, Bethel MA, Armstrong PW, Josse RG, McGuire DK, Lokhnygina Y, Cornel JH, et al; TECOS Study Group. Secondary prevention of cardiovascular disease in patients with type 2 diabetes mellitus: international insights from the TECOS trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin). *Circulation*. 2017;136:1193–1203. doi: 10.1161/CIRCULATIONAHA.117.027252
 40. The Look AHEAD Research Group; Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. *N Engl J Med*. 2013;369:145–154. doi: 10.1056/NEJMoa1212914
 41. Pandey A, Patel KV, Bahnson JL, Gaussoin SA, Martin CK, Balasubramanyam A, Johnson KC, McGuire DK, Bertoni AG, Kitzman D, et al; Look AHEAD Research Group. Association of intensive lifestyle intervention, fitness, and body mass index with risk of heart failure in overweight or obese adults with type 2 diabetes mellitus: an analysis from the Look AHEAD trial. *Circulation*. 2020;141:1295–1306. doi: 10.1161/CIRCULATIONAHA.119.044865
 42. Look AHEAD Research Group; Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. *Arch Intern Med*. 2010;170:1566–1575. doi: 10.1001/archinternmed.2010.334
 43. Kuna ST, Reboussin DM, Borradaile KE, Sanders MH, Millman RP, Zammit G, Newman AB, Wadden TA, Jakicic JM, Wing RR, et al; Sleep AHEAD Research Group of the Look AHEAD Research Group. Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes. *Sleep*. 2013;36:641–649A. doi: 10.5665/sleep.2618
 44. Jakicic JM, Egan CM, Fabricatore AN, Gaussoin SA, Glasser SP, Hesson LA, Knowler WC, Lang W, Regensteiner JG, Ribisl PM, et al; Look AHEAD Research Group. Four-year change in cardiorespiratory fitness and influence on glycemic control in adults with type 2 diabetes in a randomized trial: the Look AHEAD trial. *Diabetes Care*. 2013;36:1297–1303. doi: 10.2337/dc12-0712
 45. Look AHEAD Research Group. Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. *Lancet Diabetes Endocrinol*. 2014;2:801–809. doi: 10.1016/S2213-8587(14)70156-1
 46. Look AHEAD Research Group. Effects of a long-term lifestyle modification programme on peripheral neuropathy in overweight or obese adults with type 2 diabetes: the Look AHEAD study. *Diabetologia*. 2017;60:980–988. doi: 10.1007/s00125-017-4253-z
 47. Rubin RR, Wadden TA, Bahnson JL, Blackburn GL, Brancati FL, Bray GA, Coday M, Crow SJ, Curtis JM, Dutton G, et al; Look AHEAD Research Group. Impact of intensive lifestyle intervention on depression and health-related quality of life in type 2 diabetes: the Look AHEAD trial. *Diabetes Care*. 2014;37:1544–1553. doi: 10.2337/dc13-1928
 48. Gibbs BB, Brancati FL, Chen H, Coday M, Jakicic JM, Lewis CE, Stewart KJ, Clark JM; (for the Look AHEAD Research Group). Effect of improved fitness beyond weight loss on cardiovascular risk factors in individuals with type 2 diabetes in the Look AHEAD study. *Eur J Prev Cardiol*. 2014;21:608–617. doi: 10.1177/2047487312462823
 49. Colberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC, Horton ES, Castorino K, Tate DF. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. *Diabetes Care*. 2016;39:2065–2079. doi: 10.2337/dc16-1728
 50. Boniol M, Dragomir M, Autier P, Boyle P. Physical activity and change in fasting glucose and HbA1c: a quantitative meta-analysis of randomized trials. *Acta Diabetol*. 2017;54:983–991. doi: 10.1007/s00592-017-1037-3
 51. Boulé NG, Kenny GP, Haddad E, Wells GA, Sigal RJ. Meta-analysis of the effect of structured exercise training on cardiorespiratory fitness in type 2 diabetes mellitus. *Diabetologia*. 2003;46:1071–1081. doi: 10.1007/s00125-003-1160-2
 52. Zou Z, Cai W, Cai M, Xiao M, Wang Z. Influence of the intervention of exercise on obese type II diabetes mellitus: a meta-analysis. *Prim Care Diabetes*. 2016;10:186–201. doi: 10.1016/j.pcd.2015.10.003
 53. Umpierre D, Ribeiro PA, Kramer CK, Leitão CB, Zucatti AT, Azevedo MJ, Gross JL, Ribeiro JP, Schaan BD. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. *JAMA*. 2011;305:1790–1799. doi: 10.1001/jama.2011.576
 54. Sluik D, Buijsse B, Muckelbauer R, Kaaks R, Teucher B, Johnsen NF, Tjønneland A, Overvad K, Ostergaard JN, Amiano P, et al. Physical activity and mortality in individuals with diabetes mellitus: a prospective study and meta-analysis. *Arch Intern Med*. 2012;172:1285–1295. doi: 10.1001/archinternmed.2012.3130
 55. Gummesson A, Nyman E, Knutsson M, Karpefors M. Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes. *Diabetes Obes Metab*. 2017;19:1295–1305. doi: 10.1111/dom.12971
 56. Esposito K, Maiorino MI, Bellastella G, Chiodini P, Panagiotakos D, Giugliano D. A journey into a Mediterranean diet and type 2 diabetes: a systematic review with meta-analyses. *BMJ Open*. 2015;5:e008222. doi: 10.1136/bmjopen-2015-008222
 57. Huo R, Du T, Xu Y, Xu W, Chen X, Sun K, Yu X. Effects of Mediterranean-style diet on glycemic control, weight loss and cardiovascular risk factors among type 2 diabetes individuals: a meta-analysis. *Eur J Clin Nutr*. 2015;69:1200–1208. doi: 10.1038/ejcn.2014.243
 58. Zhao WT, Luo Y, Zhang Y, Zhou Y, Zhao TT. High protein diet is of benefit for patients with type 2 diabetes: an updated meta-analysis. *Medicine (Baltimore)*. 2018;97:e13149. doi: 10.1097/MD.00000000000013149

59. Meng Y, Bai H, Wang S, Li Z, Wang Q, Chen L. Efficacy of low carbohydrate diet for type 2 diabetes mellitus management: a systematic review and meta-analysis of randomized controlled trials. *Diabetes Res Clin Pract*. 2017;131:124–131. doi: 10.1016/j.diabres.2017.07.006
60. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, et al; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. *N Engl J Med*. 2018;378:e34. doi: 10.1056/NEJMoa1800389
61. Goday A, Bellido D, Sajaoui I, Crujeiras AB, Burguera B, García-Luna PP, Oleaga A, Moreno B, Casanueva FF. Short-term safety, tolerability and efficacy of a very low-calorie-ketogenic diet interventional weight loss program versus hypocaloric diet in patients with type 2 diabetes mellitus. *Nutr Diabetes*. 2016;6:e230. doi: 10.1038/nutd.2016.36
62. Sellahewa L, Khan C, Lakkunarajah S, Idris I. A systematic review of evidence on the use of very low calorie diets in people with diabetes. *Curr Diabetes Rev*. 2017;13:35–46. doi: 10.2174/1573399812666151005123431
63. Merrill JD, Soliman D, Kumar N, Lim S, Shariff AI, Yancy WS Jr. Low-carbohydrate and very-low-carbohydrate diets in patients with diabetes. *Diabetes Spectr*. 2020;33:133–142. doi: 10.2337/ds19-0070
64. Wycherley TP, Thompson CH, Buckley JD, Luscombe-Marsh ND, Noakes M, Wittert GA, Brinkworth GD. Long-term effects of weight loss with a very-low carbohydrate, low saturated fat diet on flow mediated dilatation in patients with type 2 diabetes: a randomised controlled trial. *Atherosclerosis*. 2016;252:28–31. doi: 10.1016/j.atherosclerosis.2016.07.908
65. Yamada Y, Uchida J, Izumi H, Tsukamoto Y, Inoue G, Watanabe Y, Irie J, Yamada S. A non-calorie-restricted low-carbohydrate diet is effective as an alternative therapy for patients with type 2 diabetes. *Intern Med*. 2014;53:13–19. doi: 10.2169/internalmedicine.53.0861
- 65a. Sainsbury E, Kizirian NV, Partridge SR, Gill T, Colagiuri S, Gibson AA. (2018). Effect of dietary carbohydrate restriction on glycaemic control in adults with diabetes: a systematic review and meta-analysis. *Diabetes Res Clin Pract*. 2018;139:239–252.
- 65b. van Zuuren EJ, Fedorowicz Z, Kuijpers T, Pijl H. (2018). Effects of low-carbohydrate- compared with low-fat-diet interventions on metabolic control in people with type 2 diabetes: a systematic review including GRADE assessments. *Am J Clin Nutr*. 2018;108:300–331.
- 65c. Korsmo-Haugen HK, Brurberg KG, Mann J, Aas AM. (2019). Carbohydrate quantity in the dietary management of type 2 diabetes: a systematic review and meta-analysis. *Diabetes Obes. Metab*. 2019;21:15–27.
- 65d. Kirkpatrick CF, Bolick JP, Kris-Etherton PM, Sikand G, Aspry KE, Soffer DE, Willard KE, Maki KC. Review of current evidence and clinical recommendations on the effects of low-carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other cardiometabolic risk factors: a scientific statement from the National Lipid Association Nutrition and Lifestyle Task Force. *J Clin Lipidol*. 2019;13:689–711.e1.
66. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. *Circulation*. 2014;129(suppl 2):S102–S138. doi: 10.1161/01.cir.0000437739.71477.ee
67. Piché ME, Tchernof A, Després JP. Obesity phenotypes, diabetes, and cardiovascular diseases. *Circ Res*. 2020;126:1477–1500. doi: 10.1161/CIRCRESAHA.120.316101
68. Wittwer JA, Golden SH, Joseph JJ. Diabetes and CVD risk: special considerations in African Americans related to care. *Curr Cardiovasc Risk Rep*. 2020;14:15. doi: 10.1007/s12170-020-00648-2
69. Kahan S, Fujioka K. Obesity pharmacotherapy in patients with type 2 diabetes. *Diabetes Spectr*. 2017;30:250–257. doi: 10.2337/ds17-0044
70. Bessesen DH, Van Gaal LF. Progress and challenges in anti-obesity pharmacotherapy. *Lancet Diabetes Endocrinol*. 2018;6:237–248. doi: 10.1016/S2213-8587(17)30236-X
71. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, et al; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2016;375:311–322. doi: 10.1056/NEJMoa1603827
72. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, et al; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. *N Engl J Med*. 2021;384:989. doi: 10.1056/NEJMoa2032183
73. Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, et al; STEP 2 Study Group. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. *Lancet*. 2021;397:971–984. doi: 10.1016/S0140-6736(21)00213-0
74. Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O'Neil PM, Rubino DM, Skovgaard D, et al; STEP 3 Investigators. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. *JAMA*. 2021;325:1403–1413. doi: 10.1001/jama.2021.1831
75. Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenz O, Rosenstock J, Rubio MA, et al; STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. *JAMA*. 2021;325:1414–1425. doi: 10.1001/jama.2021.3224
76. Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti KG, Zimmet PZ, Del Prato S, Ji L, Sadikot SM, Herman WH, et al; Delegates of the 2nd Diabetes Surgery Summit. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. *Diabetes Care*. 2016;39:861–877. doi: 10.2337/dc16-0236
77. Khorgami Z, Shoar S, Saber AA, Howard CA, Danaei G, Sclabas GM. Outcomes of bariatric surgery versus medical management for type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. *Obes Surg*. 2019;29:964–974. doi: 10.1007/s11695-018-3552-x
78. O'Brien PE, Hindle A, Brennan L, Skinner S, Burton P, Smith A, Crosthwaite G, Brown W. Long-term outcomes after bariatric surgery: a systematic review and meta-analysis of weight loss at 10 or more years for all bariatric procedures and a single-centre review of 20-year outcomes after adjustable gastric banding. *Obes Surg*. 2019;29:3–14. doi: 10.1007/s11695-018-3525-0
79. Arterburn DE, Telem DA, Kushner RF, Courcoulas AP. Benefits and risks of bariatric surgery in adults: a review. *JAMA*. 2020;324:879–887. doi: 10.1001/jama.2020.12567
80. Billeter AT, Eichel S, Scheurlen KM, Probst P, Köpf S, Müller-Stich BP. Meta-analysis of metabolic surgery versus medical treatment for macrovascular complications and mortality in patients with type 2 diabetes. *Surg Obes Relat Dis*. 2019;15:1197–1210. doi: 10.1016/j.soard.2019.04.029
81. Dicker D, Greenland P, Leibowitz M, Hoshen M, Senderey AB, Rasmussen-Torvik LJ, Balicer RD, Reges O. All-cause mortality of patients with and without diabetes following bariatric surgery: comparison to non-surgical matched patients. *Obes Surg*. 2021;31:755–762. doi: 10.1007/s11695-020-05068-0
82. Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. *BMJ*. 2011;342:d671. doi: 10.1136/bmj.d671
83. Wood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T, Paige E, Paul DS, Sweeting M, Burgess S, et al; Emerging Risk Factors Collaboration/EPIC-CVD/UK Biobank Alcohol Study Group. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. *Lancet*. 2018;391:1513–1523. doi: 10.1016/S0140-6736(18)30134-X
84. Larsson SC, Burgess S, Mason AM, Michaëlsen K. Alcohol consumption and cardiovascular disease: a Mendelian randomization study. *Circ Genom Precis Med*. 2020;13:e002814. doi: 10.1161/CIRCGEN.119.002814
85. Polsky S, Akturk HK. Alcohol consumption, diabetes risk, and cardiovascular disease within diabetes. *Curr Diab Rep*. 2017;17:136. doi: 10.1007/s11892-017-0950-8
86. Solomon CG, Hu FB, Stampfer MJ, Colditz GA, Speizer FE, Rimm EB, Willett WC, Manson JE. Moderate alcohol consumption and risk of coronary heart disease among women with type 2 diabetes mellitus. *Circulation*. 2000;102:494–499. doi: 10.1161/01.cir.102.5.494
87. Mayl JJ, German CA, Bertoni AG, Upadhyay B, Bhavne PD, Yeboah J, Singleton MJ. Association of alcohol intake with hypertension in type 2 diabetes mellitus: the ACCORD trial. *J Am Heart Assoc*. 2020;9:e017334. doi: 10.1161/JAHA.120.017334
88. Gepner Y, Golan R, Harman-Boehm I, Henkin Y, Schwarzfuchs D, Shelef I, Durst R, Kovsan J, Bolotin A, Leitersdorf E, et al. Effects of initiating moderate alcohol intake on cardiometabolic risk in adults with type 2 diabetes: a 2-year randomized, controlled trial. *Ann Intern Med*. 2015;163:569–579. doi: 10.7326/M14-1650
89. Shai I, Wainstein J, Harman-Boehm I, Raz I, Fraser D, Rudich A, Stampfer MJ. Glycemic effects of moderate alcohol intake among patients with type 2 diabetes: a multicenter, randomized, clinical intervention trial. *Diabetes Care*. 2007;30:3011–3016. doi: 10.2337/dc07-1103

90. Strelitz J, Ahern AL, Long GH, Boothby CE, Wareham NJ, Griffin SJ. Changes in behaviors after diagnosis of type 2 diabetes and 10-year incidence of cardiovascular disease and mortality. *Cardiovasc Diabetol*. 2019;18:98. doi: 10.1186/s12933-019-0902-5
91. Lv X, Sun J, Bi Y, Xu M, Lu J, Zhao L, Xu Y. Risk of all-cause mortality and cardiovascular disease associated with secondhand smoke exposure: a systematic review and meta-analysis. *Int J Cardiol*. 2015;199:106–115. doi: 10.1016/j.ijcard.2015.07.011
92. Kar D, Gillies C, Zaccardi F, Webb D, Seidu S, Tesfaye S, Davies M, Khunti K. Relationship of cardiometabolic parameters in non-smokers, current smokers, and quitters in diabetes: a systematic review and meta-analysis. *Cardiovasc Diabetol*. 2016;15:158. doi: 10.1186/s12933-016-0475-5
93. Campagna D, Alamo A, Di Pino A, Russo C, Calogero AE, Purrello F, Polosa R. Smoking and diabetes: dangerous liaisons and confusing relationships. *Diabetol Metab Syndr*. 2019;11:85. doi: 10.1186/s13098-019-0482-2
94. Liu G, Hu Y, Zong G, Pan A, Manson JE, Rexrode KM, Rimm EB, Hu FB, Sun Q. Smoking cessation and weight change in relation to cardiovascular disease incidence and mortality in people with type 2 diabetes: a population-based cohort study. *Lancet Diabetes Endocrinol*. 2020;8:125–133. doi: 10.1016/S2213-8587(19)30413-9
95. Kos K. Cardiometabolic morbidity and mortality with smoking cessation, review of recommendations for people with diabetes and obesity. *Curr Diab Rep*. 2020;20:82. doi: 10.1007/s11892-020-01352-6
96. Joseph JJ, Golden SH. Cortisol dysregulation: the bidirectional link between stress, depression, and type 2 diabetes mellitus. *Ann N Y Acad Sci*. 2017;1391:20–34. doi: 10.1111/nyas.13217
97. Dias JP, Joseph JJ, Kluiwe B, Zhao S, Shardell M, Seeman T, Needham BL, Wand GS, Kline D, Brock G, Castro-Diehl C, et al. The longitudinal association of changes in diurnal cortisol features with fasting glucose: MESA. *Psychoneuroendocrinology*. 2020;119:104698. doi: 10.1016/j.psyneuen.2020.104698
98. Powers MA, Bardsley JK, Cypress M, Funnell MM, Harms D, Hess-Fischl A, Hooks B, Isaacs D, Mandel ED, Maryniuk MD, et al. Diabetes self-management education and support in adults with type 2 diabetes: a consensus report of the American Diabetes Association, the Association of Diabetes Care & Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association. *Diabetes Care*. 2020;43:1636–1649. doi: 10.2337/dci20-0023
99. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. *Ann Intern Med*. 2004;141:421–431. doi: 10.7326/0003-4819-141-6-200409210-00007
100. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ*. 2000;321:405–412. doi: 10.1136/bmj.321.7258.405
101. Wong ND, Zhao Y, Patel R, Patao C, Malik S, Bertoni AG, Correa A, Folsom AR, Kachroo S, Mukherjee J, et al. Cardiovascular risk factor targets and cardiovascular disease event risk in diabetes: a pooling project of the Atherosclerosis Risk in Communities Study, Multi-Ethnic Study of Atherosclerosis, and Jackson Heart Study. *Diabetes Care*. 2016;39:668–676. doi: 10.2337/dc15-2439
102. Raghavan S, Vassy JL, Ho YL, Song RJ, Gagnon DR, Cho K, Wilson PWF, Phillips LS. Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults. *J Am Heart Assoc*. 2019;8:e011295. doi: 10.1161/JAHA.118.011295
103. Bancks MP, Ning H, Allen NB, Bertoni AG, Carnethon MR, Correa A, Echouffo-Tcheugui JB, Lange LA, Lloyd-Jones DM, Wilkins JT. Long-term absolute risk for cardiovascular disease stratified by fasting glucose level. *Diabetes Care*. 2019;42:457–465. doi: 10.2337/dc18-1773
104. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. *Lancet*. 2009;373:1765–1772. doi: 10.1016/S0140-6736(09)60697-8
105. Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. *Ann Intern Med*. 2009;151:394–403. doi: 10.7326/0003-4819-151-6-200909150-00137
106. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. *BMJ*. 2011;343:d4169. doi: 10.1136/bmj.d4169
107. Department of Health and Human Services, Food and Drug Administration. Guidance for industry: diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Accessed June 10, 2019. <https://www.fda.gov/media/71297/download>
108. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, et al; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med*. 2013;369:1317–1326. doi: 10.1056/NEJMoa1307684
109. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, et al; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. *N Engl J Med*. 2013;369:1327–1335. doi: 10.1056/NEJMoa1305889
110. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, et al; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2015;373:232–242. doi: 10.1056/NEJMoa1501352
111. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, et al; CARMELINA Investigators. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. *JAMA*. 2019;321:69–79. doi: 10.1001/jama.2018.18269
112. Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, Pfarr E, Keller A, Mattheus M, Baanstra D, et al; CAROLINA Investigators. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. *JAMA*. 2019;322:1155–1166. doi: 10.1001/jama.2019.13772
113. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, et al; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. *N Engl J Med*. 2015;373:2247–2257. doi: 10.1056/NEJMoa1509225
114. Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Liraglutide and renal outcomes in type 2 diabetes. *N Engl J Med*. 2017;377:839–848. doi: 10.1056/NEJMoa1616011
115. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2016;375:1834–1844. doi: 10.1056/NEJMoa1607141
116. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, et al; PIONEER 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2019;381:841–851. doi: 10.1056/NEJMoa1901118
117. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, et al; EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2017;377:1228–1239. doi: 10.1056/NEJMoa1612917
118. Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, et al; Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. *Lancet*. 2018;392:1519–1529. doi: 10.1016/S0140-6736(18)32261-X
119. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, et al; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. *Lancet*. 2019;394:121–130. doi: 10.1016/S0140-6736(19)31149-3
120. Gerstein HC, Sattar N, Rosenstock J, Ramasundararajasingam C, Pratley R, Lopes RD, Lam CSP, Khurmi NS, Heenan L, Del Prato S, et al; AMPLITUDE-O Trial Investigators. Cardiovascular and renal outcomes with efglucanate in type 2 diabetes. *N Engl J Med*. 2021;385:896–907. doi: 10.1056/NEJMoa2108269
121. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and

- mortality in type 2 diabetes. *N Engl J Med*. 2015;373:2117–2128. doi: 10.1056/NEJMoa1504720
122. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Matthews M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. *N Engl J Med*. 2016;375:323–334. doi: 10.1056/NEJMoa1515920
 123. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med*. 2017;377:644–657. doi: 10.1056/NEJMoa1611925
 124. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et al; DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2019;380:347–357. doi: 10.1056/NEJMoa1812389
 125. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, et al; VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. *N Engl J Med*. 2020;383:1425–1435. doi: 10.1056/NEJMoa2004967
 126. Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, et al; SCORED Investigators. Sotagliflozin in patients with diabetes and chronic kidney disease. *N Engl J Med*. 2021;384:129–139. doi: 10.1056/NEJMoa2030186
 127. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, et al; SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure. *N Engl J Med*. 2021;384:117–128. doi: 10.1056/NEJMoa2030183
 128. Marso SP, McGuire DK, Zinman B, Poultier NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, et al; DEVOTE Study Group. Efficacy and safety of degludec versus glargine in type 2 diabetes. *N Engl J Med*. 2017;377:723–732. doi: 10.1056/NEJMoa1615692
 129. Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Rydén L, Neal B, Malmberg K, Wedel H, Buse JB, Henry RR, et al; AleCardio Investigators. Effect of alogliptazir on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. *JAMA*. 2014;311:1515–1525. doi: 10.1001/jama.2014.3321
 130. Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, Rivellesse AA, Squatrito S, Giorda CB, Sesti G, et al; Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group; Italian Diabetes Society. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. *Lancet Diabetes Endocrinol*. 2017;5:887–897. doi: 10.1016/S2213-8587(17)30317-0
 131. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, et al; IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. *N Engl J Med*. 2016;374:1321–1331. doi: 10.1056/NEJMoa1506930
 132. Spence JD, Viscoli CM, Inzucchi SE, Dearborn-Tomazos J, Ford GA, Gorman M, Furie KL, Lovejoy AM, Young LH, Kernan WN; IRIS Investigators. Pioglitazone therapy in patients with stroke and prediabetes: a post hoc analysis of the IRIS randomized clinical trial. *JAMA Neurol*. 2019;76:526–535. doi: 10.1001/jamaneurol.2019.0079
 133. Filion KB, Azoulay L, Platt RW, Dahl M, Dormuth CR, Clemens KK, Hu N, Paterson JM, Targownik L, Turin TC, et al; CNODES Investigators. A multicenter observational study of incretin-based drugs and heart failure. *N Engl J Med*. 2016;374:1145–1154. doi: 10.1056/NEJMoa1506115
 134. Li L, Li S, Deng K, Liu J, Vandvik PO, Zhao P, Zhang L, Shen J, Bala MM, Sohani ZN, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. *BMJ*. 2016;352:i610. doi: 10.1136/bmj.i610
 135. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. *Circ Res*. 2014;114:1788–1803. doi: 10.1161/CIRCRESAHA.114.301958
 136. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riddle MC, Rydén L, Xavier D, et al, on behalf of the REWIND Trial Investigators. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. *Diabetes Obes Metab*. 2018;20:42–49. doi: 10.1111/dom.13028
 137. Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, Pagidipati NJ, Chan JC, Gustavson SM, Iqbal N, et al; EXSCEL Study Group. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. *Lancet Diabetes Endocrinol*. 2018;6:105–113. doi: 10.1016/S2213-8587(17)30412-6
 138. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. *Circulation*. 2019;139:2022–2031. doi: 10.1161/CIRCULATIONAHA.118.038868
 139. Das SR, Everett BM, Birtcher KK, Brown JM, Cefalu WT, Januzzi JL Jr, Kalyani RR, Kosiborod M, Magwire ML, Morris PB, et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. *J Am Coll Cardiol*. 2018;72:3200–3223. doi: 10.1016/j.jacc.2018.09.020
 140. Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S, Espadero RM, Woerle HJ, Broedl UC, Johansen OE. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. *Diab Vasc Dis Res*. 2015;12:90–100. doi: 10.1177/1479164114559852
 141. Perkovic V, Jardine MJ, Neal B, Bompont S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med*. 2019;380:2295–2306. doi: 10.1056/NEJMoa1811744
 142. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohávek J, et al; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med*. 2019;381:1995–2008. doi: 10.1056/NEJMoa1911303
 143. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med*. 2020;383:1413–1424. doi: 10.1056/NEJMoa2022190
 144. Fu AZ, Johnston SS, Ghannam A, Tsai K, Cappell K, Fowler R, Riehle E, Cole AL, Kalsekar I, Sheehan J. Association between hospitalization for heart failure and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: an observational study. *Diabetes Care*. 2016;39:726–734. doi: 10.2337/dc15-0764
 145. Cavender MA, Norhammar A, Birkeland KI, Jørgensen ME, Wilding JP, Khunti K, Fu AZ, Bodegård J, Blak BT, Wittbrodt E, et al; CVD-REAL Investigators and Study Group. SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL. *J Am Coll Cardiol*. 2018;71:2497–2506. doi: 10.1016/j.jacc.2018.01.085
 146. Kosiborod M, Birkeland KI, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Jørgensen ME, Wittbrodt ET, et al; CVD-REAL Investigators and Study Group. Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: results from the CVD-REAL study. *Diabetes Obes Metab*. 2018;20:1983–1987. doi: 10.1111/dom.13299
 147. Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, et al; CVD-REAL Investigators and Study Group*. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). *Circulation*. 2017;136:249–259. doi: 10.1161/CIRCULATIONAHA.117.029190
 148. Birkeland KI, Jørgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Nyström T, Eriksson JW, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. *Lancet Diabetes Endocrinol*. 2017;5:709–717. doi: 10.1016/S2213-8587(17)30258-9
 149. Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, Tangri N, Goh SY, Thuresson M, Chen H, et al; CVD-REAL Investigators and Study Group. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. *J Am Coll Cardiol*. 2018;71:2628–2639. doi: 10.1016/j.jacc.2018.03.009
 150. Dawwas GK, Smith SM, Park H. Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes. *Diabetes Obes Metab*. 2019;21:28–36. doi: 10.1111/dom.13477
 151. Kim YG, Han SJ, Kim DJ, Lee KW, Kim HJ. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study. *Cardiovasc Diabetol*. 2018;17:91. doi: 10.1186/s12933-018-0737-5

152. Paterno E, Goldfine AB, Schneeweiss S, Everett BM, Glynn RJ, Liu J, Kim SC. Cardiovascular outcomes associated with canagliflozin versus other non-gliiflozin antidiabetic drugs: population based cohort study. *BMJ*. 2018;360:k119. doi: 10.1136/bmj.k119
153. Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N. Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World). *Circulation*. 2018;137:1450–1459. doi: 10.1161/CIRCULATIONAHA.117.031227
154. Gautam S, Agiro A, Barron J, Power T, Weisman H, White J. Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis. *Cardiovasc Diabetol*. 2017;16:93. doi: 10.1186/s12933-017-0575-x
155. Toulis KA, Willis BH, Marshall T, Kumarendran B, Gokhale K, Ghosh S, Thomas GN, Cheng KK, Narendran P, Hanif W, et al. All-cause mortality in patients with diabetes under treatment with dapagliflozin: a population-based, open-cohort study in the Health Improvement Network Database. *J Clin Endocrinol Metab*. 2017;102:1719–1725. doi: 10.1210/jc.2016-3446
156. Cavender MA, Norhammar A, Birkeland KI, Jørgensen ME, Wilding JP, Khunti K, Fu AZ, Bodegård J, Blak BT, Wittbrodt E, et al; CVD-REAL Investigators and Study Group. SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL. *J Am Coll Cardiol*. 2018;71:2497–2506. doi: 10.1016/j.jacc.2018.01.085
157. Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. *Ann Intern Med*. 2019;170:764–769. doi: 10.7326/M19-0085
158. Cheng L, Li Y-Y, Hu W, Bai F, Hao H-R, Yu W-N, Mao X-M. Risk of bone fracture associated with sodium-glucose cotransporter-2 inhibitor treatment: A meta-analysis of randomized controlled trials. *Diabetes Metab*. 2019;45:436–445. doi: 10.1016/j.diabet.2019.01.010
159. Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, et al. How does empagliflozin reduce cardiovascular mortality? insights from a mediation analysis of the EMPA-REG OUTCOME trial. *Diabetes Care*. 2018;41:356–363. doi: 10.2337/dc17-1096
160. Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Ways K, Desai M, Shaw W, Capuano G, Alba M, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. *Diabetes Care*. 2015;38:403–411. doi: 10.2337/dc14-1237
161. Fulcher G, Matthews DR, Perkovic V, de Zeeuw D, Mahaffey KW, Mathieu C, Woo V, Wysham C, Capuano G, Desai M, et al; CANVAS trial collaborative group. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. *Diabetes Obes Metab*. 2016;18:82–91. doi: 10.1111/dom.12589
162. Zinman B, Marso SP, Christiansen E, Calanna S, Rasmussen S, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Hypoglycemia, cardiovascular outcomes, and death: the LEADER experience. *Diabetes Care*. 2018;41:1783–1791. doi: 10.2337/dc17-2677
163. American Diabetes Association. 6. Glycemic targets: *Standards of Medical Care in Diabetes—2021*. *Diabetes Care*. 2021;44(suppl 1):S73–S84. doi: 10.2337/dc21-S006
164. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: *Standards of Medical Care in Diabetes—2021*. *Diabetes Care*. 2021;44(suppl 1):S111–S124. doi: 10.2337/dc21-S009
165. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2019 executive summary. *Endocrine Pract*. 2019;25:69–100. doi: 10.4158/CS-2018-0535
166. Cosentino F, Grant RJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, et al; ESC Scientific Document Group. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J*. 2020;41:255–323. doi: 10.1093/eurheartj/ehz486
167. Das SR, Everett BM, Birtcher KK, Brown JM, Januzzi JL Jr, Kalyani RR, Kosiborod M, Magwire M, Morris PB, Neumiller JJ, et al. 2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2020;76:1117–1145. doi: 10.1016/j.jacc.2020.05.037
168. Brunström M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. *BMJ*. 2016;352:i717. doi: 10.1136/bmj.i717
169. The Emerging Risk Factors Collaboration; Sarwar N, Gao P, Seshasai SRK, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet*. 2010;375:2215–2222. doi: 10.1016/S0140-6736(10)60484-9
170. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavy AA, Denardo SJ, Bakris GL, Pepine CJ. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. *JAMA*. 2010;304:61–68. doi: 10.1001/jama.2010.884
171. Bergmark BA, Scirica BM, Steg PG, Fanola CL, Gurmu Y, Mosenzon O, Cahn A, Raz I, Bhatt DL; SAVOR-TIMI 53 Investigators. Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk. *Eur Heart J*. 2018;39:2255–2262. doi: 10.1093/eurheartj/ehx809
172. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. *BMJ*. 2000;321:412–419. doi: 10.1136/bmj.321.7258.412
173. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, et al; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. *N Engl J Med*. 2010;362:1575–1585. doi: 10.1056/NEJMoa1001286
174. Deedwania P. The ongoing saga of optimal blood pressure level in patients with diabetes mellitus and coronary artery disease. *J Am Heart Assoc*. 2018;7:e010752. doi: 10.1161/JAHA.118.010752
175. White WB, Jalil F, Cushman WC, Bakris GL, Bergenstal R, Heller SR, Liu Y, Mehta C, Zannad F, Cannon CP. Average clinician-measured blood pressures and cardiovascular outcomes in patients with type 2 diabetes mellitus and ischemic heart disease in the EXAMINE trial. *J Am Heart Assoc*. 2018;7:e009114. doi: 10.1161/JAHA.118.009114
176. Ilkun OL, Greene T, Cheung AK, Whelton PK, Wei G, Boucher RE, Ambrosius W, Chertow GM, Beddhu S. The influence of baseline diastolic blood pressure on the effects of intensive blood pressure lowering on cardiovascular outcomes and all-cause mortality in type 2 diabetes. *Diabetes Care*. 2020;43:1878–1884. doi: 10.2337/dc19-2047
177. Rahman F, McEvoy JW, Ohkuma T, Marre M, Hamet P, Harrap S, Mancia G, Rodgers A, Selvin E, Williams B, et al. Effects of blood pressure lowering on clinical outcomes according to baseline blood pressure and cardiovascular risk in patients with type 2 diabetes mellitus. *Hypertension*. 2019;73:1291–1299. doi: 10.1161/HYPERTENSIONAHA.118.12414
178. Wang J, Chen Y, Xu W, Lu N, Cao J, Yu S. Effects of intensive blood pressure lowering on mortality and cardiovascular and renal outcomes in type 2 diabetic patients: a meta-analysis. *PLoS One*. 2019;14:e0215362. doi: 10.1371/journal.pone.0215362
179. Böhm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, Mancia G, Redon J, Schmieder RE, Marx N, et al. Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. *Eur Heart J*. 2019;40:2032–2043. doi: 10.1093/eurheartj/ehz149
180. Beddhu S, Chertow GM, Greene T, Whelton PK, Ambrosius WT, Cheung AK, Cutler J, Fine L, Boucher R, Wei G, et al. Effects of intensive systolic blood pressure lowering on cardiovascular events and mortality in patients with type 2 diabetes mellitus on standard glycemic control and in those without diabetes mellitus: reconciling results from ACCORD BP and SPRINT. *J Am Heart Assoc*. 2018;7:e009326. doi: 10.1161/JAHA.118.009326
181. Buckley LF, Dixon DL, Wohlford GF 4th, Wijesinghe DS, Baker WL, Van Tassel BW. Effect of intensive blood pressure control in patients with type 2 diabetes mellitus over 9 years of follow-up: a subgroup analysis of high-risk ACCORDION trial participants. *Diabetes Obes Metab*. 2018;20:1499–1502. doi: 10.1111/dom.13248
182. Brouwer TF, Vehmeijer JT, Kalkman DN, Berger WR, van den Born BH, Peters RJ, Knops RE. Intensive blood pressure lowering in patients with and without type 2 diabetes: a pooled analysis from two randomized trials. *Diabetes Care*. 2018;41:1142–1148. doi: 10.2337/dc17-1722
183. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. *J Hypertens*. 2017;35:922–944. doi: 10.1097/HJH.0000000000001276

184. Buckley LF, Dixon DL, Wohlford GF 4th, Wijesinghe DS, Baker WL, Van Tassel BW. Intensive versus standard blood pressure control in SPRINT-eligible participants of ACCORD-BP. *Diabetes Care*. 2017;40:1733–1738. doi: 10.2337/dc17-1366
185. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. *Lancet*. 2016;387:957–967. doi: 10.1016/S0140-6736(15)01225-8
186. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, Woodward M, MacMahon S, Turnbull F, Hillis GS, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. *Lancet*. 2016;387:435–443. doi: 10.1016/S0140-6736(15)00805-3
187. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2018;138:e426–e483. doi: 10.1161/CIR.0000000000000597
188. Boer IH de, Bangalore S, Benetos A, Davis AM, Michos ED, Muntner P, Rossing P, Zoungas S, Bakris G. Diabetes and hypertension: a position statement by the American Diabetes Association. *Diabetes Care*. 2017;40:1273–1284. doi: 10.2337/dci17-0026
189. Hirano T. Pathophysiology of diabetic dyslipidemia. *J Atheroscler Thromb*. 2018;25:771–782. doi: 10.5551/jat.RV17023
190. Ye X, Kong W, Zafar M, Chen LL. Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies. *Cardiovasc Diabetol*. 2019;18:48. doi: 10.1186/s12933-019-0851-z
191. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;139:e1082–e1143. doi: 10.1161/CIR.0000000000000625
192. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *Lancet*. 2008;371:117–125. doi: 10.1016/S0140-6736(08)60104-X
193. de Vries FM, Denig P, Pouwels KB, Postma MJ, Hak E. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis. *Drugs*. 2012;72:2365–2373. doi: 10.2165/11638240-000000000-00000
194. Taylor F, Huffman MD, Macedo AF, Moore THM, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. *Cochrane Database Syst Rev*. 2013;CD004816.
195. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. *Lancet*. 2012;380:565–571. doi: 10.1016/S0140-6736(12)61190-8
196. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. *JAMA*. 2011;305:2556–2564. doi: 10.1001/jama.2011.860
197. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *Lancet*. 2010;375:735–742. doi: 10.1016/S0140-6736(09)61965-6
198. Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, Caputo S, Grzesk G, Kubica A, Swiatkiewicz J, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. *Am J Cardiol*. 2013;111:1123–1130. doi: 10.1016/j.amjcard.2012.12.037
199. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*. 2002;346:393–403. doi: 10.1056/NEJMoa012512
200. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, et al; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med*. 2015;372:2387–2397. doi: 10.1056/NEJMoa1410489
201. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*. 2017;376:1713–1722. doi: 10.1056/NEJMoa1615664
202. Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Edelberg JM, Goodman SG, et al; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial. *J Am Coll Cardiol*. 2019;73:387–396. doi: 10.1016/j.jacc.2018.10.039
203. Kelly S, Preiss D, Robinson JG, Djedjos CS, Elliott M, Somaratne R, Wasserman SM, Raal FJ. Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. *Lancet Diabetes Endocrinol*. 2016;4:403–410. doi: 10.1016/S2213-8587(16)00003-6
204. Fonseca VA, Handelsman Y, Staels B. Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. *Diabetes Obes Metab*. 2010;12:384–392. doi: 10.1111/j.1463-1326.2009.01181.x
205. Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, Kelly S, Stroes ESG. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. *J Am Heart Assoc*. 2019;8:e011662. doi: 10.1161/JAHA.118.011662
206. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, et al; REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *N Engl J Med*. 2019;380:11–22. doi: 10.1056/NEJMoa1812792
207. Elam M, Lovato LC, Ginsberg H. Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective. *Curr Opin Lipidol*. 2011;22:55–61. doi: 10.1097/MOL.0b013e328341a5a8
208. Haase CL, Tybjaerg-Hansen A, Qayyum AA, Schou J, Nordestgaard BG, Frikke-Schmidt R. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. *J Clin Endocrinol Metab*. 2012;97:E248–E256. doi: 10.1210/jc.2011-1846
209. Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. *BMJ*. 2014;349:g4379. doi: 10.1136/bmj.g4379
210. Martin SS, Sperling LS, Blaha MJ, Wilson PWF, Gluckman TJ, Blumenthal RS, Stone NJ. Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA Guidelines. *J Am Coll Cardiol*. 2015;65:1361–1368. doi: 10.1016/j.jacc.2015.01.043
211. Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, et al; DAPT Study Investigators. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. *JAMA*. 2016;315:1735–1749. doi: 10.1001/jama.2016.3775
212. Grant PJ. Diabetes mellitus as a prothrombotic condition. *J Intern Med*. 2007;262:157–172. doi: 10.1111/j.1365-2796.2007.01824.x
213. Sobel BE, Hardison RM, Genuth S, Brooks MM, McBane RD 3rd, Schneider DJ, Pratley RE, Huber K, Wolk R, Krishnaswami A, et al; BARI 2D Investigators. Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *Circulation*. 2011;124:695–703. doi: 10.1161/CIRCULATIONAHA.110.014860
214. Barsness GW, Holmes DR Jr, Gersh BJ. Integrated management of patients with diabetes mellitus and ischemic heart disease: PCI, CABG, and medical therapy. *Curr Probl Cardiol*. 2005;30:583–617. doi: 10.1016/j.cpcardiol.2005.06.006
215. Lee JH, Lee R, Hwang MH, Hamilton MT, Park Y. The effects of exercise on vascular endothelial function in type 2 diabetes: a systematic review and meta-analysis. *Diabetol Metab Syndr*. 2018;10:15. doi: 10.1186/s13098-018-0316-7
216. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoute PM. Endothelial dysfunction in diabetes. *Br J Pharmacol*. 2000;130:963–974. doi: 10.1038/sj.bjp.0703393
217. Potenza MA, Gagliardi S, Nacci C, Carratu' MR, Montagnani M. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. *Curr Med Chem*. 2009;16:94–112. doi: 10.2174/092986709787002853
218. Davi G, Patrono C, Catalano I, Cusuto N, Giammarresi C, Ganci A, Cosentino F, Notarbartolo A. Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus. *Arterioscler Thromb*. 1993;13:1346–1349. doi: 10.1161/01.atv.13.9.1346

219. Ferroni P, Basili S, Falco A, Davi G. Platelet activation in type 2 diabetes mellitus. *J Thromb Haemost*. 2004;2:1282–1291. doi: 10.1111/j.1538-7836.2004.00836.x
220. Angiolillo DJ, Jakubowski JA, Ferreiro JL, Tello-Montoliu A, Rollini F, Franchi F, Ueno M, Darlington A, Desai B, Moser BA, et al. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. *J Am Coll Cardiol*. 2014;64:1005–1014. doi: 10.1016/j.jacc.2014.06.1170
221. Davi G, Greslele P, Violi F, Basili S, Catalano M, Giammarresi C, Volpato R, Nenci GG, Ciabattini G, Patrono C. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. *Circulation*. 1997;96:69–75. doi: 10.1161/01.cir.96.1.69
222. Tschöepe D, Roesen P, Esser J, Schwippert B, Nieuwenhuis HK, Kehrel B, Gries FA. Large platelets circulate in an activated state in diabetes mellitus. *Semin Thromb Hemost*. 1991;17:433–438. doi: 10.1055/s-2007-1002650
223. Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. *Thromb Haemost*. 2009;101:151–156.
224. Tschöepe D, Roesen P, Kaufmann L, Schauseil S, Kehrel B, Ostermann H, Gries FA. Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. *Eur J Clin Invest*. 1990;20:166–170. doi: 10.1111/j.1365-2362.1990.tb02264.x
225. Keating FK, Sobel BE, Schneider DJ. Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. *Am J Cardiol*. 2003;92:1362–1365. doi: 10.1016/j.amjcard.2003.08.033
226. Tschöepe D, Driesch E, Schwippert B, Nieuwenhuis HK, Gries FA. Exposure of adhesion molecules on activated platelets in patients with newly diagnosed IDDM is not normalized by near-normoglycemia. *Diabetes*. 1995;44:890–894. doi: 10.2337/diab.44.8.890
227. Osende JI, Badimon JJ, Fuster V, Herson P, Rabito P, Vidhun R, Zaman A, Rodriguez OJ, Lev EI, Rauch U, et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glyemic control. *J Am Coll Cardiol*. 2001;38:1307–1312. doi: 10.1016/s0735-1097(01)01555-8
228. Duzenli MA, Ozdemir K, Aygül N, Soylu A, Tokac M. Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin. *Am J Cardiol*. 2008;102:396–400. doi: 10.1016/j.amjcard.2008.03.074
229. Price MJ, Nayak KR, Barker CM, Kandzari DE, Teirstein PS. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. *Am J Cardiol*. 2009;103:1339–1343. doi: 10.1016/j.amjcard.2009.01.341
230. Mangiacapra F, Patti G, Peace A, Gatto L, Vizzi V, Ricottini E, D'Ambrosio A, Muller O, Barbato E, Di Sciascio G. Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. *Am J Cardiol*. 2010;106:619–623. doi: 10.1016/j.amjcard.2010.04.015
231. Angiolillo DJ, Bernardo E, Capodanno D, Vivas D, Sabaté M, Ferreiro JL, Ueno M, Jimenez-Quevedo P, Alfonso F, Bass TA, et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. *J Am Coll Cardiol*. 2010;55:1139–1146. doi: 10.1016/j.jacc.2009.10.043
232. Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, Cox J, et al; ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. *N Engl J Med*. 2018;379:1529–1539. doi: 10.1056/NEJMoa1804988
233. Capodanno D, Patel A, Dharmashankar K, Ferreiro JL, Ueno M, Kodali M, Tomasello SD, Capranzano P, Seecheran N, Darlington A, et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. *Circ Cardiovasc Interv*. 2011;4:180–187. doi: 10.1161/CIRCINTERVENTIONS.110.960187
234. Bethel MA, Harrison P, Sourij H, Sun Y, Tucker L, Kennedy I, White S, Hill L, Oulhaj A, Coleman RL, et al. Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with type 2 diabetes. *Diabet Med*. 2016;33:224–230. doi: 10.1111/dme.12828
235. Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, Rasmussen L, Storey RF, Nielsen T, Eikelboom JW, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. *Circulation*. 2010;121:1188–1199. doi: 10.1161/CIRCULATIONAHA.109.919456
236. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N Engl J Med*. 2006;354:1706–1717. doi: 10.1056/NEJMoa060989
237. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, et al; CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. *J Am Coll Cardiol*. 2007;49:1982–1988. doi: 10.1016/j.jacc.2007.03.025
238. Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M, Storey RF, Im K, Murphy SA, Held P, Braunwald E, et al. Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54. *J Am Coll Cardiol*. 2016;67:2732–2740. doi: 10.1016/j.jacc.2016.03.529
239. Bhatt DL, Fox K, Harrington RA, Leiter LA, Mehta SR, Simon T, Andersson M, Himmelmann A, Ridderstråle W, Held C, et al; THEMIS Steering Committee. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. *Clin Cardiol*. 2019;42:498–505. doi: 10.1002/clc.23164
240. Arora S, Shemisa K, Vaduganathan M, Qamar A, Gupta A, Garg SK, Kumbhani DJ, Mayo H, Khalili H, Pandey A, et al. Premature ticagrelor discontinuation in secondary prevention of atherosclerotic CVD: JACC review topic of the week. *J Am Coll Cardiol*. 2019;73:2454–2464. doi: 10.1016/j.jacc.2019.03.470
- 240a. Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Andersson M, Himmelmann A, Ridderstråle W, et al. Ticagrelor in patients with stable coronary disease and diabetes. *N Engl J Med*. 2019;381:1309–1320. doi: 10.1056/NEJMoa1908077
- 240b. Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, Held C, Andersson M, Himmelmann A, Ridderstråle W, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. *Lancet*. 2019;394:1169–1180. doi: 10.1016/S0140-6736(19)31887-2
241. Cavender MA, Scirica BM, Bonaca MP, Angiolillo DJ, Dalby AJ, Dellborg M, Morais J, Murphy SA, Ophuis TO, Tenders M, et al. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. *Circulation*. 2015;131:1047–1053. doi: 10.1161/CIRCULATIONAHA.114.013774
242. Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, Aboyans V, Alings M, Kakkar AK, Keltai K, et al; COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. *Lancet*. 2018;391:219–229. doi: 10.1016/S0140-6736(17)32409-1
243. Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanus F, Metsarinne K, O'Donnell M, Dans AL, Ha JW, et al; COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. *Lancet*. 2018;391:205–218. doi: 10.1016/S0140-6736(17)32458-3
244. Anand SS, Caron F, Eikelboom JW, Bosch J, Dyal L, Aboyans V, Abola MT, Branch KRH, Keltai K, Bhatt DL, et al. Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial. *J Am Coll Cardiol*. 2018;71:2306–2315. doi: 10.1016/j.jacc.2018.03.008
245. Mehdi U, Toto RD. Anemia, diabetes, and chronic kidney disease. *Diabetes Care*. 2009;32:1320–1326. doi: 10.2337/dc08-0779
246. Saran R, Robinson B, Abbott KC, Agodoa LY, Albertus P, Ayanian J, Balkrishnan R, Bragg-Gresham J, Cao J, Chen JL, et al. US Renal Data System 2016 annual data report: epidemiology of kidney disease in the United States. *Am J Kidney Dis*. 2017;69(3 suppl 1):A7–A8. doi: 10.1053/j.ajkd.2016.12.004
247. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int*. 2005;67:2089–2100. doi: 10.1111/j.1523-1755.2005.00365.x
248. Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, de Boer IH. Clinical manifestations of kidney disease among us adults with diabetes, 1988–2014. *JAMA*. 2016;316:602–610. doi: 10.1001/jama.2016.10924
249. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, et al. Diabetic

- kidney disease: a report from an ADA Consensus Conference. *Diabetes Care*. 2014;37:2864–2883. doi: 10.2337/dc14-1296
250. de Boer IH; DCCT/EDIC Research Group. Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. *Diabetes Care*. 2014;37:24–30. doi: 10.2337/dc13-2113
 251. Pálsson R, Patel UD. Cardiovascular complications of diabetic kidney disease. *Adv Chronic Kidney Dis*. 2014;21:273–280. doi: 10.1053/j.ackd.2014.03.003
 252. Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, Hayward RA, Craven T, Coleman RL, Chalmers J; Collaborators on Trials of Lowering Glucose (CONTROL) group. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. *Lancet Diabetes Endocrinol*. 2017;5:431–437. doi: 10.1016/S2213-8587(17)30104-3
 253. Wong MG, Perkovic V, Chalmers J, Woodward M, Li Q, Cooper ME, Hamet P, Harrap S, Heller S, MacMahon S, Mancia G, Marre M, Matthews D, Neal B, Poulter N, Rodgers A, Williams B, Zoungas S; ADVANCE-ON Collaborative Group. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. *Diabetes Care*. 2016;39:694–700. doi: 10.2337/dc15-2322
 254. Ruospo M, Saglimbene VM, Palmer SC, De Cosmo S, Pacilli A, Lamacchia O, Cignarelli M, Fioretto P, Vecchio M, Craig JC, et al. Glucose targets for preventing diabetic kidney disease and its progression. *Cochrane Database Syst Rev*. 2017;6:CD010137. doi: 10.1002/14651858.CD010137.pub2
 255. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, et al; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. *N Engl J Med*. 2020;383:1436–1446. doi: 10.1056/NEJMoa2024816
 256. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, et al; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. *N Engl J Med*. 2020;383:2219–2229. doi: 10.1056/NEJMoa2025845
 257. Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Schloemer P, Tornus I, Joseph A, et al; FIDELIO-DKD Investigators. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. *Circulation*. 2021;143:540–552. doi: 10.1161/CIRCULATIONAHA.120.051898
 258. Wong ND, Sciammarella MG, Polk D, Gallagher A, Miranda-Peats L, Whitcomb B, Hachamovitch R, Friedman JD, Hayes S, Berman DS. The metabolic syndrome, diabetes, and subclinical atherosclerosis assessed by coronary calcium. *J Am Coll Cardiol*. 2003;41:1547–1553. doi: 10.1016/s0735-1097(03)00193-1
 259. Reis JP, Allen NB, Bancks MP, Carr JJ, Lewis CE, Lima JA, Rana JS, Gidding SS, Schreiner PJ. Duration of diabetes and prediabetes during adulthood and subclinical atherosclerosis and cardiac dysfunction in middle age: the CARDIA study. *Diabetes Care*. 2018;41:731–738. doi: 10.2337/dc17-2233
 260. Kowall B, Lehmann N, Mahabadi AA, Moebus S, Budde T, Seibel R, Grönemeyer D, Erbel R, Jöckel KH, Stang A. Progression of coronary artery calcification is stronger in poorly than in well controlled diabetes: results from the Heinz Nixdorf Recall Study. *J Diabetes Complications*. 2017;31:234–240. doi: 10.1016/j.jdiacomp.2016.08.011
 261. Malik S, Zhao Y, Budoff M, Nasir K, Blumenthal RS, Bertoni AG, Wong ND. Coronary artery calcium score for long-term risk classification in individuals with type 2 diabetes and metabolic syndrome from the multi-ethnic study of atherosclerosis. *JAMA Cardiol*. 2017;2:1332–1340. doi: 10.1001/jamacardio.2017.4191
 262. Erbel R, Lehmann N, Churzidse S, Rauwolf M, Mahabadi AA, Möhlenkamp S, Moebus S, Bauer M, Kälsch H, Budde T, et al; Heinz Nixdorf Recall Study Investigators. Progression of coronary artery calcification seems to be inevitable, but predictable – results of the Heinz Nixdorf Recall (HNR) study. *Eur Heart J*. 2014;35:2960–2971. doi: 10.1093/eurheartj/ehu288
 263. Elkeles RS, Godsland IF, Feher MD, Rubens MB, Roughton M, Nugara F, Humphries SE, Richmond W, Flather MD; PREDICT Study Group. Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study. *Eur Heart J*. 2008;29:2244–2251. doi: 10.1093/eurheartj/ehn279
 264. Yeboah J, Erbel R, Delaney JC, Nance R, Guo M, Bertoni AG, Budoff M, Moebus S, Jöckel KH, Burke GL, et al. Development of a new diabetes risk prediction tool for incident coronary heart disease events: the Multi-Ethnic Study of Atherosclerosis and the Heinz Nixdorf Recall Study. *Atherosclerosis*. 2014;236:411–417. doi: 10.1016/j.atherosclerosis.2014.07.035
 265. Raggi P, Shaw LJ, Berman DS, Callister TO. Prognostic value of coronary artery calcium screening in subjects with and without diabetes. *J Am Coll Cardiol*. 2004;43:1663–1669. doi: 10.1016/j.jacc.2003.09.068
 266. Roos CJ, Kharagitsingh AV, Jukema JW, Bax JJ, Scholte AJ. Comparison by computed tomographic angiography—the presence and extent of coronary arterial atherosclerosis in South Asians versus Caucasians with diabetes mellitus. *Am J Cardiol*. 2014;113:1782–1787. doi: 10.1016/j.amjcard.2014.03.005
 267. Blanke P, Naoum C, Ahmadi A, Cheruvu C, Soon J, Arepalli C, Gransar H, Achenbach S, Berman DS, Budoff MJ, et al. Long-term prognostic utility of coronary CT angiography in stable patients with diabetes mellitus. *JACC: Cardiovasc Imaging*. 2016;9:1280–1288. doi: 10.1016/j.jccimg.2015.12.027
 268. Beller E, Meinel FG, Schoeppe F, Kunz WG, Thierfelder KM, Hausleiter J, Bamberg F, Schoepf UJ, Hoffmann VS. Predictive value of coronary computed tomography angiography in asymptomatic individuals with diabetes mellitus: systematic review and meta-analysis. *J Cardiovasc Comput Tomogr*. 2018;12:320–328. doi: 10.1016/j.jcct.2018.04.002
 269. Min JK, Labounty TM, Gomez MJ, Achenbach S, Al-Mallah M, Budoff MJ, Cademartiri F, Callister TO, Chang HJ, Cheng V, et al. Incremental prognostic value of coronary computed tomographic angiography over coronary artery calcium score for risk prediction of major adverse cardiac events in asymptomatic diabetic individuals. *Atherosclerosis*. 2014;232:298–304. doi: 10.1016/j.atherosclerosis.2013.09.025
 270. Muhlestein JB, Lappé DL, Lima JA, Rosen BD, May HT, Knight S, Blumke DA, Towner SR, Le V, Bair TL, et al. Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. *JAMA*. 2014;312:2234–2243. doi: 10.1001/jama.2014.15825
 271. Sharma A, Coles A, Sekaran NK, Pagidipati NJ, Lu MT, Mark DB, Lee KL, Al-Khalidi HR, Hoffmann U, Douglas PS. Stress testing versus CT angiography in patients with diabetes and suspected coronary artery disease. *J Am Coll Cardiol*. 2019;73:893–902. doi: 10.1016/j.jacc.2018.11.056
 272. Khazai B, Luo Y, Rosenberg S, Wingrove J, Budoff MJ. Coronary atherosclerotic plaque detected by computed tomographic angiography in subjects with diabetes compared to those without diabetes. *PLoS One*. 2015;10:e0143187. doi: 10.1371/journal.pone.0143187
 273. Deseive S, Straub R, Kupke M, Broersen A, Kitslaar PH, Stocker TJ, Massberg S, Hadamitzky M, Hausleiter J. Impact of diabetes on coronary artery plaque volume by coronary CT angiography and subsequent adverse cardiac events. *J Cardiovasc Comput Tomogr*. 2019;13:31–37. doi: 10.1016/j.jcct.2018.09.008
 274. Kwan AC, May HT, Cater G, Sibley CT, Rosen BD, Lima JA, Rodriguez K, Lappe DL, Muhlestein JB, Anderson JL, et al. Coronary artery plaque volume and obesity in patients with diabetes: the factor-64 study. *Radiology*. 2014;272:690–699. doi: 10.1148/radiol.14140611
 275. Kim U, Leipsic JA, Sellers SL, Shao M, Blanke P, Hadamitzky M, Kim Y-J, Conte E, Andreini D, Pontone G, et al. Natural history of diabetic coronary atherosclerosis by quantitative measurement of serial coronary computed tomographic angiography: results of the PARADIGM study. *JACC Cardiovascular Imaging*. 2018;11:1461–1471. doi: 10.1016/j.jcmg.2018.04.009
 276. Won KB, Lee SE, Lee BK, Park HB, Heo R, Rizvi A, Lin FY, Kumar A, Hadamitzky M, Kim YJ, et al. Longitudinal assessment of coronary plaque volume change related to glycemic status using serial coronary computed tomography angiography: A PARADIGM (Progression of Atherosclerotic Plaque Determined by Computed tomographic Angiography Imaging) substudy. *J Cardiovasc Comput Tomogr*. 2019;13:142–147. doi: 10.1016/j.jcct.2018.12.002
 277. Halon DA, Azencot M, Rubinshtein R, Zafrir B, Flugelman MY, Lewis BS. Coronary computed tomography (CT) angiography as a predictor of cardiac and noncardiac vascular events in asymptomatic type 2 diabetics: a 7-year population-based cohort study. *J Am Heart Assoc*. 2016;5:e003226. doi: 10.1161/JAHA.116.003226
 278. Elliott MD, Heitner JF, Kim H, Wu E, Parker MA, Lee DC, Kaufman DB, Bonow RO, Judd R, Kim RJ. Prevalence and prognosis of unrecognized myocardial infarction in asymptomatic patients with diabetes: a two-center study with up to 5 years of follow-up. *Diabetes Care*. 2019;42:1290–1296. doi: 10.2337/dc18-2266
 279. Giusca S, Kelle S, Nagel E, Buss SJ, Voss A, Puntmann V, Fleck E, Katus HA, Korosoglou G. Differences in the prognostic relevance of myocardial ischaemia and scar by cardiac magnetic resonance in patients with and without diabetes mellitus. *Eur Heart J Cardiovasc Imaging*. 2016;17:812–820. doi: 10.1093/ehjci/jev220

280. Schelbert EB, Cao JJ, Sigurdsson S, Aspelund T, Kellman P, Aletras AH, Dyke CK, Thorgeirsson G, Eiriksdottir G, Launer LJ, et al. Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults. *JAMA*. 2012;308:890–896. doi: 10.1001/2012.jama.11089
281. Acharya T, Aspelund T, Jonasson TF, Schelbert EB, Cao JJ, Sathya B, Dyke CK, Aletras AH, Sigurdsson S, Thorgeirsson G, et al. Association of unrecognized myocardial infarction with long-term outcomes in community-dwelling older adults: the ICELAND MI study. *JAMA Cardiol*. 2018;3:1101–1106. doi: 10.1001/jamacardio.2018.3285
282. Turkbey EB, Backlund JY, Genuth S, Jain A, Miao C, Cleary PA, Lachin JM, Nathan DM, van der Geest RJ, Soliman EZ, et al; DCCT/EDIC Research Group. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. *Circulation*. 2011;124:1737–1746. doi: 10.1161/CIRCULATIONAHA.111.022327
283. Curtis JM, Horton ES, Bahnon J, Gregg EW, Jakicic JM, Regensteiner JG, Ribisl PM, Soberman JE, Stewart KJ, Espeland MA; Look AHEAD Research Group. Prevalence and predictors of abnormal cardiovascular responses to exercise testing among individuals with type 2 diabetes: the Look AHEAD (Action for Health in Diabetes) study. *Diabetes Care*. 2010;33:901–907. doi: 10.2337/dc09-1787
284. Turrini F, Scarlini S, Mannucci C, Messori R, Giovanardi P, Magnavacchi P, Cappelli C, Evandri V, Zanasi A, Romano S, et al. Does coronary atherosclerosis deserve to be diagnosed early in diabetic patients? The DADDY-D trial. Screening diabetic patients for unknown coronary disease. *Eur J Intern Med*. 2015;26:407–413. doi: 10.1016/j.ejim.2015.05.006
285. Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Heller GV, Iskandrian AE, Wittlin SD, Filipchuk N, et al; DIAD Investigators. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. *JAMA*. 2009;301:1547–1555. doi: 10.1001/jama.2009.476
286. Zellweger MJ, Haaf P, Marau N, Osterhues HH, Keller U, Müller-Brand J, Jeger R, Pfister O, Brinkert M, Burkard T, et al; BARDOT Investigators. Predictors and prognostic impact of silent coronary artery disease in asymptomatic high-risk patients with diabetes mellitus. *Int J Cardiol*. 2017;244:37–42. doi: 10.1016/j.ijcard.2017.05.069
287. Acampa W, Cantoni V, Green R, Maio F, Daniele S, Nappi C, Gaudieri V, Punzo G, Petretta M, Cuocolo A. Prognostic value of normal stress myocardial perfusion imaging in diabetic patients: a meta-analysis. *J Nucl Cardiol*. 2014;21:893–902; quiz 890. doi: 10.1007/s12350-014-9918-0
288. Heydari B, Juan YH, Liu H, Abbasi S, Shah R, Blankstein R, Steigner M, Jerosch-Herold M, Kwong RY. Stress perfusion cardiac magnetic resonance imaging effectively risk stratifies diabetic patients with suspected myocardial ischemia. *Circ Cardiovasc Imaging*. 2016;9:e004136. doi: 10.1161/CIRCIMAGING.115.004136
289. Murthy VL, Naya M, Foster CR, Gaber M, Hainer J, Klein J, Dorbala S, Blankstein R, Di Carli MF. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. *Circulation*. 2012;126:1858–1868. doi: 10.1161/CIRCULATIONAHA.112.120402
290. Larghat AM, Swoboda PP, Biglands JD, Kearney MT, Greenwood JP, Plein S. The microvascular effects of insulin resistance and diabetes on cardiac structure, function, and perfusion: a cardiovascular magnetic resonance study. *Eur Heart J Cardiovasc Imaging*. 2014;15:1368–1376. doi: 10.1093/ehjci/jeu142
291. Orringer CE, Blaha MJ, Blankstein R, Budoff MJ, Goldberg RB, Gill EA, Maki KC, Mehta L, Jacobson TA. The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction. *J Clin Lipidol*. 2021;15:33–60. doi: 10.1016/j.jacl.2020.12.005
292. Hecht H, Blaha MJ, Berman DS, Nasir K, Budoff M, Leipsic J, Blankstein R, Narula J, Rumberger J, Shaw LJ. Clinical indications for coronary artery calcium scoring in asymptomatic patients: expert consensus statement from the Society of Cardiovascular Computed Tomography. *J Cardiovasc Comput Tomogr*. 2017;11:157–168. doi: 10.1016/j.jcct.2017.02.010
293. Dave CV, Schneeweiss S, Wexler DJ, Brill G, Paterno E. Trends in clinical characteristics and prescribing preferences for SGLT2 inhibitors and GLP-1 receptor agonists, 2013–2018. *Diabetes Care*. 2020;43:921–924. doi: 10.2337/dc19-1943
294. Honigberg MC, Chang LS, McGuire DK, Plutzky J, Aroda VR, Vaduganathan M. Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease: a review. *JAMA Cardiol*. 2020;5:1182–1190. doi: 10.1001/jamacardio.2020.1966
295. Reiter-Brennan C, Cainzos-Achirica M, Soroosh G, Saxon DR, Blaha MJ, Eckel RH. Cardiometabolic medicine – the US perspective on a new subspecialty. *Cardiovasc Endocrinol Metab*. 2020;9:70–80. doi: 10.1097/XCE.0000000000000224
296. Elhussein A, Bancks M, Knowler WC, Peters AL, Vaughan EM, Maruthur NM, Clark J, Pilla SJ. 37-OR: Racial and socioeconomic disparities in the use of newer classes of diabetes medications. *Diabetes*. 2020;69(suppl 1):37-OR. doi: 10.2337/db20-37-OR
297. Mccoy RG, Houten HV, Ross J, Karaca-Mandic P, Montori VM, Shah N. 38-OR: Differences in diabetes medication use between commercial and Medicare advantage beneficiaries, 2013–2018. *Diabetes*. 2020;69(suppl 1):38-OR. doi: 10.2337/db20-38-OR
298. Andary R, Fan W, Wong ND. Control of cardiovascular risk factors among US adults with type 2 diabetes with and without cardiovascular disease. *Am J Cardiol*. 2019;124:522–527. doi: 10.1016/j.amjcard.2019.05.035
299. Kotseva K, De Backer G, De Bacquer D, Rydén L, Hoes A, Grobbee D, Maggioni A, Marques-Vidal P, Jennings C, Abreu A, et al. Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. *Eur J Prev Cardiol*. Published online March 20, 2020; doi: 10.1177/2047487320908698
300. Hood CM, Gennuso KP, Swain GR, Catlin BB. County health rankings: relationships between determinant factors and health outcomes. *Am J Prev Med*. 2016;50:129–135. doi: 10.1016/j.amepre.2015.08.024
301. Havranek EP, Mujahid MS, Barr DA, Blair IV, Cohen MS, Cruz-Flores S, Davey-Smith G, Dennison-Himmelfarb CR, Lauer MS, Lockwood DW, et al; on behalf of the American Heart Association Council on Quality of Care and Outcomes Research, Council on Epidemiology and Prevention, Council on Cardiovascular and Stroke Nursing, Council on Lifestyle and Cardiometabolic Health, and Stroke Council. Social determinants of risk and outcomes for cardiovascular disease: a scientific statement from the American Heart Association. *Circulation*. 2015;132:873–898. doi: 10.1161/CIR.0000000000000228
302. Churchwell K, Elkind MSV, Benjamin RM, Carson AP, Chang EK, Lawrence W, Mills A, Odom TM, Rodriguez CJ, Rodriguez F, et al; on behalf of the American Heart Association. Call to action: structural racism as a fundamental driver of health disparities: a presidential advisory from the American Heart Association. *Circulation*. 2020;142:e454–e468. doi: 10.1161/CIR.0000000000000936
303. Hill-Briggs F, Adler NE, Berkowitz SA, Chin MH, Gary-Webb TL, Navas-Acien A, Thornton PL, Haire-Joshu D. Social determinants of health and diabetes: a scientific review. *Diabetes Care*. 2021;44:258–279. doi: 10.2337/dci20-0053
304. National Academies of Sciences, Engineering, and Medicine. *Integrating Social Care into the Delivery of Health Care: Moving Upstream to Improve the Nation's Health*. National Academies Press; 2019. Accessed September 25, 2020. <https://www.nap.edu/catalog/25467> doi: 10.17226/25467
305. National Academies of Sciences, Engineering, and Medicine. *Investing in Interventions That Address Non-Medical, Health-Related Social Needs: Proceedings of a Workshop*. National Academies Press; 2019. Accessed September 25, 2020. <https://www.nap.edu/catalog/25544> doi: 10.17226/25544
306. Downer S, Berkowitz SA, Harlan TS, Olstad DL, Mozaffarian D. Food is medicine: actions to integrate food and nutrition into healthcare. *BMJ*. 2020;369:m2482. doi: 10.1136/bmj.m2482
307. Haire-Joshu D, Hill-Briggs F. The next generation of diabetes translation: a path to health equity. *Annu Rev Public Health*. 2019;40:391–410. doi: 10.1146/annurev-publhealth-040218-044158
308. Kotseva K; EUROASPIRE Investigators. The EUROASPIRE surveys: lessons learned in cardiovascular disease prevention. *Cardiovasc Diagn Ther*. 2017;7:633–639. doi: 10.21037/cdt.2017.04.06
309. Wood DA, Kotseva K, Connolly S, Jennings C, Mead A, Jones J, Holden A, De Bacquer D, Collier T, De Backer G, et al; EUROACTION Study Group. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. *Lancet*. 2008;371:1999–2012. doi: 10.1016/S0140-6736(08)60868-5